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Chapter 1
General introduction and outline of thesis
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10 Chapter 1
Breast cancer is the most common cancer in women and the leading cause of cancer 
death among females, accounting for 23% of the total cancer cases and 14% of cancer 
deaths.1 In the Netherlands, 12.000 women are diagnosed with the disease annually 
and the lifetime risk of developing breast cancer is 12-13%. The incidence of breast 
cancer is still increasing, which likely results from changes in reproductive factors 
(including the increased use of postmenopausal hormone therapy) as well as an 
increased screening intensity.2 Breast cancer is strongly related to age. Only 5% of all 
breast cancers occur in women under 40 years old.3 The age distribution of breast 
cancer shows a bimodal characterization and early- and late-onset modes are observed 
near ages 50 and 70 years, respectively (Figure 1).4 Over the last decades, mortality 
trends for breast cancer are declining. Currently, 90% of breast cancer patients are 
expected to survive at least five years. The increase in breast cancer survival seen since 
the mid-1970s has been attributed to improved systemic treatment. Nonetheless, 
surgery is still the cornerstone of the curative treatment of breast cancer. 
HIstoRy of BReAst CAnCeR suRGeRy
The local treatment of breast cancer has undergone a dramatic paradigm shift during 
the last century, characterized by a more conservative surgical approach. The radical 
mastectomy, published in a landmark paper by Dr. William Halsted in 1894, was 
regarded as standard of care for every breast cancer patient regardless of any tumor 
characteristic or status of the axilla for several decades. As this operation included 
an en bloc excision of the breast gland, both pectoral muscles and all relevant lymph 
nodes, it was associated with a high morbidity.5 In an attempt to decrease morbidity, 
the modified radical mastectomy was introduced, in which both pectoral muscles were 
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figure 1.  Bimodal age distribution at diagnosis for 
invasive female breast cancer cases (n = 94,813) in the 
National Cancer Institute’s Surveillance, Epidemiology, 
and End Results Program during the years 1994 
through 1997.4
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operations was equal, while the morbidity was markedly decreased.6, 7 During the 1970s, 
the breast-conserving therapy was introduced, which comprised of a lumpectomy in 
combination with radiotherapy to the breast. While the survival rates were equal for 
mastectomy and lumpectomy,8 the surgical morbidity and patients’ self-image owing 
to better cosmetic outcome were ameliorated.9, 10 In the 1990s, the sentinel lymph 
node procedure was introduced to further reduce surgical extent.11 The sentinel lymph 
node procedure prevents the morbidity of an axillary lymph node dissection in lymph 
node negative patients. In line with this changing surgical approach of breast cancer, 
preoperative or neoadjuvant chemotherapy was introduced in early breast cancer to 
down size breast tumors in order to improve surgical possibilities and increase the rate 
of breast-conserving surgery.
PARt I: neoAdjuvAnt systemIC tHeRAPy
Neoadjuvant chemotherapy in breast cancer treatment defines the use of cytotoxic 
chemotherapy before any local treatment, either surgery or radiotherapy. Although 
other terms such as ‘primary’, ‘preoperative’, ‘induction’, ‘upfront’ or ‘initial’ are perhaps 
more accurate descriptions, it was decided during the 2003 Consensus Conference to 
retain the more commonly used term ‘neoadjuvant’.12 
The use of neoadjuvant chemotherapy in breast cancer was introduced almost 
simultaneously with the establishment of adjuvant chemotherapy in the 1970s in 
patients with locally advanced disease in order to convert inoperable tumors into 
operable tumors. At present, neoadjuvant chemotherapy is the standard of care for 
patients with locally advanced and inflammatory breast cancer. Soon after reaching 
positive results in locally advanced breast cancer, randomized controlled trials were 
conducted to evaluate neoadjuvant chemotherapy in earlier, operable stages. A major 
benefit of neoadjuvant chemotherapy is the increase in breast conservation rate, which 
is associated with less morbidity and improved body image compared with complete 
breast removal. However, concerns exist on local control after down staging of the 
tumor and the delay of surgery in patients with tumors resistant to chemotherapy. 
Besides an increase in breast conservation, an increase in overall survival was 
also anticipated with the use of neoadjuvant chemotherapy in early stage breast cancer. 
The rationale for this survival benefit was derived from several experimental studies, 
in which an increase in the proliferation index of residual tumor was shown after 
removal of the primary tumor, which resulted in acceleration of tumor growth.13, 14 
This increase in tumor growth was repressed by preoperative chemotherapy, which 
diminished the release of circulating growth factors and prolonged survival.15 A 
more theoretical advantage is the Goldie–Coldman hypothesis, which proposes that, 
as a tumor cell population increases, an ever-expanding number of drug-resistant 
phenotypic variants arise that are more difficult to eradicate with chemotherapy.16 
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Moreover, early introduction of systemic therapy in the biological life of the tumor 
could tackle micrometastatic tumor cells several months earlier than in the adjuvant 
setting. Upon these considerations, it was reasoned that neoadjuvant chemotherapy 
might improve overall survival in early stage breast cancer patients.
Since the mid-1980s, several trials have been conducted to evaluate the efficiency 
of neoadjuvant chemotherapy compared with adjuvant chemotherapy in early stage 
breast cancer. In Chapter 2, a meta-analysis of these trials is performed in order to 
assess the overall effectiveness of neoadjuvant chemotherapy on clinical outcome.
Prediction of tumor response to therapy: towards personalized treatment
Neoadjuvant chemotherapy facilitates the  in vivo  monitoring of changes in tumor 
volume during systemic treatment. The achievement of complete eradication of local 
disease by systemic neoadjuvant therapy is strongly associated with a favorable long-
term prognosis.17 So, a pathological complete response during neoadjuvant therapy 
reflects chemosensitivity of distant micrometastasic disease. These findings have led to 
the use of pathological complete response as a surrogate marker for prognosis of survival 
and its use in clinical trials provides an early indication of drug activity. Moreover, 
the assessment of tumor response during neoadjuvant therapy is an excellent study 
model to identify predictive factors. A predictive factor is any clinical or biological 
characteristic associated with a response or lack of a response to a specific treatment. 
Identification of predictive factors may lead to more personalized treatment strategies. 
In Chapter 3, predictive factors are identified that are capable of predicting 
pathological complete and overall clinical tumor response to preoperative 
anthracycline-based chemotherapy. For this, the pre-treatment core biopsies of women 
with operable breast cancer who enrolled in the European Organization for Research 
and Treatment of Cancer (EORTC) trial 10902 were used.
One of the most important predictive factors of tumor response to chemotherapy 
is the estrogen receptor (ER) status of the tumor. Several neoadjuvant chemotherapy 
studies have demonstrated that patients with ER negative tumors are more likely to 
achieve a pathological complete response than those with ER positive tumors.18-20 
Moreover, these studies found that, when patients with ER negative tumors achieved 
a pathological complete response, their survival was comparable to that of ER positive 
patients. Translating these results to the adjuvant setting, some authors have argued 
that chemotherapy should not be administrated to patients with node negative, ER 
positive breast cancer, but, instead, should be treated with hormonal treatment alone. 
Young age (< 40 years) at the time of diagnosis of breast cancer is an independent 
factor of poor prognosis and current consensus guidelines have included young age 
as an absolute indication for adjuvant systemic chemotherapy irrespective of other 
tumor characteristics, such as stage, grade, or ER status.21 However, young patients 
with hormone receptor positive breast cancer might receive limited benefit from 
Thesis Mieog.indb   12 22-09-11   19:49
13Introduction
chemotherapy alone. Due to the fact that breast cancer at a young age is a relatively 
rare event and accounts for 5-7.5% of all cases, limited data on predictive and 
prognostic factors are available for this patient group. Therefore, concerns exist on 
the overtreatment with chemotherapy of these young patients. In particular the long-
term toxicity of chemotherapy and the implications of possible fertility impairment 
and premature menopause are of concern in young women.22 More refined knowledge 
of predictive and prognostic factors in young breast cancer patients will be of use in 
guiding systemic therapy in these women.
In Chapter 4, the effect of chemotherapy is studied in young patients with breast 
cancer in relation to hormone receptor status. In this study, the paraffin-embedded 
tumor material was used from a large cohort early stage breast cancer patients younger 
than 40 years who participated in one of four EORTC trials.
In Chapter 5, prognostic factors are identified in the above-described cohort 
and in the node negative subpopulation of which most patients did not receive 
chemotherapy. 
Resistance to therapy and breast cancer stem cells
Despite recent advances in systemic therapy and radiotherapy, a significant proportion 
of early stage breast cancer patients still develop loco regional recurrences and distant 
metastases. Often, these recurrences occur after a considerable follow-up period. 
This phenomenon, referred as tumor dormancy, is a particular clinical problem in 
breast cancer, where disease recurrences are witnessed 20 years after initial curative 
treatment.23 Recent biological research has provided evidence that the cancer stem cell 
theory might explain these treatment failures. 
Cancer stem cells, defined as a small subset of tumor cells with stem cell-like 
features, including epithelial-to-mesenchymal transition, have the capacity of self-
renewal and differentiation; giving rise to heterogeneous tumor cell population.24 
Various studies have shown that cancer stem cells have the ability to survive drugs 
and radiotherapy by a number of properties including high expression of ABC 
drug transporters, higher levels of DNA repair, and more anti-apoptotic traits.25-27 
Selective survival of cancer stem cells might provide opportunities for understanding 
treatment resistance and tumor dormancy.  Several cancer stem cell markers have been 
suggested for breast cancer. However, expression of the detoxifying enzyme aldehyde 
dehydrogenase-1 (ALDH1) has shown the most promise as a clinically relevant 
prognostic cancer stem cell marker in breast cancer.28-30 
Breast cancer stem cells could also provide a biological explanation for the well-
known age-specific difference in breast cancer survival (Figure 1). Young age (< 65 
years) is associated with more aggressive tumors with a relatively high risk of distant 
metastasis and loco-regional recurrence,3 whereas old age is associated with more 
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indolent tumors.31, 32 However, it is unknown whether the expression of ALDH1 is 
associated with age and has an influence on clinical outcome. 
In Chapter 6, the age distribution of ALDH1 expression and its prognostic role 
in young and elderly patients was analyzed using the long-term follow-up data of a 
large cohort of breast cancer patients primarily treated with surgery at the Leiden 
University Medical Center.
To further elucidate the biological pathways involved in the formation and 
growth of cancer stem cells, the role of the putative coagulation protein tissue factor 
(TF) has been suggested. A large number of tumor types show tumoral expression of 
TF and the complex of TF and activated factor VII (TF:FVII) have been implicated 
in tumor growth and metastasis. TF exhibits its effect through a protease activated 
receptor-2 (PAR2)-dependent pathway, which results in proliferation, increased 
oncogene expression and cell migration. TF expression and the TF:FVII/PAR2 axis has 
been linked to cancer stem cells. However, the role of TF and its alternatively spliced 
isoform (asTF), which exhibit its role through an integrin-related pathway, have not 
been tested in breast cancer. 
In Chapter 7, the expression of TF and asTF in early breast cancer was assessed 
as well as the association with clinicopathological characteristics, patient outcome and 
ALDH1 expression in the above-described cohort.
PARt II: ImAGe-GuIded suRGeRy
Intraoperative tumor visualization
The main challenge in the surgical treatment of breast cancer is the complete removal 
of tumor tissue taking into account an adequate tumor-free margin and an acceptable 
cosmetic result. During breast-conserving surgery, the surgeon has to rely on palpation 
and visual inspection to discriminate tumor tissue from normal tissue. The distinction 
between tumor and normal tissue is often not evident, resulting in irradical resections 
in 5 to 40% of patients undergoing breast-conserving surgery, which requires additional 
resection or intensified radiotherapy regimens.33-35 Particularly, after neoadjuvant 
chemotherapy the assessment of remnant cells may be difficult and tumor response 
can be either under- or overestimated owing to fibrosis, weakening of the tumor 
margins and resolution of edema. Local recurrence rates following breast-conservative 
therapy of 6.7 to 11% are reported,36 which can be explained by remnant tumor tissue 
that is not identified during surgery. Loco regional recurrences are associated with a 
decrease in overall survival.36 Therefore, there is a need for a diagnostic tool that can 
discriminate tumor tissue from normal tissue in real-time during surgery.
Optical imaging using near-infrared (NIR) fluorescence is a new technique 
that can be used to visualise structures in real-time during surgery. Advantages of 
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NIR fluorescent light (700-900nm) include high tissue penetration (millimetres to 
centimetres deep) and low autofluorescence, thereby providing sufficient contrast.37 
Because the human eye is insensitive to NIR wavelengths, the use of NIR light does 
not alter the surgical field. Several imaging systems have recently become available 
that are capable of visualizing NIR fluorescence in real-time (reviewed in 38). Besides 
these imaging systems, tumor-targeted NIR fluorescent contrast agents (“probes”) are 
necessary to visualize cancer cells. Various mechanisms are available for probes to target 
tumor cells: they can target increased metabolism, upregulated enzymes, or specific 
cell surface markers. Therefore, the use of NIR fluorescence imaging can be of great 
value in the intraoperative detection of critical anatomical structures and oncologic 
targets. The ultimate goal of NIR fluorescence imaging is a real-time visualization of 
cancer cells during surgery in order to achieve an increase of the radical resection rate 
and thereby an improvement in breast cancer outcome. 
In Chapter 8, a novel, hand-held, intraoperative NIR fluorescence imaging 
system is tested. The minimal detection limits, resolving power and intraoperative 
utility are addressed in primary breast cancer and metastatic colorectal cancer in two 
syngeneic rat models. 
In Chapter 9, the technique of NIR fluorescence imaging is assessed in a 
syngeneic breast cancer rat model using a protease-activated NIR probe and the 
accuracy is determined of intraoperative tumor detection to obtain an adequate 
tumor-free resection margin.
In Chapter 10, the technique of NIR fluorescence imaging is assessed in a 
syngeneic breast cancer rat model using monoclonal antibodies conjugated to a NIR 
fluorescence dye and its utility for image-guided resection is tested. 
sentinel lymph node mapping
The sentinel lymph node (SLN) procedure, as introduced in the treatment of breast 
cancer by Giuliano et al,11 is currently regarded as standard of care in staging of the 
axilla. The SLN is the first lymph node that receives lymphatic drainage from a tumor, 
and identification of the SLN and analysis for tumor involvement should predict the 
status of the remaining lymph nodes. 
Despite widespread acceptance of SLN procedure, the current technique can be 
improved. The SLN procedure utilizes a gamma ray-emitting radiotracer or a blue dye 
or a combination. Radiocolloids require involvement of a nuclear medicine physician, 
can be difficult to localize with a handheld gamma probe and there is some exposure to 
ionizing radiation. Moreover, the time-window for SLN identification after injection 
of the radiocolloid is limited. Blue dyes cannot be seen easily through skin and fat and 
allow limited visualization of afferent lymphatic vessels and the SLN. Surgical time 
needed to complete the SLN procedure may take up to 30-45 minutes, in particular 
when identification is difficult, requiring extensive axillary exploration.
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NIR fluorescence imaging using the NIR fluorescence agent indocyanine 
green has the potential to provide an alternative for, or an addition to, conventional 
techniques used for SLN mapping.39 Indocyanine green (ICG) is currently the only 
clinically available NIR fluorophore that can be used for SLN mapping. Preclinically, 
ICG adsorbed to human serum albumin (ICG:HSA) improves its performance as a 
lymphatic tracer. The benefit of ICG:HSA for SLN mapping of breast cancer has not 
yet been assessed in a clinical trial. 
In Chapter 11, the development of a miniaturized version of the fluorescence-
assisted resection and exploration (FLARE) imaging system is described. Using this 
Mini-FLARE, preclinical and clinical optimization of the lymphatic tracer ICG:HSA 
was performed, followed by a more refined optimization in a phase II clinical trial. 
During this dose-escalating trial, the use of NIR fluorescence was directly compared 
with the combination of radioactive colloid and blue dye in breast cancer patients 
undergoing SLN mapping. 
In Chapter 12, a double-blind, randomized clinical study is performed to 
determine if ICG:HSA has advantages over ICG alone in the SLN mapping in breast 
cancer. 
Finally, Chapter 13 includes a summary of this thesis as well as a general discussion. 
Chapter 14 provides a summary in Dutch.
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Chapter 2
neoadjuvant chemotherapy for operable 
breast cancer: a Cochrane systematic 
review
Mieog JSD, van der Hage JA, van de Velde CJH
Br J Surg 2007; 94:1189-200 and Cochrane Database Syst Rev 2007: CD005002




Neoadjuvant chemotherapy for early breast cancer can avoid mastectomy by shrinkage 
of tumor volume. Additional potential advantages are early introduction of systemic 
therapy, determination of chemosensitivity and early availability of prognostic 
information. However, concerns exist about local control after downsized surgery and 
the delay of local treatment in patients with tumors resistant to chemotherapy. This 
review assesses the effectiveness of neoadjuvant chemotherapy on clinical outcome.
methods 
All randomized trials comparing neoadjuvant and adjuvant chemotherapy for early 
breast cancer were assessed for eligibility and quality, and data were extracted by two 
independent reviewers. Hazard ratios (HR) were derived for time-to-event outcomes 
directly or indirectly using the methods described by Parmar et al. Relative risks were 
derived for dichotomous outcomes. Meta-analyses were performed using fixed effect 
model.
Results
Fourteen studies randomizing 5,500 women were eligible for analysis. Median follow-
up ranged from 18 to 124 months. Eight studies described a satisfactory method of 
randomization. Overall survival was equivalent in both groups. In the neoadjuvant 
group, the mastectomy rate was lower (relative risk = 0.71, 95% CI = 0.67 to 0.75, 
P < .0001) without hampering local control (HR = 1.12, 95% CI = 0.92 to 1.37, P 
= .25). Neoadjuvant chemotherapy was associated fewer adverse effects. Pathological 
complete response is associated with better survival than residual disease (HR = 0.48, 
95% CI = 0.33 to 0.69, P < .0001).
Conclusion
Neoadjuvant chemotherapy is an established treatment option for early breast cancer 
in order to down stage surgical requirement, to evaluate chemosensitivity and to 
facilitate translational research.
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IntRoduCtIon
Neoadjuvant, or preoperative, chemotherapy is the administration of chemotherapy 
before surgical treatment. Its use in breast cancer was introduced in the early 
1980s in patients with locally advanced disease in order to convert inoperable into 
operable tumors.1 Soon after achieving positive results in the locally advanced setting, 
randomized controlled trials were conducted to evaluate the technique for earlier, 
operable stages. A major benefit of neoadjuvant chemotherapy is its potential to 
increase breast conservation, which is associated with less morbidity and improved 
body image compared with complete breast removal.2 However, there is concern about 
local control after down staging of the tumor and the delay to surgery in patients with 
tumors resistant to chemotherapy.
In their recently published meta-analysis on neoadjuvant and adjuvant 
chemotherapy, Mauri and colleagues3 reported equivalent overall and disease-free 
survival rates, but an increased loco regional recurrence risk in the neoadjuvant group, 
particularly when surgery was withheld. However, this analysis excluded studies for 
which no peer-reviewed journal publication was available.4 In addition, relative risks 
(RRs) for time-to-event data were used, whereas the hazard ratio (HR) would be a more 
appropriate statistic when individual patient data are not available.5, 6 Furthermore, the 
change of local treatment in the neoadjuvant group was not assessed in a quantitative 
way and adverse effects were not analyzed. Finally, since the appearance of this 
publication, several studies have reported long-term follow-up results.
In the present report, the available evidence from randomized controlled trials 
is reviewed systematically to assess the effectiveness of neoadjuvant chemotherapy, 
compared with adjuvant chemotherapy, on treatment-related outcomes in women 
with operable breast cancer. The association between breast conservation surgery and 
loco regional recurrence is analyzed in detail. A substantial version of this review has 
appeared in the Cochrane Library.
mAteRIAl And metHods
search, selection and data collection
The Specialised Register maintained by the Editorial Base of the Cochrane Breast 
Cancer Group (CBCG) was searched using the codes ‘early’, ‘locally advanced’ and 
‘chemo’. The register includes both published and unpublished (including ongoing) 
trials and applies no language restrictions. Details of the search strategy are described 
in the Group’s module in The Cochrane Library. Properly randomized controlled trials 
were selected that compared neoadjuvant with adjuvant chemotherapy in women with 
operable breast cancer (T1–3 N0–2 M0; American Joint Committee on Cancer stages 
Thesis Mieog.indb   25 22-09-11   19:49
26 Chapter 2
I–IIIA). Two independent reviewers assessed eligibility and quality, and extracted data 
from the included trials. Disagreements were resolved by consensus. Data were entered 
into Review Manager 4.2.7 and analyzed using Review Manager 1.0.2 (Cochrane 
Collaboration, Oxford, UK).
data analysis
Time-to-event outcomes were overall survival and time to loco regional recurrence 
as first event, for which the HR is the most appropriate statistic.5, 6 When possible, the 
HR and associated variances were extracted directly from the trial publication. If not 
reported, they were obtained indirectly using the methods described by Parmar et al.7 
and the Excel® (Microsoft, Redmond, Washington, USA) spreadsheet developed by 
Matthew Sydes (Cancer Division) in collaboration with the Meta-analysis Group of 
the Medical Research Council Clinical Trials Unit, London. To allow for immature 
follow-up, the numbers at risk were adjusted based on estimated minimum and 
maximum follow-up times. A pooled HR was obtained from the derived observed 
minus expected number of events and the variance for each trial using the fixed-
effect model.8 The pooled HR represents the overall risk of an event associated with 
neoadjuvant versus adjuvant chemotherapy.
The association between pathological complete response and overall survival 
was analyzed in the neoadjuvant treatment arm. Pathological complete response was 
defined as complete disappearance of invasive carcinoma on histological examination 
after chemotherapy. The survival rate of patients with a complete response was 
compared with that of patients with residual disease using the univariate meta-analysis 
technique described above.
For loco regional treatment, data were used from studies in which the treatment 
protocol allowed the derivation of differences in breast conservation rate, preferably 
after follow-up, between research and control arms to calculate RRs. Mastectomy was 
scored as an event. Patients with no information available on loco regional treatment 
were excluded from the analyses. In the neoadjuvant group, the change in originally 
planned local treatment strategy was analyzed and the local recurrence rate in patients 
with down staged breast conservation versus preplanned breast conservation was 
compared. For adverse effects, the number of World Health Organization grade III 
and IV events of postoperative complications, cardiotoxicity, chemotherapy-related 
infectious complications (leucopenia, neutropenia or infection), nausea and vomiting, 
and alopecia were extracted. For these outcomes, a pooled RR was obtained using the 
fixed-effect (Mantel–Haenszel) model. For clinical interpretation, the pooled RR was 
converted to risk difference and numbers needed to treat (NNT).
The I2 statistic was used to test for heterogeneity across studies.9 An I2 value 
greater than 50% was considered to represent substantial heterogeneity. Subgroup 
analyses were conducted for treatment arm (neoadjuvant, ‘sandwich’) and loco 
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regional treatment (breast-conserving surgery, mastectomy, exclusive radiotherapy). 
χ2 tests for interaction were applied to these subgroup analyses.10 Publication bias was 




On 4 August 2005, the Specialised Register of the CBCG contained 5,749 references 
of which 753 were identified during the search (Figure 1). After detailed evaluation 
of 73 references, 14 were included in this review (Table 1). In total, 5,500 women 
were randomized to either neoadjuvant or adjuvant chemotherapy. Median follow-
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resolved by consensus. Data were entered into Review
Manager 4.2.7 and analysed using Review Manager 1.0.2
(Cochrane Collaboration, Oxford, UK).
Data analysis
Time-to-event outcomes were overall survival and time
to locoregional recurrence as first event, for which the
HR is the most appropriate statistic5,6. When possible,
the HR and associated variances were extracted directly
from the trial publication. If not reported, they were
obtained indirectly using the methods described by Parmar
et al.7 and the Excel (Microsoft, Redmond, Washington,
USA) spreadsheet developed by Matthew Sydes (Cancer
Division) in collaboration with the Meta-analysis Group
of the Medical Research Council Clinical Trials Unit,
London. To allow for immature follow-up, the numbers
at risk were adjusted based on estimated minimum and
maximum follow-up times. A pooled HR was obtained from
the derived observed minus expected number of events and
the variance for each trial using the fixed-effect model8.
The pooled HR represents the overall risk of an event
associated with neoadjuvant versus adjuvant chemotherapy.
The association between pathological complete response
and overall survival was analysed in the neoadjuvant
treatment arm. Pathological complete response was defined
as complete disappearance of invasive carcinoma on
histological examination after chemotherapy. The survival
rate of patients with a complete response was compared
with that of patients with residual disease using the
univa iate met -analysis technique described above.
For locoregional treatment, data were used from studies
in which the treatment protocol allowed the derivation
References to RCTs and CCTs in the
Specialised Register of the Cochrane
Breast Cancer Group (n = 5749)
Potentially relevant references to
RCTs identified and screened for
retrieval (n = 190)
References to RCTs retrieved for
more detailed evaluation (n = 73)
Potentially appropriate RCTs to
be included in the meta-analysis
(n = 19)
References to RCTs excluded (n = 563)
Preoperative versus preoperative (n = 52)
References coded as early stage
or locally advanced and
chemotherapy (n = 753)
Change to originally planned surgery (n = 5)
RCTs included in meta-analysis (n = 14)
RCTs with usable information, by outcome
Overall survival (n = 10)
Time to locoregional recurrence (n = 11)
Type of locoregional treatment (n = 10)
Adverse effects (n = 7)
Pathological complete response (n = 4)
References to RCTs excluded (n = 117)
References to RCTs excluded (n = 54)
Adjuvant chemotherapy (n = 65)
Adjuvant chemotherapy (n = 2)
Not properly randomized (n = 3)
References to RCTs excluded from
meta-analysis (n = 5)
Preoperative versus preoperative (n = 10)
No data extractable (n = 3)
Improper randomization (n = 1)
Additional references to RCTs already
   included or excluded (n = 39)
Part of NSABP-B18 (n = 1) 
Fig. 1 Flow chart of papers assessed for analysis. Search strategy applied 4 August 2005. RCT, randomized controlled trial; CCT,
controlled clinical trial; NSABP, National Surgical Adjuvant Breast and Bowel Project
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figure 1. flow chart of papers assessed for analysis. Search strategy applied 4 August 2005. RCT, randomized 
controlled trial; CCT, controlled clinical trial; NSABP, National Surgical Adjuvant Breast and Bowel Project.
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up ranged from 24 to 124 months. In eight studies, patients in the neoadjuvant arm 
received part of the chemotherapy courses after local treatment.12, 15, 17, 19-21, 23, 24 In seven 
studies, tamoxifen was administered to eligible patients and started after surgery.14, 16, 
19, 20, 22, 23, 25 In one study, tamoxifen was administered before surgery.23 Four studies gave 
both groups the same local treatment.15, 19, 20, 24 Three studies administered preoperative 
radiotherapy.17, 18, 24 Eight studies described a satisfactory method of randomization.13, 
14, 16, 19, 22-24 Six studies reported a satisfactory method of concealment of allocation.15, 16, 
21-23, 25 The randomization method was not reported in the remaining studies. Overall, 
98.2% of the patients included in time-to-event outcomes were analyzed by intention 
to treat. For loco regional treatment, data on 5,292 (97.0%) of the 5,453 women 
randomized were available for analysis. For adverse effects, data on 3,382 (96.9%) of 
the 3,490 patients randomized were available for analysis.
Table 1. Characteristics of the included studies 
Study Inclusion 
period












Neo Adj Neo Adj Neo Adj
ABCSG12 1991-1999 423 II-IIIA CMF (3 of 6)a n.a. n.a. n.a. n.a. n.a. 33 41
Bordeaux13 1985-1989 272 II-IIIA EVM/MTV (6 of 6) 124 62 59 23 9 55b 100
ECTO14 1996-2002 902c II-IIIA AT + CMF (4 of 4) 50 87 90 3 4 35 66
Edinburgh15 n.a. 79 II-IIIA CAP (4 of 6)d n.a. n.a. n.a. n.a. n.a. 100 100
EORTC16 1991-1999 698 I-IIIA FEC (4 of 4) 120 65 66 14 13 63 77
Institut Curie17 1983-1986 196 II-IIIA FAC (2 of 6) 54 n.a. n.a. 18 20 23 36
Institut Curie18 1986-1990 414 II-IIIA FAC (2 of 6) 105 65 60 27e 19e 37f 35f
Japan19 1995-1997 50 II-III FEC (2 of 5) 24 84 80 10 8 100 100
Lithuania20 1994-1997 100 II CMF (2 of n.a.) 42 n.a. n.a. 2 6 0 0
London21 1990-1993 210 I-IIIA MMM (4 of 8)d > 60 78 87 20 16 11 8
NSABP22 1988-1993 1523 I-IIIA AC (4 of 4) 114g 69 70 15 13 32 40
Royal 
Marsden23
1990-1995 309 I-IIIA MM(M) (4 of 4) 112 70 63 9 6 11 22
St Petersburg24 1985-1990 271 IIb-IIIa TMF (1-2 of 6) 53 86 78 n.a. n.a. 100 100
USA25 1990-1998 53 II FLAC + G(M)-CSF 
(5 of 5)
108 87 72 12 7 58 59
* Values in parentheses are number of courses given before operation as a proportion of total number 
of courses. a Lymph node-positive patients received three courses of epirubicin, cyclophosphamide 
after surgery. b After 10 year median follow-up initial rate was 37%. c Three-arm study; second 
postoperative arm included 453 patients. d Patients with estrogen-positive tumors received endocrine 
therapy. e After 5-year median follow-up. f After 5-year median follow-up. Initial rate was 18%. g Mean. 
 
ABCSG, Austrian Breast and Colorectal Cancer Study Group; ECTO, European Cooperative Trial in Operable 
Breast Cancer; EORTC, European Organization for Research and Treatment of Cancer; NSABP, National 
Surgical Adjuvant Breast and Bowel Project. CMF, cyclophosphamide, methotrexate, fluorouracil; EVM/
MTV, epirubicin, vincristine, methotrexate/mitomycin C, thiotepa, vindesine; AT, doxorubicin, paclitaxel; 
CAP, cyclophosphamide, doxorubicin, prednisolone; FEC, fluorouracil, epirubicin, cyclophosphamide; 
FAC, fluorouracil, doxorubicin, cyclophosphamide; MMM, mitozantrone, mitomycin C, methotrexate; AC, 
doxorubicin, cyclophosphamide; TMF, thiotepa, methotrexate, fluorouracil; FLAC, fluorouracil, leucovorin, 
doxorubicin, cyclophosphamide; GM-CSF, granulocyte–macrophage colony-stimulating factor; n.a., not available.
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meta-analyses
Overall survival
Ten studies reported overall survival data on 4,620 randomized women and 1,139 
estimated deaths. There was no survival difference between neoadjuvant and adjuvant 
chemotherapy (HR = 0.98, 95% CI = 0.87 to 1.09; Figure 2). The associated funnel 
plot shows a symmetrical distribution (Figure 3). Of note, no study demonstrated a 
significant effect in favor of neoadjuvant or adjuvant chemotherapy.
1192 J. S. D. Mieog, J. A. van der Hage and C. J. H. van de Velde
local treatment15,19,20,24. Three studies administered pre-
operative radiotherapy17,18,24. Eight studies described a
satisfactory method of randomization13,14,16,19,22–24. Six
studies reported a satisfactory method of concealment of
allocation15,16,21–23,25. The randomization method was not
reported in the remaining studies. Overall, 98·2 per cent
of the patients included in time-to-event outcomes were
analysed by intention to treat. For locoregional treatment,
data on 5292 (97·0 per cent) of the 5453 women random-
ized were available for analysis. For adverse effects, data on




Ten studies reported overall survival data on 4620
randomized women and 1139 estimated d aths. There was
no survival difference between neoadjuvant and adjuvant
chemotherapy (HR 0·98 (95 p r cent co fidence interval
(c.i.) 0·87 to 1·09)) (Fig. 2). The associated funnel plot
shows a symmetrical distribution (Fig. 3). Of note, no study
demonstrated a significant effect in favour of neoadjuvant
or adjuvant chemotherapy.
Locoregional recurrence
Eleven studies reported time to locoregional recurrence
data on 5041 randomized women and 570 estimated
recurrences. There was a significant difference in
favour of adjuvant chemotherapy (Fig. 4). However, in
three studies, more than one-third of patients received
exclusive radiotherapy and no surgery after complete
tumour regression13,17,18. The recurrence rates for these
patients were reported separately in only one study13.
In this study, after a 10-year follow-up there was a
































































Test for heterogeneity: c2 = 5·16, 5 d.f., P = 0·40, I2 = 3·1%






Test for heterogeneity: c2 = 1·52, 3 d.f., P = 0·68, I2 = 0%
Test for overall effect: Z = 0·87, P = 0·39
'Sandwich'
Test for heterogeneity: c2 = 7·26, 9 d.f., P = 0·61, I2 = 0%
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Fig. 2 Overall survival of patients who had neoadjuvant or adjuvant chemotherapy stratified by treatment arm protocol (neoadjuvant or
‘sandwich’). Hazard ratios are given with 95 per cent confidence intervals. NSABP, National Surgical Adjuvant Breast and Bowel
Project; ECTO, European Cooperative Trial in Operable Breast Cancer; EORTC, European Organization for Research and
Treatment of Cancer
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figure 2. overall survival of patients who had neoadjuvant or adjuvant chemotherapy stratified by 
treatment arm p ot col (n oadjuvant or ‘sa dwi h’). H zard ratios re given with 95% CI. NSABP, National 
Surgical Adjuvant Breast and Bowel Project; ECTO, European Cooperative Trial in Operable Breast Cancer; 
EORTC, European Organization for Research and Treatment of Cancer.
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Fig. 3 Funnel plot of the studies reporting on overall survival.
The symmetrical distribution indicates a low risk of publication
bias
was omitted after neoadjuvant chemotherapy. Therefore,
it was decided to exclude these studies from the
analysis of locoregional recurrence, because of inadequate
locoregional treatment. After this exclusion, the remaining
eight studies demonstrated no difference in locoregional
recurrence rate between the neoadjuvant and adjuvant
groups (HR 1·12 (95 per cent c.i. 0·92 to 1·37)).
When patients were analysed according to type of
surgery, locoregional recurrence rates were not influenced
by the timing of chemotherapy in those who had breast-
conserving surgery or women who underwent mastectomy
(Fig. 5). Two studies reported a non-significant increase in
locoregional recurrence in patients who could be treated by
breast-conserving surgery because of downstaging of the
tumour compared with patients for whom the initial plan
before the administration of neoadjuvant chemotherapy









































































Test for heterogeneity: c2 = 3·22, 7 d.f., P = 0·86, I2 = 0%





Test for heterogeneity: c2 = 5·67, 2 d.f., P = 0·06, I2 = 64·7%
Test for overall effect: Z = 2·36, P = 0·02
Inadequate local treatment
Test for heterogeneity: c2 = 10·76, 10 d.f., P = 0·38, I2 = 7.0%
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Fig. 4 Time to locoregional recurrence in patients who had neoadjuvant or adjuvant chemotherapy. Hazard ratios are given with
95 per cent confidence intervals. The pooled result excluding three studies that omitted surgery in a vast proportion of patients showed
a non-significant increase in the neoadjuvant group. This recurrence rate was lower than that in the three excluded trials (χ2 for
difference = 1·66, 1 d.f., P = 0·20). ECTO, European Cooperative Trial in Operable Breast Cancer; NSABP, National Surgical
Adjuvant Breast and Bowel Project; EORTC, European Organization for Research and Treatment of Cancer
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figure 3. funnel plot of the studies reporting on overall survival. The symmetrical distribution indicates a 
low risk of publication bias.
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Loco regional recurrence
Eleven studies reported time to loco regional recurrence data on 5,041 randomized 
women and 570 estimated recurrences. There was a significant difference in favor of 
adjuvant chemotherapy (Figure 4). However, in three studies, more than one-third 
of patients received exclusive radiotherapy and no surgery after complete tumor 
regression.13, 17, 18 The recurrence rates for these patients were reported separately in 
only one study.13 In this study, after a 10-year follow-up, there was a loco regional 
recurrence rate of 30% when surgery was omitted after neoadjuvant chemotherapy. 
Therefore, it was decided to exclude these studies from the analysis of loco regional 
recurrence, because of inadequate loco regional treatment. After this exclusion, the 
remaining eight studies demonstrated no difference in loco regional recurrence rate 
between the neoadjuvant and adjuvant groups (HR = 1.12, 95% CI = 0.92 to 1.37, P = 
.25). 
When patients were analyzed according to type of surgery, loco regional 
recurrence rates were not influenced by the timing of chemotherapy in those who 
had breast-conserving surgery or women who underwent mastectomy (Figure 5). 
Two studies reported a non-significant increase in loco regional recurrence in patients 
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Fig. 3 Funnel plot of the studies reporting on overall survival.
The symmetrical distribution indicates a low risk of publication
bias
was omitted after neoadjuvant chemotherapy. Therefore,
it was ecided to exclude these studies from the
analysis of locoregional recurrence, because of inadequate
locoregional treatment. After this exclusion, the remaining
eight studies demonstrated no difference in locoregional
recurrence rate between the neoadjuvant and adjuvant
groups (HR 1·12 (95 per cent c.i. 0·92 to 1·37)).
When patients were analysed according to type of
surgery, locoregional recurrence rates were not influenced
by the timing of chemotherapy in those who had breast-
conserving surgery or women who underwent mastectomy
(Fig. 5). Two studies reported a non-significant increase in
locoregional recurrence in patients who could be treated by
breast-conserving surgery because of downstaging of the
tumour compared with patients for whom the initial plan
before the administration of neoadjuvant chemotherapy









































































Test for heterogeneity: c2 = 3·22, 7 d.f., P = 0·86, I2 = 0%





Test for heterogeneity: c2 = 5·67, 2 d.f., P = 0·06, I2 = 64·7%
Test for overall effect: Z = 2·36, P = 0·02
Inadequate local treatment
Test for heterogeneity: c2 = 10·76, 10 d.f., P = 0·38, I2 = 7.0%
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Fig. 4 Time to locoregional recurrence in patients who had neoadjuvant or adjuvant chemotherapy. Hazard ratios are given with
95 per cent confidence intervals. The pooled result excluding three studies that omitted surgery in a vast proportion of patients showed
a non-significant increase in the neoadjuvant group. This recurrence rate was lower than that in the three excluded trials (χ2 for
difference = 1·66, 1 d.f., P = 0·20). ECTO, European Cooperative Trial in Operable Breast Cancer; NSABP, National Surgical
Adjuvant Breast and Bowel Project; EORTC, European Organization for Research and Treatment of Cancer
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fi ure 4. ime to loco regional recurrence in patients who h d neoadjuvant or adjuvant ch motherapy. 
Hazard ratios are given with 95 per cent confidence intervals. The pooled result excluding three studies that 
omitted surgery in a vast proportion of patients showed a non-significant increase in the neoadjuvant group. 
This recurrence rate was lower than that in the three excluded trials (χ2 for difference = 1.66, 1 d.f., P = .20). 
ECTO, European Cooperative Trial in Operable Breast Cancer; NSABP, National Surgical Adjuvant Breast and 
Bowel Project; EORTC, European Organization for Research and Treatment of Cancer.
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who could be treated by breast-conserving surgery because of down staging of the 
tumor compared with patients for whom the initial plan before the administration of 
neoadjuvant chemotherapy was breast-conserving surgery (Figure 6).




































Test for heterogeneity: c2 = 3·98, 3 d.f., P = 0·26, I2 = 24·5%



























Test for heterogeneity: c2 = 2·09, 3 d.f., P = 0·55, I2 = 0%
Test for overall effect: Z = 0·58, P = 0·56
Subtotal
Test for heterogeneity: not applicable
Test for overall effect: not applicable
Exclusive radiotherapy
Test for heterogeneity: c2 = 6·08, 7 d.f., P = 0·53, I2 = 0%
Test for overall effect: Z = 0·94, P = 0·35
Total
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Fig. 5 Locoregional recurrence rates in patients who had neoadjuvant or adjuvant chemotherapy stratified by type of surgery. Relative
risks are given with 95 per cent confidence intervals. There was no difference between breast-conserving surgery and mastectomy
(χ2 = 0·01, 1 d.f., P = 0·92). ECTO, European Cooperative Trial in Operable Breast Cancer; EORTC, European Organization for
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Test for heterogeneity: c2 = 0·70, 1 d.f., P = 0·40, I2 = 0%
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Fig. 6 Locoregional recurrence rates in the neoadjuvant group after downstaged versus preplanned breast-conserving surgery (BCS).
Relative risks are given with 95 per cent confidence intervals (c.i.). The recurrence rate was non-significantly higher in the downstaged
group, represented by a risk difference of 7·5 (95 per cent c.i. 1·7 to 13·2) per cent; risk in adjuvant group was 11·1 per cent. EORTC,
European Organization for Research and Treatment of Cancer; NSABP, National Surgical Adjuvant Breast and Bowel Project
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figure 5. loco regional recurrence rates in patients who had neoadjuvant or adjuvant chemotherapy 
stratified by type of surgery. Relat ve risks are give  with 95% CI. There was no diffe ence betwe n breast-
conserving surgery and mastectomy (χ2 = 0.01, 1 d.f., P = .92). ECTO, European Cooperative Trial in Operable 
Breast Cancer; EORTC, European Organization for Research and Treatment of Cancer; NSABP, National 
Surgical Adjuvant Breast and Bowel Project.




































Test for heterogeneity: c2 = 3·98, 3 d.f., P = 0·26, I2 = 24·5%



























Test for heterogeneity: c2 = 2·09, 3 d.f., P = 0·55, I2 = 0%
Test for overall e fect: Z = 0·58, P = 0·56
Subt tal
Test for h terogeneity: not applicable
Test for overall effect: not applicable
Exclusive radiotherapy
Test for heterogeneity: c2 = 6·08, 7 d.f., P = 0·53, I2 = 0%
Test for overall effect: Z = 0·94, P = 0·35
Total
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Fig. 5 Locoregional recurrence rates in patients who had neoadjuvant or adjuvant chemotherapy stratified by type of surgery. Relative
risks are given with 95 per ce t confidence intervals. There was no difference between breast-conserving surgery and mastectomy
(χ2 = 0·01, 1 d.f., P = 0·92). ECTO, European Cooperative Trial in Operable Breast Cancer; EORTC, European Organization for
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Test for heterogeneity: c2 = 0·70, 1 d.f., P = 0·40, I2 = 0%









0·5 1 2 5
Fig. 6 Locoregional recurrence rates in the neoadjuvant group after downstaged versus preplanned breast-conserving surgery (BCS).
Relative risks are given with 95 per cent confidence intervals (c.i.). The recurrence rate was non-significantly higher in the downstaged
group, represented by a risk difference of 7·5 (95 per cent c.i. 1·7 to 13·2) per cent; risk in adjuvant group was 11·1 per cent. EORTC,
European Organization for Research and Treatment of Cancer; NSABP, National Surgical Adjuvant Breast and Bowel Project
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fi ure 6. loco regional recurrence r tes i  the neoadjuvant group after down staged versus preplanned 
bre st-conserving surgery (BCs). Relative risks are given with 95% CI. The recurrence rate was non-
significantly higher in the down staged group, represented by a risk difference of 7.5% (95% CI = 1.7 to 13.2); 
risk in adjuvant group was 11.1%. EORTC, European Organization for Research and Treatment of Cancer; 
NSABP, National Surgical Adjuvant Breast and Bowel Project.
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Loco regional treatment
In ten studies, the protocol allowed derivation of differences in type of loco regional 
treatment after neoadjuvant chemotherapy. These studies contained 5,292 women of 
whom 2,395 underwent mastectomy (Figure 7). There was a statistically significant 
decrease in mastectomy rate in favor of neoadjuvant chemotherapy (RR = 0.71, 95% 
CI = 0.67 to 0.75, P < .001), representing a risk difference of 16.6% (95% CI = 15.1 to 
18.1; NNT = 6). Two studies accounted for the substantial heterogeneity (I2 = 83.2%) 
in the forest plot. One study had an intensive chemotherapy regimen and achieved 
high response rates, allowing more conservative treatment.14 In the other, all patients 
in the adjuvant chemotherapy arm underwent mastectomy as only those with tumors 
unsuitable for conservative treatment were included.13 The remaining eight studies (I2 
= 25.8%) showed a pooled RR of 0.82 (95% CI = 0.76 to 0.89, P < .001), representing a 
risk difference of 8.0% (95% CI = 6.3 to 9.7; NNT = 13).
Five studies reported the change in the originally planned local treatment after 
neoadjuvant chemotherapy (Table 2). Of the 1,549 assessable women, 397 (25.6%, 95% 
CI = 23.5 to 27.8) had their surgical treatment down staged; in 66 women (4.3%, 95% 
CI = 3.3 to 5.3) tumor progression necessitated more radical surgery than originally 


























































Test for heterogeneity: c2 = 9·43, 7 d.f., P = 0·22, I2 = 25·8%




Test for heterogeneity: c2 = 0·16, 1 d.f., P = 0·69, I2 = 0%








878 of 2422 1517 of 2870 100·00 0·71 (0·67, 0·75)
Test for heterogeneity: c2 = 53·66, 9 d.f., P < 0·001, I2 = 83·2%
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Fig. 7 Rate of local treatment (mastectomy) in the neoadjuvant and adjuvant chemotherapy groups. Relative risks are given with
95 per cent confidence intervals (c.i.). Two studies accounted for the substantial heterogeneity (χ2 for difference = 44·07, 1 d.f.,
P < 0·001). Neoadjuvant chemotherapy reduced the absolute mastectomy rate by 16·6 (95 per cent c.i. 15·1 to 18·1) per cent; risk in
adjuvant group was 52·9 per cent. NSABP, National Surgical Adjuvant Breast and Bowel Project; EORTC, European Organization for
Research and Treatment of Cancer; ABCSG, Austrian Breast and Colorectal Cancer Study Group; ECTO, European Cooperative
Trial in Operable Breast Cancer
Table 2 Change of local treatment after neoadjuvant chemotherapy
Study BCS → BCS Mast. → Mast. Mast. → BCS Mast. → RT BCS → RT BCS → Mast. Total
Bordeaux13 — 49 40 44 0 0 133
EORTC16 60 190 60 0 0 14 324
Institut Curie18 — 36 62 102 0 0 200
NSABP22 435 187 69 0 0 52 743
Royal Marsden23 113 16 19 0 1 0 149
Total 608 478 250 146 1 66 1549
Surgical requirement was downstaged in 397 women (25·6 (95 per cent confidence interval 23·5 to 27·8) per cent). BCS, breast-conserving surgery; Mast.,
modified radical mastectomy; RT, radiotherapy; EORTC, European Organization for Research and Treatment of Cancer; NSABP, National Surgical
Adjuvant Breast and Bowel Project.
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figure 7. mastectomy rate in the neoadjuvant and adjuvant chemotherapy groups. Two studies accounted 
for the substantial heterogeneity (χ2 for difference = 44.07, 1 d.f., P < .001). Neoadjuvant chemotherapy 
re ced the absolute mastectomy rate by 16.6% (95% CI = 15.1 to 18.1); risk in adjuvant group was 52.9%. 
NSABP, National Surgical Adjuvant Breast and Bowel Project; EORTC, European Organization for Research 
and Treatment of Cancer; ABCSG, Austrian Breast and Colorectal Cancer Study Group; ECTO, European 
Cooperative Trial in Operable Breast Cancer.
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Pathological complete response
Four studies reported overall survival data in association with a pathological complete 
response in a total of 1,290 assessable women; there were 381 estimated deaths.16, 22-24 
In these studies the pathological complete response rate ranged from 4.0 to 29.2%. 
Patients with a pathological complete response had improved overall survival (HR = 
0.48, 95% CI = 0.33 to 0.69, P < .001).
Adverse effects
Four studies reported infectious complications due to chemotherapy. The data set 
consisted of 327 events in 2,799 women. A significant decrease in the rate of such 
complications in the neoadjuvant chemotherapy group was demonstrated (RR = 0.69, 
95% CI = 0.56 to 0.84, P < .001) with an absolute risk difference of 4.2% (95% CI = 
2.3 to 5.6; NNT = 24; Figure 8). Cardiotoxicity events were less frequent in women 
receiving neoadjuvant chemotherapy (RR = 0.74, 95% CI = 0.53 to 1.04, P = .08).
dIsCussIon
This review demonstrates that neoadjuvant chemotherapy results in overall survival 
rates equivalent to those associated with adjuvant chemotherapy, while permitting 
more breast-conserving therapy. Neoadjuvant treatment is associated with a decrease 
in adverse events and does not adversely affect loco regional control of disease. The 
findings relating to time-to-event data are in concordance with those of the earlier 
meta-analysis of Mauri and colleagues.3 However, more studies were available for 
analysis in the present review and Cochrane Collaboration methodology was used.6
The present study, however, has some limitations. First, the maximum median 
follow-up of the included studies is 10 years, which may be too short to identify 
differences in clinical outcome. The latest Early Breast Cancer Trialists’ Collaborative 
Group report demonstrated the importance of extended follow-up (15–20 years) in 
Table 2. Change of local treatment after neoadjuvant chemotherapy 
Study BCS → BCS Mast → Mast Mast → BCS Mast → RT BCS → RT BCS → Mast Total
Bordeaux13 — 49 40 44 0 0 133
EORTC16 60 190 60 0 0 14 324
Institut Curie18 — 36 62 102 0 0 200
NSABP22 435 187 69 0 0 52 743
Royal Marsden23 113 16 19 0 1 0 149
Total 608 478 250 146 1 66 1549
Surgical requirement was down staged in 397 women (25.6% (95% CI = 23.5 to 27.8)). 
BCS, breast-conserving surgery; Mast, modified radical mastectomy; RT, radiotherapy; EORTC, European 
Organization for Research and Treatment of Cancer; NSABP, National Surgical Adjuvant Breast and Bowel 
Project.
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early-stage breast cancer trials.26 Furthermore, this report estimated that for every four 
recurrences one breast cancer death can be avoided over the next 15 years. Another 
limitation is that seven of the 11 studies reporting on loco regional recurrence 
provided this outcome as a RR instead of a HR,13, 14, 18-20, 22, 25 thereby adversely affecting 
the accuracy of the pooled analysis. Third, the effect of neoadjuvant chemotherapy 
on breast conservation may be overestimated by detection and performance bias; the 
unblinded physician assessing tumor response may be more prone to advising breast-
conserving therapy. Moreover, as time passes and recurrences develop, subsequent 
salvage mastectomies will decrease the breast conservation rate. Most studies reported 
only the initial breast conservation rates. Despite these limitations, the included studies 
were properly randomized and study quality was generally adequate. In addition, the 
funnel plot showed a symmetrical distribution suggesting a low risk of publication 
bias.
Neoadjuvant chemotherapy increases the breast conservation rate. It is well 
known that breast-conserving surgery is associated with a higher loco regional 
recurrence rate than mastectomy, without, however, affecting long-term overall 
survival.27 The limited and non-significant increase in loco regional recurrence 
rate in the neoadjuvant group can, therefore, be explained by the increased breast 
conservation rate and the fact that a substantial proportion of patients in three 
studies had no surgery after neoadjuvant chemotherapy. To date, direct evidence of 
local recurrence after down staged surgery following neoadjuvant chemotherapy is 
still lacking. In the present analysis, no clear risk difference between down staged and 
preplanned conservative surgery could be found. However, this indirect comparison is 
based on limited data without correction for confounding effects.
This review demonstrates that the increased local recurrence rate associated 
with neoadjuvant treatment is greatly reduced after excluding studies in which 
patients received exclusive radiotherapy after complete tumor regression. This finding 
emphasizes the importance of incorporating surgery in the loco regional treatment 
strategy after neoadjuvant chemotherapy. Otherwise stated, the clinical assessment of 
tumor response by conventional means is insufficiently sensitive safely to withhold 
surgery. Recently, the introduction of magnetic resonance imaging (MRI) in the 
monitoring of tumor response has been shown to be of benefit in the assessment of 
surgical strategy after down staging by neoadjuvant chemotherapy.28 However, concern 
exists about the higher false-positive rate of MRI.29
The rate of chemotherapy-related infectious complications was significantly 
lower in the neoadjuvant group. However, no obvious explanation is available. The 
actual number of chemotherapy courses received was equal in both treatment arms. 
It is possible that the immune system of patients who underwent primary surgery 
was already depressed as a result of surgical stress, making them more vulnerable to 
the negative effects of chemotherapy. In the neoadjuvant group, on the other hand, 
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patients were able to recover from the chemotherapy before they had surgery. The 
rate of cardiotoxicity also appeared to be lower in the neoadjuvant group. Known 
factors influencing cardiotoxicity are anthracycline use, taxane use, increasing age, 
previous cardiac disease and radiotherapy. The present analysis is driven by the 
European Cooperative Trial in Operable Breast Cancer (ECTO) 2005 study.14 Because 
this study added a taxane to the anthracycline chemotherapy regimen, the assessment 
of cardiotoxicity was an important endpoint. No imbalance in prognostic variables 
or difference in method of assessment was found between the treatment arms. An 
additional literature search did not provide a satisfactory explanation for the reduced 
risk and, as it does not reach statistical significance, it may be explained simply by 
chance.
Apart from higher breast conservation rates and fewer adverse effects, 
neoadjuvant chemotherapy facilitates monitoring of tumor response. By adjusting the 
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Fig. 8 Adverse effects in the neoadjuvant and adjuvant chemotherapy groups. Relative risks are given with 95 per cent confidence
intervals. EORTC, European Organization for Research and Treatment of Cancer; ECTO, European Cooperative Trial in Operable
Breast Cancer; NSABP, National Surgical Adjuvant Breast and Bowel Project
Locoregional treatment
In ten studies, the protocol allowed derivation of
differences in type of locoregional treatment after
neoadjuvant chemotherapy. These studies contained 5292
women of whom 2395 underwent mastectomy (Fig. 7).
There was a statistically significant decrease in mastectomy
rate in favour of neoadjuvant chemotherapy (RR 0·71
(95 per cent c.i. 0·67 to 0·75)), representing a risk difference
of 16·6 (95 per cent c.i. 15·1 to 18·1) per cent (NNT 6).
Two studies accounted for the substantial heterogeneity
(I2 = 83·2 per cent) in the forest plot. One study had
an intensive chemotherapy regimen and achieved high
response rates, allowing more conservative treatment14.
In the other, all patients in the adjuvant chemotherapy
arm underwent mastectomy as only those with tumours
unsuitable for conservative treatment were included13.
The remaining eight studies (I2 = 25·8 per cent) showed
a pooled RR of 0·82 (95 per cent c.i. 0·76 to 0·89),
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fi ure 8. Adver e effects in the neoadjuvant and adjuvant chemotherapy groups. EORTC, European 
Organization for Research and Treatment of Cancer; ECTO, European Cooperative Trial in Operable Breast 
Cancer; NSABP, National Surgical Adjuvant Breast and Bowel Project.
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dose or switching to another drug in the case of treatment resistance, a patient may 
be saved the unnecessary burden of toxic side-effects.30-32 This review suggests that 
neoadjuvant chemotherapy avoids a mastectomy in about 25% of patients. Conversely, 
a small percentage of patients (< 5%) originally suitable for breast conservation will 
require a mastectomy owing to disease progression while receiving neoadjuvant 
chemotherapy. This is an ethical concern. However, the included studies did not allow 
regimen change on tumor progression and it is reasonable to expect the percentage 
to be lower if switching to other cytotoxic drugs is permitted. Concerns might also 
be raised about the postoperative and thus ‘blind’ administration of chemotherapy 
to patients with tumors resistant to therapy. Such patients receive all chemotherapy 
courses while experiencing only the harmful side-effects, whereas resistance can 
be detected and adequately dealt with in the neoadjuvant setting. Although tumor 
response rate is an important predictor of survival, its role as a surrogate endpoint in 
clinical trials remains controversial.33
The introduction of neoadjuvant therapy has had a great impact on breast cancer 
research. The assessment of tumor behavior in situ during neoadjuvant therapy and the 
correlation of this behavior with clinical outcome is an excellent model with which 
to determine the predictive role of classical and molecular tumor characteristics. The 
ultimate goal of this translational research is the introduction of tailor-made treatment 
strategies based on individual risk profiles. Neoadjuvant therapy offers an excellent 
setting in which to determine the most efficient treatment approach for an individual 
patient.34
A suggested disadvantage of neoadjuvant chemotherapy is alteration of 
the lymphatic network, hampering the accuracy of sentinel lymph node biopsy.35 
However, a recently published meta-analysis has demonstrated equivalent accuracy 
of sentinel lymph node biopsy after neoadjuvant chemotherapy and primary surgery.36 
The apparent safety of this procedure after chemotherapy could decrease the need for 
axillary lymph node dissection, thereby reducing morbidity.37 Whether this will affect 
prognosis, particularly in the situation of a clinically suspect axilla, remains unclear.
This systematic review demonstrates that neoadjuvant chemotherapy for early-
stage breast cancer is safe. It induces tumor down staging and thereby an increase in 
breast conservation. Loco regional control of disease is not significantly influenced by 
neoadjuvant chemotherapy. Finally, it is an excellent tool with which to evaluate the 
tumor in situ and to facilitate translational research.
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The aim of this retrospective study was to identify markers capable of predicting 
pathological complete (pCR) and overall clinical tumor response to preoperative 
anthracycline-based chemotherapy and clinical outcome in women with operable 
breast cancer. 
methods 
Therefore, we used the pre-treatment core biopsies from 107 patients who were 
enrolled in the EORTC trial 10902 to analyze tumor characteristics and the oncogenic 
markers Bcl-2, p53, ER, PgR, HER2, and p21. Median follow-up was 7 years (95% CI 
= 6.89 to 7.45). 
Results
pCR was seen in seven patients (6.5%) and was associated with improved overall 
survival (hazard ratio = 0.39, 95% CI = 0.05 to 2.56, P = .30). At multivariate logistic 
regression analysis, pCR was independently predicted by p53 overexpression estimated 
by immunohistochemistry (odds ratio (OR) = 16.83, 95% CI = 1.78 to 159.33, P = 
.01). Fifty-eight patients showed clinical tumor response (>50% decrease in tumor 
size), however responders experienced no benefit in clinical outcome. Clinical tumor 
response was independently predicted by p53 overexpression (OR = 5.57, 95% CI = 
1.58 to 19.65, P = .008) and small clinical tumor size (OR = 10.26, 95% CI = 2.01 to 
52.48, P = .005). At multivariate Cox regression analysis, negative pathological lymph 
node status, low tumor grade and use of tamoxifen showed improved overall survival. 
Conclusion
In conclusion, our data suggest p53 expression is of predictive significance in 
anthracycline-containing chemotherapeutic regimens. 
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IntRoduCtIon
Preoperative chemotherapy for large, but early stage breast cancer, has been subject 
of interest for over two decades. The efficacy of preoperative chemotherapy has been 
demonstrated in several prospective randomized trials showing similar survival 
and locoregional control rates in patients receiving preoperative chemotherapy and 
postoperative chemotherapy. Tumor down staging due to preoperative chemotherapy 
was found to increase breast-conserving therapy rates.1 2
Response of breast tumors following preoperative chemotherapy can be 
assessed either clinically or pathologically. Patients with responding tumors showed 
an improved overall and disease-free survival and particularly pathological complete 
response (complete disappearance of malignant cells on microscopic examination; 
pCR) is suggested as a surrogate marker for these clinical endpoints.2-5
Translational research using preoperative tumor tissue biopsies is an excellent 
study model to analyze the predictive value of different tumor characteristics for 
response to chemotherapy.6 To date, a large number of oncogenic markers in breast 
cancer have been studied using classical survival analyses.7 8 However, published data 
on the relation between tumor characteristics and pathological and clinical tumor 
response are still limited.
We have used data from a prospective randomized trial comparing pre- versus 
postoperative chemotherapy to study the correlation between pathological and clinical 
tumor response and patient and tumor characteristics. Tumor characteristics included 
oncogenic markers analyzed on pre-treatment biopsy specimens and classic tumor 
characteristics. In addition, we assessed the prognostic significance of these clinical 




All patients participated in a prospectively randomized trial (EORTC 10902) that 
compared preoperative chemotherapy versus the same chemotherapeutic regimen 
administered postoperatively in patients with operable breast cancer.1 This trial accrued 
698 women with early stage breast cancer between 1991 and 1999. The eligibility criteria 
for this trial have been described previously.1 Efforts were made to obtain diagnostic 
biopsy material from all patients randomized to preoperative chemotherapy. For the 
present analysis, we included patients who had received preoperative chemotherapy 
with known pathological and clinical tumor response and from whom biopsy material 
were available for pathological evaluation. We used pre-treatment biopsy material for 
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immunohistochemical analyses in order to avoid interference of the chemotherapeutic 
regime on the expression levels of oncogenic markers.9 10
treatment
Chemotherapy consisted of four cycles of preoperative fluorouracil 600 mg/m2, 
epirubicin 60 mg/m2, and cyclophosphamide 600 mg/m2 (FEC) administered 
intravenously, at intervals of every 3 weeks. Surgical therapy followed within 4 
weeks of the fourth course of chemotherapy. Surgery consisted of either a modified 
radical mastectomy or breast-conserving surgery (wide local excision of the tumor or 
quadrantectomy plus axillary dissection and adjuvant radiotherapy). Recommended 
guidelines for radiotherapy have been described previously.1 If radiotherapy was 
indicated, it was administered after surgery. Patients older than 50 years also received 
tamoxifen 20 mg daily for at least 2 years, regardless of their estrogen receptor and 
nodal status.
Pathological tumor response
Surgical tumor specimens were examined for the presence of microscopic residual 
tumor. If no signs of residual malignant cells at the primary site were seen with 
histological examination, this was scored as a pathological complete response (pCR). 
The specimens still containing invasive malignant cells were graded as pINV.
Clinical tumor response
The tumor response classification system used in EORTC 10902 was according to 
the UICC.11 Clinical tumor size was scored by the local investigators before the start 
of chemotherapy as well as at the time of surgery by both clinical examination and 
mammography. The product of the two greatest perpendicular diameters was used to 
compare tumor size before and after chemotherapy.
Clinical complete response (cCR) was defined as complete disappearance of 
all clinically detectable malignant disease by palpation and mammography. Clinical 
partial response (cPR) was defined as 50% decrease in total tumor size after four cycles 
of preoperative chemotherapy. An increase of 25% in tumor size after a minimum of 
two courses of preoperative chemotherapy was considered to be progressive disease 
(cPD). If patients did not meet one of the above-mentioned criteria after four cycles 
of chemotherapy, they were classified as having stable disease (cSD). For the purpose 
of this analysis, we distinguished between patients with overall clinical response (cCR 
and cPR) and patients with non-responding tumors (cSD and cPD).
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Histology and immunohistochemistry
Blocks were collected from core needle biopsies taken before the start of chemotherapy. 
All immunohistochemical analyses were performed in one reference laboratory 
by two pathologists who were unaware of the clinical outcome of the patients. 
Invasive carcinomas were histologically graded according to the method of Bloom 
and Richardson, adapted by Elston and Ellis.12 Bcl-2 was assessed using Clone 
124 (Boehringer Mannheim, Germany) and scored according to van Slooten and 
colleagues (staining 3 indicates positive status).13 p53 accumulation was detected using 
Do-7 monoclonal antibody (NovaCastra, Newcastle on Tyne, United Kingdom) and a 
semi-quantitative system based on the sum of the mean staining intensity (0 to 3; none 
to strong) and an estimation of the percentage of positive cell nuclei (0 to 4; 0% to 
>75%); this allowed a sum score of 0 to 7, with staining 4 being considered positive.14 
Estrogen receptor status (ER) was estimated using the monoclonal antibody DAKO-
ER 1D5 (Dako, Glostrup, Denmark; staining indicates positive status).14 Progesterone 
receptor status (PgR) was measured using mPRI monoclonal antibody (Transbio, 
Paris, France; staining indicates positive status).14 HER2 expression was assessed using 
the monoclonal antibody 3B5 (staining score 0, 1 and 2 indicates a negative result 
and 3 resembles a positive result).15 p21 was measured using the monoclonal antibody 
EA10 (Calbiochem, Cambridge, MA, USA; 3 indicates a positive result).13 14
statistical analysis
Overall survival time was defined as the time between randomization and death from 
any cause. Distant disease-free survival was defined as the time between the date of 
randomization and the date of distant disease relapse or death from any cause whichever 
came first. Correlations between the two tumor response classification systems and 
patient and tumor characteristics were tested using the Pearson’s Chi-square test or 
the Fisher’s Exact test. A multivariate logistic regression model was fitted that was 
based on all characteristics that had a P-value up to .10 in the univariate analysis. 
The effect of patient and tumor characteristics on the survival endpoints was assessed 
using the Cox proportional hazards regression model to estimate hazard ratios and 
their 95% confidence intervals. A multivariate Cox regression model was fitted that 
was based on all characteristics that had a P-value up to .10 in the univariate analysis. 
Survival curves of the tumor response groups were estimated using the Kaplan-Meier 
technique. The statistical analyses were performed using SPSS software (SPSS Inc., 
Chicago, II, USA). A two-sided significance level of 0.05 was used.
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Results
Patient and tumor characteristics 
EORTC 10902 trial randomized 350 patients to preoperative chemotherapy and 
321 patients received this allocated treatment. Tumor response was assessable in 
301 patients. For 194 of these patients no data was available on histological and 
immunohistochemical analyses. Thus, we were able to include 107 patients in this 
study. Patient and tumor characteristics are listed in Table 1.
 
         table 1. Patient and tumor characteristics
Characteristic N %
Age at diagnosis
< 40 years 11 10


















Stable disease 47 44











































a Assessed prior to the delivery of 
chemotherapy.  
b Assessed after the delivery of chemotherapy. 
BCT, breast conservative treatment; 
pCR, pathological complete response.
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The median age at diagnosis was 49.8 years. Seven (6.5%) pathological complete 
responses following preoperative chemotherapy were seen and 58 (54%) patients had 
clinically responding tumors. All but one of the patients with pCR was clinically 
graded as responders. At the time of analysis, the median follow-up period was seven 
years (95% CI = 6.89 to 7.45); 31 (29%) patients have died and of the patients alive, 
10 (9.3%) have experienced a distant relapse. Although otherwise stipulated in the 
treatment protocol, 9 (17%) women older than 50 years did not use tamoxifen and 
four (7.4%) women in the younger group did use tamoxifen.
Prognostic value of pathological tumor response 
The association of pCR with overall survival and distant disease-free survival is 
shown in Figure 1. Patients with a pCR had an overall survival rate after 7 years of 
86% compared with 68% for patients with residual disease (pINV) on pathological 
examination (hazards ratio (HR) = 2.87, 95% CI = 0.39 to 21.14, P = .30). Patients with 
a pCR had a distant disease-free survival rate at 7 years follow-up of 86%, compared to 
59% for patients with pINV (HR = 3.62, 95% CI = 0.50 to 26.33, P = .21).
Prognostic value of clinical tumor response 
Patients with a clinical tumor response had an overall survival rate after 7 years of 67% 
(Figure 2). Non-responders had an overall survival rate of 75% (HR = 0.71, 95% CI = 
0.34 to 1.45, P = .35). Patients with clinical response had a distant disease-free survival 
rate after 7 years of 61% compared to 61% for patients with non-responding tumors 
(HR = 0.94, 95% CI = 0.51 to 1.74, P = .84; Figure 2).
 
figure 1. Pathological tumor response and overall (left panel) and distant disease-free survival (right panel). 
pCR = pathological complete response; pINV = invasive tumor cells on pathological examination.
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Predictive characteristics for pathological and clinical response 
We assessed the predictive value of patient and tumor characteristics and expression of 
oncogenic markers in pre-treatment core needle biopsies. Table 2 lists the relationships 
between dichotomized characteristics and pathological and clinical tumor response. 
Pathological lymph node status and p53 status were significantly correlated with 
pathological tumor response. Including both variables in the multivariate analysis 
(Table 3) revealed an independent relationship of p53 overexpression with pCR (odds 
ratio (OR) = 16.83, 95% CI = 1.78 to 159.33, P = .01) and a non-significant association 
of negative pathological lymph node status. Clinical tumor response was predicted by 
clinical tumor size, tumor grade, p53 status, PgR status, and HER2 status (Table 2). At 
multivariate analysis, p53 overexpression (OR = 5.57, 95% CI = 1.58 to 19.65, P = .008) 
and small clinical tumor size (OR = 10.26, 95% CI = 2.01 to 52.48, P = .005) remained 
as independent predictive factors of clinical tumor response (Table 3).
figure 2. Clinical tumor response and overall (left panel) and distant disease-free survival (right panel). 
table 3. Multivariate logistic regression analysis of tumor characteristics and 
pathological complete tumor response (N = 99) and clinical response (N = 94)
Characteristic Pathological response Clinical response
oR 95% CI P oR 95% CI P
Lymph node negativea 8.47 0.88–81.82 0.07
Positive p53 statusb 16.83 1.78-159.33 0.01 5.57 1.58–19.65 0.008
Tumor size < 2 cmb 10.26 2.01–52.48 0.005
Grade IIIab 1.58 0.41–6.13 0.51
Negative PgR statusb 2.37 0.89–6.31 0.08
Positive HER2 expressionb 2.93 0.47–18.14 0.25
a Assessed after to the delivery of chemotherapy. b Assessed prior the delivery of chemotherapy.
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Prognostic characteristics for overall survival and distant disease-free survival 
Table 4 shows the prognostic value of patient and tumor characteristics in predicting 
clinical outcome. Significant prognostic variables for overall and distant disease-
free survival were age, use of tamoxifen, and pathological lymph node status. In 
addition, histological tumor grade was significantly associated with overall survival. 
Overexpression of p53 was non-significantly related with poorer overall (HR = 1.72, 
95% CI = 0.82 to 3.62, P = .15) and distant disease-free survival (HR = 1.39, 95% CI = 
0.70 to 2.74, P = .35).
table 2. Association of tumor response and patient and tumor characteristics
pCR, pathological complete response; pINV, invasive tumor cells on pathological examination.
Characteristic Pathological response Clinical response
pCR pInv P Responders non-responders P
N % N % N % N %
Age at diagnosis 1.00 0.22
< 40 years 0 0 11 100 8 73 3 27
> 40 years 7 7 89 93 50 52 46 48
Clinical tumor size 0.60 0.001
< 2 cm 0 0 18 100 16 89 2 11
> 2 cm 7 8 82 92 42 47 47 53
Clinical nodal status 1.00 0.43
Negative 4 7 58 93 36 58 26 42
Positive 3 7 42 93 22 49 23 51
Pathological nodal status 0.04 0.17
Negative 6 13 39 87 28 62 17 38
Positive 1 2 61 98 30 48 32 52
Histological grade 0.61 0.05
I & II 5 6 77 94 40 49 42 51
III 2 11 17 89 14 74 5 26
BCL-2 status 0.36 0.23
Negative 3 12 22 88 15 60 10 40
Positive 3 5 56 95 27 46 32 54
P53 status 0.004 0.001
Negative 1 1 72 99 32 44 41 56
Positive 5 19 21 81 21 81 5 19
ER status 0.13 0.13
Negative 3 14 18 86 14 67 7 33
Positive 3 4 68 96 34 48 37 52
PgR status 0.68 0.007
Negative 4 8 46 92 33 66 17 34
Positive 2 4 47 96 19 39 30 61
HER2 status 0.47 0.09
Negative 5 5 87 95 46 50 46 50
Positive 1 10 9 90 8 80 2 20
P21 status 1.00 0.53
Negative 3 7 42 93 25 56 20 44
Positive 3 6 44 94 23 49 24 51
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N/O, number of patients/ observed number of events; SR, survival rate; HR, hazard rate; pCR, pathological 
complete response; pINV, invasive tumor cells on pathological examination.
Characteristic Overall survival Distant disease-free survival
N/O 7-year SR HR 95% CI P N/O
7-year 
SR HR 95% CI P
Age at diagnosis 0.01 0.03
< 40 years 11/7 45 1.00 11/7 36 1.00
> 40 years 96/24 73 0.34 0.14–0.78 96/34 64 0.40 0.18–0.92
Surgery 0.62 0.29
Mastectomy 57/17 66 1.00 57/24 58 1.00
Breast conserving 50/14 74 0.83 0.41–1.69 50/17 64 0.72 0.36–1.33
Tamoxifen 0.01 0.01
No 59/24 60 1.00 59/30 48 1.00
Yes 48/7 84 0.34 0.15–0.79 48/11 77 0.39 0.19–0.77
Radiotherapy 0.11 0.32
No 20/8 56 1.00 20/9 51 1.00
Yes 87/23 74 0.52 0.23–1.16 87/32 63 0.69 0.33–1.44
Clinical tumor size 0.63 0.35
< 2 cm 18/4 72 1.00 18/5 67 1.00
> 2 cm 89/27 70 1.30 0.45–3.72 89/36 59 1.57 0.61–4.00
Clinical response 0.35 0.84
Responders 58/19 67 1.00 58/22 61 1.00
Non-responders 49/12 75 0.71 0.34–1.45 49/19 61 0.94 0.51–1.74
Pathological tumor 
size 0.35 0.26
< 2 cm 50/13 75 1.00 50/17 64 1.00
> 2 cm 57/18 66 1.41 0.69–2.88 57/24 58 1.43 0.77–2.67
Pathological response 0.30 0.21
pCR 7/1 86 1.00 7/1 86 1.00
pINV 100/30 68 2.87 0.39–21.14 100/40 59 3.62 0.47–26.33
Clinical nodal status 0.51 0.37
Negative 62/17 73 1.00 62/22 64 1.00
Positive 45/14 67 1.27 0.62–2.57 45/19 56 1.33 0.72–2.55
Pathological nodal 
status 0.01 0.00
Negative 45/8 84 1.00 45/8 81 1.00
Positive 62/23 61 2.82 1.23–6.44 62/33 46 4.15 1.90–9.06
Histological grade 0.05 0.23
I & II 82/20 74 1.00 82/29 64 1.00
III 19/9 55 2.23 1.01–4.91 19/9 50 1.58 0.75–3.33
BCL-2 status 0.30 0.12
Negative 25/8 70 1.00 25/11 54 1.00
Positive 59/12 79 0.62 0.26–1.53 59/16 73 0.55 0.25–1.18
P53 status 0.15 0.35
Negative 73/19 73 1.00 73/27 62 1.00
Positive 26/11 58 1.72 0.82–3.62 26/12 52 1.39 0.70–2.74
ER status 0.16 0.59
Negative 21/9 60 1.00 21/9 56 1.00
Positive 71/19 71 0.57 0.26–1.26 71/27 61 0.81 0.38–1.74
PgR status 0.14 0.16
Negative 50/19 62 1.00 50/23 52 1.00
Positive 49/12 75 0.58 0.28–1.19 49/16 68 0.64 0.34–1.20
HER2 status 0.87 0.74
Negative 92/27 70 1.00 92/37 59 1.00
Positive 10/3 69 1.11 0.34–3.66 10/3 70 0.82 0.25–2.66
P21 status 0.24 0.28
Negative 45/12 72 1.00 45/16 65 1.00
Positive 47/17 64 1.56 0.74–3.28 47/12 53 1.44 0.75–2.76
table 4. Univariate Cox regression analyses for overall and distant disease-free survival
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The prognostic factors found to be trend significant at univariate analyses 
were included in multivariate analyses to identify independent prognostic factors of 
overall and distant disease-free survival (Table 5). Negative pathological lymph node 
status and use of tamoxifen were both independently associated with improved overall 
and distant disease-free survival. In addition, histological tumor grade III was an 
independent prognostic factor of poorer overall survival.
dIsCussIon
In this analysis, we demonstrated a significant independent association between p53 
overexpression and pathological complete and clinical tumor response to 4 cycles 
of preoperative FEC. However, pCR as a prognostic factor for overall survival, as 
well as for distant disease-free survival, did not reach statistical significance in this 
patient population, although a clear trend was demonstrated (Figure 1). This finding 
is in accordance with other randomized controlled trials studying preoperative 
chemotherapy in primary operable breast cancer, while pCR in these studies was a 
significant prognostic factor.2 16-18
In this study, clinical tumor response showed no prognostic benefit (Figure 2). 
This result is in disagreement with other reports2 16 17 and most probably resembles 
a selection bias as the data derived from our larger study population suggest an 
association of non-response with poorer overall survival (HR = 1.43, 95% CI = 0.91 
to 2.24, P = .12). However, the fact that clinical responders in the current group 
had no favorable prognosis implies that the results concerning the predictive value 
of characteristics for clinical response must be interpreted with caution. Moreover, 
determining clinical tumor response after preoperative chemotherapy is difficult and 
can be either under- or overestimated due to fibrosis, weakening of the tumor margins 
and resolution of edema, suggesting prognostic superiority of pathologically evaluated 
tumor response.19-22
Although pCR in our study was associated with p53 overexpression and higher 
survival rate, p53 overexpression was not translated in improved clinical outcome. In 
contrast, p53 overexpression was non-significantly related with poorer overall and 
distant disease-free survival. Hypothetically, the short-lived benefits of better response 
table 5. Multivariate Cox regression analyses of characteristics predicting for overall 
(N = 101) and distant disease-free survival (N = 107)
Characteristic Overall survival Distant disease-free survival
HR 95% CI P HR 95% CI P
Lymph node negativea 4.30 1.71–10.82 0.002 5.19 2.35–11.46 0.000
Use of tamoxifen 0.41 0.17–1.00 0.05 0.34 0.17–0.69 0.003
Age < 40 years 2.13 0.81–5.65 0.13 2.28 0.98–5.32 0.06
Grade IIIab 3.02 1.28–7.12 0.01
a Assessed after to the delivery of chemotherapy. b Assessed prior the delivery of chemotherapy.  
HR, hazard ratio.
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of p53 positive tumors may be overcast by rapid re-growth of micro-metastases after 
initial remission of the primary tumor, reflecting their aggressive biology. However, 
analysis of the hypothesis that survival in the pCR subgroup is dependent on p53 
status was not possible due to the limited power of the current study.
p53, a nuclear protein, plays an essential role in the regulation of cell cycle 
and functions as a tumor suppressor. Breast cancer patients with p53 mutations or 
protein accumulation measured by immunohistochemistry in their tumors have 
worse survival.23-26 Meanwhile, the literature of the predictive value of p53 status on 
tumor response to preoperative anthracycline-based chemotherapy is conflicting.7 
Most studies find no association between p53 expression and tumor response to 
anthracyclines.27-32 Others have associated p53 overexpression with both resistance14 33-
35 and sensitivity10 36 to preoperative anthracycline-based chemotherapy. Interpretation 
of the above literature is complicated since the definition of response varies across 
studies, the correlation between p53 protein accumulation and the presence of 
mutations is not absolute and numerous non-standardized immunohistochemistry 
techniques have been used, limiting the possibility to draw valid conclusions.37
The pathological lymph node status after preoperative chemotherapy is in 
our data an independent prognostic factor for both overall and distant disease-free 
survival. This finding has also been noted by others.3 38-40 However, the pre-treatment 
clinical lymph node status was poorly correlated with clinical outcome. At the 
time this trial was conducted, the pre-treatment nodal status was determined by 
palpation only. Nowadays, imaging techniques such as ultrasound are more feasible in 
establishing nodal status.41 Future trials should include this technique to provide more 
reliable information of the actual response of lymph node metastases to preoperative 
chemotherapy and to determine the subsequent prognostic significance of such a 
response.
At this time, it is not possible to select patient who will benefit from 
chemotherapy. However, data have begun to emerge from microarray studies which 
may lead to the introduction of tailored treatment strategies based upon custom-made 
risk profiles rather than the classic guidelines derived from traditional randomized 
clinical trials.42-45
In conclusion, our data derived from a prospective randomized trial suggest that 
p53 overexpression estimated by immunohistochemistry is an independent predictive 
factor of tumor response after preoperative anthracycline-based chemotherapy in 
operable breast cancer patients. However, this conclusion must be limited to the 
regime used in this trial (FE60C), which is probably suboptimal today.46 Moreover, 
the relatively small sample size requires conformation in larger studies and the use of 
p53 measurements should be restricted to clinical trial settings. Prospectively derived 
data on the predictive and prognostic value of p53 is on the way from the neoadjuvant 
EORTC trial 10994.47 48
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Breast cancer at a young age is associated with an unfavorable prognosis. Very young 
patients with breast cancer therefore are advised to undergo adjuvant chemotherapy 
irrespective of tumor stage or grade. However, chemotherapy alone may not be 
adequate in young patients with hormone receptor positive breast cancer. Therefore, 
we studied the effect of adjuvant chemotherapy in young patients with breast cancer in 
relation to hormone receptor status.
methods 
Paraffin-embedded tumor material was collected from 480 early-stage breast cancer 
patients younger than 40 years who participated in one of four European Organization 
for Research and Treatment of Cancer trials. Using immunohistochemistry, we assessed 
estrogen receptor (ER) status and progesterone receptor (PgR) status in a standardized 
way. Endpoints in this study were overall survival (OS) and distant metastasis-free 
survival (DMFS). The median follow-up period was 7.3 years.
Results
Overall, patients with ER positive tumors had better OS rates (hazard ratio (HR) = 
0.63, 95% CI = 0.43 to 0.93, P = .02) compared with those with ER negative tumors. 
However, in the subgroup of patients who received chemotherapy, no significant 
difference in OS (HR = 0.87, 95% CI = 0.50 to 1.52, P = .63) and DMFS (HR = 1.36, 
95% CI = 0.82 to 2.26, P = .23) was found between patients with ER positive tumors or 
those with ER negative tumors. These differences were similar for PgR status.
Conclusion
Very young patients with hormone receptor positive tumors benefit less from adjuvant 
systemic chemotherapy than hormone receptor negative patients. These results 
confirm that chemotherapy alone cannot be considered optimal adjuvant systemic 
treatment in young breast cancer patients with hormone receptor positive tumors.
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IntRoduCtIon
Breast cancer in premenopausal women is associated with worse outcome compared 
with postmenopausal patients.1 Approximately 7% of women diagnosed with breast 
cancer are younger than 40 years old.2 Very young women (that is, younger than 35 
years old), especially, are at a high risk of developing distant metastases. Therefore, 
they are recommended to receive adjuvant systemic chemotherapy regardless of 
tumor stage or grade.3 In addition, high local regional recurrence rates after breast-
conserving therapy have been reported in young premenopausal patients with breast 
cancer.4 Although it is clear that young age is an independent prognosticator of 
adverse outcome in breast cancer, controversies regarding the optimal treatment in 
this population exist.
Adjuvant systemic chemotherapy in premenopausal patients has been shown 
to improve survival,1 but controversy about the role of chemotherapy in patients with 
hormone receptor positive tumors still exists. Aebi and colleagues clearly showed that 
the endocrine effects of chemotherapy alone might not be sufficient for very young 
patients with breast cancer.5 In this study, it was shown that patients younger than 35 
years with estrogen receptor (ER) positive tumors and treated with cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF) had a significantly worse disease-free survival 
compared with ER negative patients. 
To detect whether we could confirm these data by finding similar results, we 
studied the efficacy of chemotherapy in young patients with breast cancer according to 
ER status and progesterone receptor (PgR) status and selected patients aged younger 
than 40 years at the time of diagnosis from four European Organization for Research 
and Treatment of Cancer (EORTC) trials that were conducted by the EORTC Breast 
Cancer Group and Radiotherapy Group.
mAteRIAl And metHods
study participants
Data were collected from four EORTC trials. In total, 9,938 patients participated in 
these trials; 934 of these patients were 40 years old or younger at the time of diagnosis. 
The trial designs are summarized below.
EORTC trial 10801 (1980 to 1986, median follow-up 13.4 years) was conducted 
to assess the safety of breast-conserving treatment. In this trial, patients were randomly 
assigned between breast-conserving surgery combined with radiotherapy and radical 
mastectomy. Six cycles of adjuvant chemotherapy with cyclophosphamide 100 mg/
m2 given orally on days 1 to 14, methotrexate 40 mg/m2 given intravenously on days 1 
and 8, and 5-fluorouracil 600 mg/m2 (CMF) given intravenously on days 1 and 8 were 
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indicated for all patients under the age of 55 with positive nodes. A total of 902 patients 
were randomly assigned.6
EORTC trial 10854 (1986 to 1991, median follow-up 10.8 years) studied 
the question of whether one course of perioperative chemotherapy given directly 
after surgery yields better results in terms of treatment outcome than surgery 
alone. Perioperative chemotherapy consisted of a single course of doxorubicin 
50 mg/m2, 5-fluorouracil 600 mg/m2, and cyclophosphamide 600 mg/m2 (FAC) 
administered intravenously within 36 hours after surgery. For axillary lymph node 
positive premenopausal patients in the perioperative chemotherapy group, adjuvant 
chemotherapy consisting of five cycles of CMF was recommended. For node positive 
patients younger than 50 years who did not receive perioperative chemotherapy, 
one conventional course of FAC followed by five cycles of CMF after surgery was 
recommended. Postmenopausal patients were recommended to receive tamoxifen. A 
total of 2,795 patients were included.7
EORTC trial 10902 (1991 to 1999, median follow-up 6.1 years) was set up to 
determine the value of preoperative chemotherapy. Patients were randomly assigned 
to receive four cycles of chemotherapy either before or after surgery. Chemotherapy 
consisted of four cycles of 5-fluorouracil 600 mg/m2, epirubicin 60 mg/m2, and 
cyclophosphamide 600 mg/m2 (FEC) administered intravenously at 3-weekly intervals. 
In the preoperative chemotherapy group, surgical therapy followed within 4 weeks 
of the fourth course of chemotherapy. In the postoperative chemotherapy group, the 
first cycle was given within 36 hours after surgery. Patients not younger than 50 years 
received tamoxifen for 2 years. A total of 698 patients were randomly assigned.8
EORTC trial 22881 (1989 to 1996, median follow-up 5.1 years) was conducted 
to study the effect of an additional dose of 16 Gy radiation to the tumor bed among 
early stage breast cancer patients who received 50 Gy radiotherapy after lumpectomy. 
Patients with a microscopically incomplete resection were assigned to receive boost 
doses of 10 or 26 Gy. Premenopausal patients with axillary lymph node involvement 
received six cycles of adjuvant CMF, and all postmenopausal patients received 
tamoxifen 20 mg per day during at least 2 years. A total of 5,569 patients were enrolled.9
In all trials, if adjuvant chemotherapy was indicated, patients received either 
CMF or an anthracyclin-based regimen (FAC or FEC). Adjuvant hormonal therapy for 
premenopausal hormone receptor-positive patients was not yet recommended at the 
time these trials were conducted. In the two oldest trials, tamoxifen administration was 
not even recorded. This explains the high number of patients for whom no information 
was found on tamoxifen use. In the trials in which tamoxifen use was recorded, less 
than 5% of patients aged less than 40 years received tamoxifen. Therefore, we have to 
assume that only a very small fraction of the patient population in this study received 
tamoxifen.
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Hormone receptor staining
Paraffin-embedded tumor material was collected from 480 patients age less than 
40 years. Tumors were histologically graded using hematoxylin and eosin slides as 
described previously.10 Immunohistochemical staining for ER and PgR status was 
performed using a tissue microarray.11-14 Three core biopsies were taken from each 
tumor block and inserted into a donor block. Immunohistochemical staining for ER 
was performed using the monoclonal antibody DAKO-ER, 1D5 (DakoCytomation 
Denmark A/S, Glostrup, Denmark), for PgR using the monoclonal antibody mPRI 
(TRANSBIO, Paris, France). Immunohistochemical staining was scored using a 
semiquantative system based on the percentage of positive nuclei. After the percentage 
of positive nuclei in three core biopsies was counted, the mean value was taken. For 
both ER and PgR, tumors with more than 10% of the tumor cells showing nuclear 
staining were considered positive.
statistical analysis
Analyses were performed for distant metastasis-free survival (DMFS) and overall 
survival (OS). DMFS was defined as the interval from time of randomization to time 
of distant metastasis or death, whichever came first. OS was defined as time from 
randomization to death from any cause. Survival curves were estimated using the 
Kaplan-Meier method. Differences in survival were analyzed using Cox proportional 
hazard models. The statistical analyses were performed using SPSS software (SPSS 
Inc., Chicago, IL, USA). A direct comparison of patients who received chemotherapy 
versus those who did not receive chemotherapy was not feasible. (This would have 
introduced a selection bias in this retrospective analysis as the vast majority of patients 
receiving chemotherapy had positive axillary lymph nodes.) Therefore, conclusions in 
this explorative analysis were based on indirect comparisons.
Results
Participants
Paraffin-embedded tumor specimens were collected from 480 patients aged less than 
40 years at the time of diagnosis (Table 1). For 12 patients, ER status could not be 
scored, and for 16 patients, PgR status could not be scored. Positive ER status and 
positive PgR status were found in 288 (60%) and 223 (46%) patients, respectively. 
Two hundred patients received prolonged adjuvant systemic chemotherapy, whereas 
279 patients did not receive adjuvant systemic chemotherapy. Of the patients not 
receiving chemotherapy, 94% were node negative, whereas 85% of patients who did 
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receive chemotherapy were node positive. Characteristics related to adjuvant systemic 
chemotherapy treatment are listed in Table 2. At the time of the analysis, the median 
follow-up was 7.3 years, 106 (22%) patients had died, and 155 (32%) patients developed 



















1 During the period of time in which these trials were conducted, tamoxifen was not routinely given to 
premenopausal patients with estrogen receptor positive tumors. 2 All patients who received tamoxifen had ER-
positive tumors. ER, estrogen receptor; PgR, progesterone receptor.



















Table 3. Distribution of events according to ER status and chemotherapy1
No adjuvant chemotherapy Adjuvant chemotherapy
N % N %
Deaths  
(number of events = 106)
ER positive 19 18 35 33
ER negative 29 27 19 18
Distant metastasis or death  
(number of events = 155)
ER positive 37 24 54 35
ER negative 38 25 21 14
1Missing data not shown. ER, estrogen receptor.
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overall results
Estrogen receptor status
Overall, patients with ER positive tumors had better OS rates compared with ER 
negative patients (hazard ratio (HR) = 0.63, 95% CI = 0.43 to 0.93, P = .02; Figure 
1A). Survival rates at 7 years were 82% for the ER positive group and 77% for the ER 
negative group. DMFS rates were 70% for the ER positive group and 66% for the ER 
negative group (HR = 0.90, 95% CI = 0.65 to 1.24, P = .51; Figure 1B).
Progesterone receptor status
PgR status yielded similar results: patients with PgR positive tumors had better OS 
(HR = 0.59, 95% CI = 0.40 to 0.88, P = .01). However, for DMFS this difference was not 
of statistical significance (HR = 0.78, 95% CI = 0.57 to 1.01, P = .14).
Table 2. Patient and tumor characteristics specified by adjuvant chemotherapy1
1Missing data not shown. ER, estrogen receptor; CMF, cyclophosphamide, methotrexate, and 5-fluorouracil; 
PgR, progesterone receptor.
Characteristic No adjuvant chemotherapy (N = 279) Adjuvant chemotherapy (N = 200)
N % N %
ER status
Positive 161 58 126 63
  Anthracycline-based 66
  CMF 60
Negative 110 39 70 35
  Anthracycline-based 48
  CMF 22
PgR status
Positive 135 48 88 44
Negative 135 48 105 53
Tumor size
< 2 cm 187 67 105 53
> 2 cm 76 27 75 38
Nodal status
Negative 259 93 29 15
Positive 18 6 170 85
Surgery
Breast conserving 247 89 146 73
Mastectomy 32 11 53 27
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Patients who did not receive prolonged adjuvant chemotherapy
Estrogen receptor status
In patients who did not receive adjuvant systemic chemotherapy, positive ER status 
was associated with better OS (HR = 0.41, 95% CI = 0.23 to 0.74, P < .01; Figure 
1C). Survival rates at 7 years were 90% for the ER positive group and 77% for the ER 
negative group. Also, DMFS rates at 7 years were significantly better for ER positive 
patients: 80% versus 64% (HR = 0.59, 95% CI = 0.37 to 0.92, P = .02; Figure 1D).
Progesterone receptor status
In patients who did not receive adjuvant systemic chemotherapy, positive PgR status 
was associated with better OS (HR = 0.44, 95% CI = 0.24 to 0.80, P < .01). Survival 
rates at 7 years were 88% for the PgR positive group and 75% for PgR negative group. 
DMFS rates at 7 years were 79% for PgR positive patients and 67% for PgR negative 
patients (HR = 0.66, 95% CI = 0.42 to 1.04, P = .07).
Patients who received prolonged adjuvant systemic chemotherapy
Estrogen receptor status
In the group of 200 patients who did receive adjuvant systemic chemotherapy, treatment 
outcome was not significantly different between ER positive and ER negative breast 
cancer patients. Survival rates at 7 years were 70% for the ER positive group and 75% 
for the ER negative group (HR = 0.87, 95% CI = 0.50 to 1.52, P = .63; Figure 1E), and 
DMFS rates were 59% for the ER positive group and 70% for the ER negative group 
(HR = 1.36, 95% CI = 0.82 to 2.26, P = .23; Figure 1F). No further subgroup analyses 
specified by type of chemotherapy were performed since these groups would have had 
insufficient numbers and events.
Progesterone receptor status
According to PgR status, no difference in treatment outcome for patients who have 
received adjuvant systemic chemotherapy was found. In both the PgR positive and PgR 
negative patient groups, the survival rate at 7 years was 72% (HR 0.84, 95% CI 0.49 to 
1.43; P = .51). Also, DMFS rates did not differ significantly between the PgR positive 
group (59%) and the PgR negative group (64%; HR 1.02, 95% CI 0.65 to 1.60; P = .93).
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figure 1. Overall and distant disease-free survival for all patients (A, B), patients who did not receive adjuvant 
chemotherapy (C, D) and patients who received chemotherapy (E, F) according to estrogen recepter status. 
All patients 
Patients who did not receive chemotherapy 
ER positive 
ER negative P = .02 
ER positive 
ER negative P < .001 
ER positive 
ER negative P = .63 
ER positive 
ER negative P = .51 
ER positive 
ER negative P = .02 
ER positive 
ER negative P = .02 
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multivariate analysis
Multivariate Cox regression OS analyses were performed separately for ER status and 
PgR status. Other covariates included nodal status, tumor size, and the administration 
of prolonged adjuvant chemotherapy. Both ER status (relative risk (RR) = 1.65) and 
PgR status (RR = 1.56; data not shown) remained independent prognostic factors with 
a significant impact on OS (Table 4).
dIsCussIon
This pooled analysis of patients 40 years old or younger demonstrated that hormone 
receptor positive patients experienced no survival advantage of prolonged adjuvant 
CMF chemotherapy compared with hormone receptor negative patients. However, in 
patients who did not receive adjuvant chemotherapy, hormone receptor positive status 
was associated with improved survival rates compared with hormone receptor negative 
status. In overall multivariate analyses, both ER positive status and PgR positive status 
remained independent prognostic factors of overall survival.
Our study has some limitations. First, the current analysis retrospectively 
uses heterogeneous data from different randomized trials. Second, adjuvant CMF 
chemotherapy to a large extent has been replaced by anthracycline-containing 
chemotherapeutic regimens because of higher treatment efficacy in patients with 
breast cancer regardless of hormone receptor or menopausal status.1 Also, taxanes 
are increasingly being used, showing additional survival benefits. Therefore, different 
effects might have been demonstrated when newer chemotherapy regimens were used 
throughout the included studies. Third, the direct comparison between administration 
of chemotherapy versus no chemotherapy in hormone receptor positive and hormone 
receptor negative patients would have been very interesting. However, the confounding 
effect of axillary lymph node status would have introduced a significant selection bias 
because the majority of patients who received chemotherapy had positive axillary lymph 
nodes. Nevertheless, in multivariate analysis including axillary lymph node status, 
tumor size, and the administration of prolonged adjuvant chemotherapy, hormone 
receptor status remained an independent prognostic factor for OS. Fourth, the survival 
curves of the ER positive and ER negative group depicted in Figure 1E (overall survival 
in patients receiving chemotherapy) are crossing. This implies that that the proportional 
Table 4. Multivariate Cox regression analysis of overall survival
Characteristic Relative risk 95% CI P
eR negative 1.65 1.09-2.50 .02
node positive 1.70 0.79-3.66 .17
tumor size > 2 cm 1.66 1.09-2.52 .02
Adjuvant chemotherapy 1.02 0.48-2.17 .96
ER, estrogen receptor.
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hazards assumption is not justified. The rapid decrease in survival benefit after a couple 
of years in the ER positive group may well be explained by the chemotherapy-induced 
amenorrhea and the associated low estrogen levels. Unfortunately, no information 
on the number of patients who have become amenorrheatic could be retrieved in 
order to test this hypothesis. Despite these limitations, this pooled analysis of four 
randomized controlled trials used individual patient data with renewed pathological 
analysis of hormone receptor status. Because less than 5% of the study population 
received tamoxifen, the effect of chemotherapy alone in hormone receptor positive 
patients could be well studied. By assessing hormone receptor status centrally, we have 
provided standardized measurements for all tumors in the study. 
Adjuvant systemic chemotherapy is a well-established treatment modality in 
premenopausal breast cancer. In patients 35 years old or younger, administration of 
chemotherapy is advocated regardless of nodal status, tumor size, or grade.3 However, 
the efficacy of chemotherapy in premenopausal patients with ER positive breast 
cancer has been questioned.5 Our findings are in accordance with data from Aebi and 
colleagues,5 who demonstrated that young premenopausal patients with breast cancer 
treated with adjuvant CMF chemotherapy had a higher risk of relapse and death than 
older premenopausal patients, especially if their tumors were ER positive. In addition, 
several neoadjuvant chemotherapy studies have demonstrated that patients with ER 
negative tumors are more likely to achieve a pathological complete response than 
those with ER positive tumors.15-17 Moreover, these studies found that when patients 
with ER negative tumors achieved a pathological complete response their survival was 
comparable with that of ER positive patients.
To optimize adjuvant systemic treatment in premenopausal patients with 
breast cancer, several investigators have studied the role of ovarian suppression by 
luteinizing hormone-releasing hormone (LHRH) agonists. Recently, the Early Breast 
Cancer Overview group reported a meta-analysis of individual patient data on the use 
of LHRH agonists.18 When chemotherapy alone was compared with chemotherapy 
in combination with an LHRH agonist, a difference between younger and older 
premenopausal women with hormone receptor positive disease was found. In patients 
40 years old or younger, the addition of an LHRH agonist significantly reduced the risk 
of recurrence and death (HR = 0.74, P = .01). This effect was greatest in the group age 
younger than 35 years, whereas in the group older than 40 years, the addition of an 
LHRH agonist did not improve outcome. When chemotherapy alone was compared 
with LHRH agonist with or without tamoxifen in younger premenopausal patients 
with hormone receptor positive tumors, the endocrine therapy improved outcome 
(mortality HR = 0.82, P = .15). Conversely, in hormone receptor negative patients, the 
same comparison significantly favored treatment with chemotherapy (62.1% increased 
rate of recurrence or death; P = .003). To date, no trial has compared an LHRH agonist 
against chemotherapy with tamoxifen in both arms. This relevant and important issue 
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needs to be resolved. Although these results underline the fact that chemotherapy 
may be equivalent to hormonal ovarian suppression in terms of treatment outcome 
in hormone receptor positive patients, these results firmly demonstrate a beneficial 
effect of LHRH agonists as additional therapy, especially in young patients with breast 
cancer.
Three important ongoing trials are specifically investigating ovarian function 
suppression (Suppression of Ovarian Function Trial, or SOFT), an aromatase inhibitor 
(Tamoxifen and EXemestane Trial, or TEXT), and the need for chemotherapy 
(Premenopausal Endocrine Responsive CHEmotherapy, or PERCHE) in adjuvant 
treatment for young patients with hormone receptor-positive breast cancer.19
The 2005 St. Gallen Consensus Committee on adjuvant therapy for early-
stage breast cancer recommended that the first consideration in treatment selection 
be endocrine responsiveness.20 Three categories are identified: endocrine responsive, 
endocrine nonresponsive, and tumors of uncertain endocrine responsiveness. These 
categories refer to the groups of tumors that are responsive to endocrine therapies 
alone, chemotherapy alone, and chemotherapy and endocrine therapy combinations, 
respectively. The 2005 Panel viewed tamoxifen as a standard adjuvant treatment for 
premenopausal endocrine responsive patients. The combination of tamoxifen with an 
LHRH agonist is recommended for very young patients, especially in intermediate- 
and high-risk groups, and for premenopausal patients of any age at high risk, especially 
if chemotherapy did not induce amenorrhea. The use of aromatase inhibitors in 
premenopausal patients is not recommended outside of clinical trials, except when 
tamoxifen is contraindicated, especially in node positive disease. Chemotherapy in 
addition to hormone therapy is advised for endocrine responsive patients with node 
positive disease.
In this retrospective pooled analysis of four studies using heterogeneous 
chemotherapy regimens, we have demonstrated that treatment efficacy of adjuvant 
chemotherapy is less in young patients with hormone receptor positive tumors 
compared with young patients with hormone receptor negative tumors. Therefore, we 
conclude that chemotherapy alone is not a sufficient systemic treatment strategy in 
young patients with hormone receptor positive breast cancer. Hormone responsiveness 
is the key for tailoring therapy for young patients with breast cancer.
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Young age at the time of diagnosis of breast cancer is an independent factor of poor 
prognosis. In many treatment guidelines, the recommendation is to treat young 
patients with adjuvant chemotherapy regardless of tumor characteristics. However, 
limited data on prognostic factors are available for young breast cancer patients. The 
purpose of this study was to determine the prognostic value of established clinical and 
pathological prognostic factors in young breast cancer patients.
methods
Data from four European Organisation for Research and Treatment of Cancer (EORTC) 
clinical trials were pooled, resulting in a dataset consisting of 9,938 early breast cancer 
patients with a median follow-up of 11 years. For 549 patients aged less than 40 years 
at the time of diagnosis, including 341 node negative patients who did not receive 
chemotherapy, paraffin tumor blocks were processed for immunohistochemistry 
using a tissue microarray. Cox proportional hazard analysis was applied to assess the 
association of clinical and pathological factors with overall and distant metastasis free 
survival. 
Results
For young patients, tumor size (P = .01), nodal status (P = .006) and molecular subtype 
(P = .02) were independent prognostic factors for overall survival. In the node negative 
subgroup, only molecular subtype was a prognostic factor for overall survival (P = .02). 
Young node negative patients bearing luminal A tumors had an overall survival rate 
of 94% after 10 years follow-up compared to 72% for patients with basal-type tumors. 
Conclusion
Molecular subtype is a strong independent prognostic factor in breast cancer patients 
younger than 40 years of age. These data support the use of established prognostic 
factors as a diagnostic tool to assess disease outcome and to plan systemic treatment 
strategies in young breast cancer patients.
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IntRoduCtIon
The incidence of early stage breast cancer in young women is increasing. At present, 
breast cancer at a young age, that is, less than 40 years, accounts for approximately 5 
to 7.5% of the total number of cases diagnosed each year in Western Europe and the 
US.1-3 Based upon multiple retrospective analyses that demonstrated the unfavorable 
impact of young age on prognosis in breast cancer, several current consensus 
guidelines have included age under 35 years as an absolute indication for adjuvant 
systemic chemotherapy irrespective of other tumor characteristics.4-6 These guidelines 
imply that for young patients with favorable tumor features such as small tumor size 
and negative axillary nodal status, adjuvant chemotherapy and hormonal therapy 
for patients with hormone receptor positive tumors is advised although absolute 
treatment benefits are not well known. Moreover, the long-term toxicity of adjuvant 
chemotherapy and the implications of possible fertility impairment and premature 
menopause are of particular concern in young women.7 In addition to an increased 
risk of developing distant metastases, local recurrence rates after mastectomy or breast 
conserving therapy are also higher than in older patients,5 and although an additional 
boost dose of radiotherapy after breast-conserving surgery decreases the risk of local 
recurrence especially in young women,8 these loco-regional recurrence rates are still 
significantly higher compared with mastectomy in young patients. 
Retrospective analyses have demonstrated breast cancer at a very young age to 
be associated with higher grade, estrogen receptor negative tumors, a more advanced 
stage of disease at the time of diagnosis, and the presence of BRCA-1 or -2 germline 
mutations.9-13 Recent gene expression profiling studies showed that tumors of young 
women showed a higher probability of PI3K, Myc, and β-catenin deregulation and 
lower mRNA levels of estrogen receptor-α, estrogen receptor-β and progesterone 
receptor, but higher levels of HER2, and epidermal growth factor receptor.14, 15 
More refined knowledge of prognostic factors in young breast cancer patients 
will be of use in guiding therapy, including adjuvant chemotherapy, in these women. 
The prognostic value of molecular subtype based on immunohistochemistry is 
uncertain within the group of young breast cancer patients. Therefore, we pooled 
the data of four randomized European Organisation for Research and Treatment 
of Cancer (EORTC) early stage breast cancer trials and collected and characterized 
tumor material of patients younger than 40 years in order to perform multivariate 
prognostic factor analyses. 




The data used in this study were obtained from four randomized phase III EORTC 
clinical trials that included patients with early stage breast cancer. The trials randomized 
between two types of loco-regional therapy and between different timing of the same 
type of systemic therapy. The detailed features of these trials have been described in 
detail previously.16-19 The trial protocols are summarized below:
EORTC trial 10801 (1980 to 1986, median follow-up 13.4 years) was conducted 
in order to assess the safety of breast conserving treatment. Patients were randomized 
between breast conserving surgery combined with radiotherapy and modified radical 
mastectomy. Six cycles of adjuvant chemotherapy with cyclophosphamide 100 mg/
m2 given orally on days 1 to 14, methotrexate 40 mg/m2 given intravenously on Days 
1 and 8, and 5-fluorouracil 600 mg/m2 (CMF) given intravenously on Days 1 and 8, 
were indicated for all node positive patients under the age of 55. No information was 
collected on hormonal therapy. A total number of 902 patients were randomized of 
which 113 patients aged less than 40 years at the time of diagnosis.16 
EORTC trial 10854 (1986 to 1991, median follow-up 10.8 years) studied the 
question of whether one course of peri-operative chemotherapy given directly after 
surgery yields better results in terms of treatment outcome than surgery alone. Peri-
operative chemotherapy consisted of one single course of doxorubicin 50 mg/m², 
5-fluorouracil 600 mg/m², and cyclophosphamide 600 mg/m² (FAC), administered 
intravenously within 36 hours after surgery. Node positive premenopausal patients in 
the peri-operative chemotherapy group were recommended to receive an additional 
five cycles of CMF. Node positive premenopausal patients in the surgery alone group 
were advised to receive one conventional course of FAC followed by five cycles of 
CMF. Prolonged adjuvant systemic treatment was left to the discretion of the local 
investigators. A total number of 2,795 patients were included of which 396 patients 
aged less than 40 years at time of diagnosis.17
EORTC trial 10902 (1991 to 1999, median follow-up 10 years) was set up to 
compare pre-operative adjuvant chemotherapy with postoperative chemotherapy. 
Chemotherapy consisted of four cycles of 5-fluorouracil 600 mg/m2, epirubicin 60 
mg/m2, and cyclophosphamide 600 mg/m2 (FEC) administered intravenously, at 
three-weekly intervals. A total number of 698 patients were randomized of which 125 
patients aged less than 40 years at time of diagnosis.18, 20
EORTC trial 22881 (1989 to 1996, median follow-up 10.8 years) studied the 
value of a boost dose after primary breast conserving surgery. Patients with stage I or 
II breast cancer who had undergone microscopically complete surgical removal of the 
tumor and axillary dissection were randomly assigned to undergo 50 Gy irradiation of 
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the whole breast with or without an additional dose of 16 Gy to the tumor bed. Patients 
with a microscopically incomplete excision were assigned to receive booster doses of 
10 or 26 Gy. Patients with axillary lymph node involvement received adjuvant systemic 
therapy: premenopausal patients received chemotherapy (CMF, FEC, or FAC), and 
postmenopausal patients received tamoxifen. A total number of 5,569 patients were 
randomized of which 558 patients aged less than 40 years at time of diagnosis.8, 19
Adjuvant hormonal therapy for premenopausal hormone receptor positive 
patients was not yet recommended at the time these trials were conducted. In the 
oldest two trials, tamoxifen administration was not even recorded. In the trials 
where tamoxifen use was recorded, less than 5% of patients under 40 years received 
tamoxifen. Therefore, we assumed that only a very small fraction of the young patients 
in these studies received tamoxifen.
Collection of tumor material and immunohistochemistry
A request was sent to participating institutions to submit paraffin blocks containing a 
representative part of the tumor from all patients aged less than 40 years at the time of 
diagnosis except for those who had participated in EORTC trial 10902 and received 
neoadjuvant chemotherapy (this group of patients was excluded for this study to avoid 
the influence of down-staging by preoperative chemotherapy). Tumor tissue was 
collected and processed for immunohistochemistry using a tissue microarray. Three 
core biopsies of 0.6 mm were taken from every tumor specimen and placed in a so-
called donor block. This procedure has been described previously.21-24 A representative 
standard histological section from each individual tumor was stained with H&E to 
assess tumor type, to perform histological grading according to Elston and Ellis, 
and to assess the presence and extent of lymphangio invasion (none versus one to 
five versus more than five vessels).25 ER, PgR, HER2 and P53 expression levels were 
assessed using immunohistochemistry. Detailed procedures have been described 
previously.26-28 In summary, a tissue microarray slide was stained and scored counting 
the percentage of positive cells and taking the mean value of the three tumor biopsies. 
For ER expression, tumors with >1% of the tumor cells showing nuclear staining were 
considered positive. For PgR expression, tumors with >10% of the tumor cells showing 
nuclear staining were considered positive. For P53 accumulation, a semi-quantitative 
system was used based on the sum of the mean staining intensity (0 to 3; none to 
strong) and an estimation of the percentage of positive cell nuclei (0 to 4; 0% to >75%); 
this allowed a sum score of 0 to 7, with staining ≥4 being considered positive.26, 27 HER2 
expression was scored estimating the level of membranous staining (0, 1+, 2+, or 3+). 
Strong membranous staining in >30% of tumor cells (3+) was considered positive. The 
molecular breast cancer subtypes were approximated using histological grade and the 
ER, PgR, and HER2 status of the primary tumor. Patients were categorized as follows: 
luminal A (ER+ or PgR+ and HER2- and grade 1 or 2), luminal B (ER+ or PgR+ and 
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Characteristic All patients (N = 549) Node negative (N = 341)
N % N %
Age distribution
<30 years 57 10 40 12
31 to 35 years 178 32 107 31
35 to 40 years 314 58 194 57
Pathological tumor size
T1a-b 37 7 30 10
T1c 296 60 241 64
T2 158 32 82 26
T3 6 1 2 1
Missing 32 26
Surgery
Breast conserving 446 81 299 88
Mastectomy 102 19 42 12
Adjuvant chemotherapy1
No 326 60 304 89
Yes 221 40 37 11
ER status
Positive 310 66 115 41
Negative 158 34 165 59
Missing 81 61
PgR status
Positive 223 48 141 51
Negative 241 52 136 49
Missing 85 64
Tumor type
Ductal 497 96 306 96
Lobular 17 3 10 3
Other 5 1 4 1
Missing 30 21
Histological grade
I 76 15 54 17
II 165 32 93 29
III 276 53 172 54
Missing 32 22
Lymphangio invasion
None 357 69 243 76
1-5 vessels 86 17 49 15
> 5 vessels 76 14 27 9
Missing 30 22
HER2 status
Negative 346 74 216 63
Positive 119 26 64 19
Missing 84 61
P53 status
Negative 331 71 198 72
Positive 133 29 78 28
Missing 85 65
Table 1. Characteristics of study participants
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HER2+; or ER+ or PgR+ and HER2- and grade 3), HER2 (ER- and PgR- and HER2+), 
and basal type (ER- and PgR- and HER2-). Estimations of tumor grade and protein 
expression levels were scored by two investigators (MJV and JAH) simultaneously who 
had to come to an agreement in case of different views. 
statistical analyses
Data analysis was performed at the Leiden University Medical Center using SPSS 
for Mac (version 18.0; SPSS, Chicago, IL, USA). The χ² test was used to compare the 
distribution of baseline characteristics among groups. Endpoints studied were overall 
survival and distant metastasis free survival. Overall survival time was defined as 
the time between randomization and death from any cause. Distant metastasis free 
survival time was defined as time to distant metastasis or death if the latter event 
occurred before a distant metastasis was diagnosed. Survival analyses were performed 
using the Kaplan Meier method. Covariates included patient age, and tumor- and 
treatment related characteristics. Tumor characteristics were tumor size, nodal status, 
histological grade, hormone receptor status, HER2 status, P53 status, molecular 
subtype and lymphangio invasion. Treatment characteristics were type of surgery and 
administration of chemotherapy. Tamoxifen use was not included because of the high 
rate of missing data for this variable. Cox proportional hazard regression models were 
used to estimate hazard ratios (HR) with 95% confidence intervals (CI). A multivariate 
Cox regression model was fitted that was based on all characteristics that had a P-value 
up to .10 in the univariate analysis. Variables determining molecular subtype were not 
included in multivariate analyses if molecular subtype was included. A 5% significance 
level was used and all tests are two-sided. 
continued All patients (N = 549) Node negative (N = 341)
N % N %
Molecular subtype
Luminal A 154 34 79 29
Luminal B 157 34 86 32
HER-2 35 8 90 34
Basal (triple-negative) 111 24 14 5
Missing 92 72
1 EORTC trial 10854 randomized between one course of peri-operative chemotherapy which was not considered 
as prolonged chemotherapy. ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; PgR, 
progesterone receptor. 
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Results
Prognostic factors in young patients 
A total of 9,938 early stage breast cancer patients participated in the four trials. Of 
this dataset, 1,192 (12%) patients were aged less than 40 years at the time of diagnosis. 
Paraffin embedded tumor material was obtained and processed into a tissue microarray 
for 549 patients aged less than 40 years (Table 1). Median age of these patients was 36.8 
years. Tumors were subdivided according to molecular subtype: 111 patients (24%) 
aged less than 40 years had triple-negative tumors, 154 (34%) patients had luminal A 
tumors, 157 (34%) had luminal B tumors and 35 (8%) had HER2 tumors. Twenty-nine 
percent of tumors were P53 positive (Table 1). At time of analysis, 143 of 549 patients 
had died and 64 patients had developed distant metastases and were still alive. 
At univariate analysis, pathological tumor size, nodal status, histological grade, 
lymphangio invasion, progesterone receptor status, molecular subtype, type of surgery 
and adjuvant chemotherapy were significantly associated with overall and distant 
metastasis free survival (Supplementary Table 1). HER2 and P53 status did not show 
an association with overall or distant metastasis free survival and were not included at 
subsequent multivariate analysis. At multivariate analysis (Table 2), pathologic tumor 
size, nodal status, and molecular subtype remained the only independent prognostic 
factors for both overall survival and distant metastasis free survival. For distant 
metastasis free survival, molecular subtype was a trend-significant prognostic factor 
(P = .06; Table 2).
Table 2. Multivariate analysis of prognostic factors in 549 patients aged less than 
40 years
Characteristic Overall survival Distant disease-free survival
HR 95% CI P HR 95% CI P
pT2 + pT3 1.68 1.12-2.52 0.01 1.61 1.14-2.25 0.006
Lymph node positive 2.62 1.31-5.23 0.006 2.21 1.24-3.96 0.008
Lymphangio invasion 0.75 0.73
No vessels 1 1
1 to 5 vessels 0.93 0.53-1.62 0.97 0.61-1.53
>5 vessels 1.18 0.71-1.97 1.17 0.75-1.83
Molecular subtype 0.02 0.06
Basal 1 1
Luminal A 0.50 0.29-0.86 0.69 0.44-1.08
HER2 0.42 0.17-1.04 0.45 0.21-0.99
Luminal B 0.92 0.56-1.48 1.01 0.67-1.53
Breast conserving therapy 0.76 0.47-1.24 0.27 0.81 0.53-1.23 0.33
Adjuvant chemotherapy 0.68 0.35-1.33 0.26 0.65 0.37-1.13 0.13
HR, hazard ratio; CI, confidence interval
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Prognostic factors in young node negative patients 
The subgroup of node negative patients aged less than 40 years consisted of 640 
patients. Of 341 patients, tumor material was available for analysis (Table 1). Of these 
node negative patients, 304 (89%) patients did not receive adjuvant chemotherapy. 
At univariate analysis, pathological tumor size, histological grade, ER status 
and molecular subtype were significantly associated with overall survival and distant 
metastasis free survival (Supplementary Table 2). In addition, PgR status and the 
administration of adjuvant chemotherapy were significantly associated with overall 
survival. Figure 1 shows the impact of molecular subtype, histological grade and 
pathological tumor size, respectively, on overall and distant metastasis free survival in 
the subgroup of node-negative patients aged less than 40 years. Ten-year survival rates 
for the molecular subtypes were 94% for luminal A, 93% for HER2, 78% for luminal 
B and 72% for basal (Figure 1). Of note, the overall survival rate for young patients 
bearing a grade I tumor was 92% at 11 years of follow-up, whereas patients with grade 
III tumors had a survival rate of 72% (Figure 1). 
At multivariate analysis (Table 3), molecular subtype was associated with 
overall survival (overall P = .02; basal subtype versus luminal A subtype: HR = 0.22, 
95% CI = 0.08 to 0.60, P = .003) and distant metastasis free survival (overall P = .08; 
basal subtype versus luminal A subtype: HR = 0.46, 95% CI = 0.25 to 0.85, P = .013).
dIsCussIon
In this study, we performed a retrospective pooled analysis to gain further insight into 
tumor characteristics of young breast cancer patients. In young patients, molecular 
subtype was the strongest prognostic factor of the covariates studied, distinguishing 
young patients with a favorable prognosis from young patients with an unfavorable 
prognosis.
In our study, young node negative patients with luminal A and HER2 tumors 
had excellent long-term overall survival rates of 94% and 93%, respectively, and distant 
disease-free survival rates of 83% and 79%, respectively, at 10-year follow-up (Figure 
1). Of note, only 3 out of 86 young node negative patients with luminal A tumors 
received adjuvant chemotherapy. Therefore, these data suggest that molecular subtype 
can be utilized in adjuvant treatment planning in young node negative patients. 
Recently, Cancello et al. showed that very young patients with basal, luminal B or 
HER2, but not luminal A breast cancer have a worse prognosis when compared with 
older patients with similar characteristics of disease.29
Several authors have previously described the independent prognostic role 
of histological grade in young breast cancer patients. Sundquist et al. showed that 
patients bearing histological grade III tumors had a poor overall survival of 41% at 
the 11-year follow-up in a Swedish cohort of 107 patients aged less than 40 years.30 
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Figure 1. Overall and distant disease free survival for node negative patients aged less than 40 years stratified by 
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Although histological grade was associated with overall survival, it did not reach 
statistical significance (Grade I versus III: HR = 4.19; 95% CI = 0.91 to 19.5). Kollias 
et al. demonstrated in a cohort of 2,879 patients that the worse prognosis of the age 
group younger than 35 years (N = 120) was explained by the higher proportion of 
histological grade III breast cancers in the young group.31 In a recent study, high 
histological grade and young age were identified as the most important risk factors 
for local relapse.32 Our study suggests that histological grade (as part of molecular 
subtype) is an important prognostic factor in young breast cancer patients.
Among the established prognostic and predictive factors in young breast cancer 
patients, the estrogen receptor status is of particular interest. Recently, we showed 
that adjuvant chemotherapy provides limited survival benefit in hormone receptor 
positive young breast cancer patients.33 The Korean Breast Cancer Society recently 
reported that young age was associated with a greater probability of death in breast 
cancer patients.34 When studied in more detail, the survival difference was only found 
in the hormone receptor positive group.34 As these data were collected from 1992 
onwards, young hormone receptor positive patients received tamoxifen, in contrast 
to the patients in our study who were treated before adjuvant tamoxifen treatment 
became a standard in a large proportion of breast cancer patients with hormone 
receptor positive disease. These observations suggest that tamoxifen therapy might 
provide less survival benefit in young hormone receptor positive breast cancer patients 
as compared to older hormone receptor positive breast cancer patients. However, 
several trials have suggested an equal effect of endocrine therapy as compared to 
chemotherapy in hormone receptor positive premenopausal breast cancer patients.35, 
36 In our data set of older EORTC trials, young hormone receptor positive patients 
did not receive hormonal therapy. Notwithstanding, in our study, young patients with 
luminal A tumors had an excellent prognosis, which might have been augmented with 
the administration of hormonal therapy.  
The current study has a number of limitations. First, the study design was a 
retrospective analysis of four heterogeneous randomized trials that were not primarily 
Table 3. Multivariate analysis of prognostic factors in 341 node negative patients aged 
less than 40 years
Characteristic Overall survival Distant disease-free survival
HR 95% CI P HR 95% CI P
pT2 + pT3 1.75 0.99-3.10 0.06 1.33 0.83-2.15 0.24
Molecular subtype 0.02 0.08
Basal 1 1
Luminal A 0.22 0.08-0.60 0.46 0.25-0.85
HER2 0.25 0.03-1.85 0.53 0.16-1.73
Luminal B 0.87 0.48-1.59 0.82 0.49-1.38
Adjuvant chemotherapy 0.96 0.38-2.45 0.94
HR, hazard ratio; CI, confidence interval
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designed to test differences in outcome between young and old patients. Second, 
tumor material could not be collected for all patients aged less than 40 years and this 
could introduce selection bias. However, patient and traditional tumor characteristics 
were evenly distributed between the group for which tumor blocks were available 
and the group for which no tumor blocks could be collected (Supplementary Table 
3). Third, information on tamoxifen use is largely missing. However, in the trials 
in which tamoxifen use was recorded, less than 5% of the patients younger than 40 
years received tamoxifen. Despite these limitations, the current pooled analysis used 
individual patient data of four high-quality randomized controlled trials with renewed 
histopathological analysis to assess prognostic factors in young breast cancer patients. 
These data provide a robust estimate of the value of prognostic factors in young breast 
cancer patients. We believe our data justify a more critical view concerning current 
adjuvant chemotherapy guidelines in young low-risk breast cancer patients. 
In conclusion, the established prognostic factors molecular subtype (including 
hormone receptor status, histological grade and HER2 receptor status), tumor size 
and nodal status remain independent prognostic factors on disease outcome in young 
breast cancer patients. In particular, molecular subtype was strongly associated with 
overall and distant metastasis free survival. Future treatment guidelines concerning 
young breast cancer patients should be refined based upon tumor characteristics, 
probably derived from microarray driven translational research projects, and not 
based upon age alone.37-39
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suPPlementARy dAtA
Supplementary Table 1. Univariate analysis for prognostic factors in 549 patients aged 
less than 40 years
Characteristic Overall survival Distant disease-free survival
HR 95% CI P HR 95% CI P
pT2 + pT3 2.22 1.56-3.16 <0.01 1.90 1.41-2.56 <0.01
Lymph node positive 2.19 1.57-3.05 <0.01 1.88 1.42-2.48 <0.01














Lymphangio invasion 0.02 0.01
No vessels












ER+ 0.77 0.53-1.12 0.17 0.92 0.67-1.26 0.61
PgR+ 0.67 0.47-0.97 0.03 0.80 0.59-1.09 0.16
HER2+ 1.09 0.73-1.64 0.67 1.02 0.72-1.44 0.93
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P53+ 1.25 0.85-1.84 0.26 0.87 0.62-1.22 0.42
Breast conserving therapy 0.55 0.38-0.79 <0.01 0.66 0.48-0.92 0.01
Adjuvant chemotherapy 1.87 1.34-2.61 <0.01 1.55 1.17-2.05 <0.01
Supplementary Table 2. Univariate analysis of prognostic factors in 341 node-negative 
patients aged less than 40 years. 
HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PgR, progesterone receptor; HER2, human 
epidermal growth factor receptor 2.
1 Two patients with pathological tumor size larger than 5 cm were excluded from the analysis. 2 37 patients 
received adjuvant chemotherapy. HR, hazard ratio; CI, confidence interval; ER, estrogen receptor; PgR, 
progesterone receptor; HER2, human epidermal growth factor receptor 2.
Characteristic Tumor material available  
(N = 549)
Tumor material not available 
(N = 643) P



















































Characteristic Overall survival Distant disease-free survival
HR 95% CI P HR 95% CI P
pT2 + pT31 2.40 1.45-3.97 <0.01 1.58 1.03-2.42 0.04


















Lymphangio invasion 0.87 0.36
No vessels












ER+ 0.57 0.34-0.97 0.04 0.63 0.41-0.96 0.03
PgR+ 0.56 0.32-0.95 0.03 0.71 0.46-1.08 0.11
HER2+ 0.85 0.44-1.65 0.63 0.91 0.54-1.53 0.72



















P53+ 1.41 0.80-2.48 0.24 0.90 0.57-1.47 0.68
Breast conserving therapy 0.92 0.45-1.85 0.81 1.31 0.68-2.52 0.41
Adjuvant chemotherapy2 1.97 1.03-3.76 0.04 1.12 0.60-2.08 0.72
Supplementary Table 3. Patient and tumor characteristics of patients aged < 40 years 
from whom tumor material was available for immunohistochemical analysis and of 
patients aged < 40 years from whom tumor material was not available.
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Part IB
Resistance to therapy and cancer stem cells
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The purpose of this study was to compare expression and prognostic effect of the breast 
cancer stem cell marker aldehyde dehydrogenase-1 (ALDH1) in young and elderly 
breast cancer patients. 
methods 
The study population (N = 574) consisted of all early breast cancer patients primarily 
treated with surgery in our center between 1985 and 1994. Median follow-up was 
17.9 years (range: 0.1 to 23.5). Tissue microarray slides were immunohistochemically 
stained for ALDH1 expression and quantified by two independent observers who were 
blinded to clinical outcome. Assessment of the prognostic effect of ALDH1 expression 
was stratified according to age and systemic treatment.
Results
Complete lack of expression of ALDH1 was found in 40% of tumors. With increasing 
age more tumors showed complete absence of ALDH1 expression (P < .001). In 
patients aged > 65 years, ALDH1 status was not associated with any clinical outcome. 
Conversely, in patients aged < 65 years, ALDH1 positivity was an independent risk 
factor of worse outcome for relapse free period (hazard ratio = 1.71, 95% CI = 1.09 to 
2.68, P = .021) and relative survival (relative excess risks of death = 2.36, 95% CI = 1.22 
to 3.68, P = .016). Ten-year relative survival risk was 57% in ALDH1 positive patients 
compared to 83% in ALDH1 negative patients.
Conclusion
ALDH1 expression and its prognostic effect are age-dependent. Our results support the 
hypothesis that breast cancer biology is different in elderly patients compared to their 
younger counterparts and emphasizes the importance of taking into consideration 
age-specific interactions in breast cancer research.
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IntRoduCtIon
Age at diagnosis of breast cancer is an important independent prognostic factor. 
Young age is associated with more aggressive tumors with a relatively high risk of 
distant metastasis and loco-regional recurrence,1 whereas old age is associated with 
more indolent tumors.2, 3 Although tumor characteristics differ considerably between 
age groups (including hormone receptor and human epidermal growth factor 
receptor 2 (HER2) status), these tumor characteristics can only account for part of 
the divergence in survival witnessed between age groups.2 Little is known about the 
impact and significance of various prognostic and predictive factors in elderly as 
compared to their younger counterparts. As is the case with randomized trials, elderly 
are underrepresented in translational studies on molecular markers.4, 5 This caveat 
is especially worrisome since studies show that the relative survival in elderly breast 
cancer patient is lower, despite more favorable tumor characteristics, which is probably 
due to the fact that these patients receive less aggressive treatment.6 Molecular markers 
could aid to guide therapy in the fit elderly. Moreover, specific age-interactions might 
underlie pathophysiological processes in the development of primary breast cancer 
and subsequent local and distant metastases. Therefore, breast cancer researchers 
should account for age-specific differences.4 
Recent evidence in tumor biology supports the cancer stem cell theory and may 
also provide a biological reason for the age-associated survival difference.7 According 
to this theory, cancer stem cells, defined as a small subset of tumor cells with stem 
cell-like features including epithelial-to-mesenchymal transition, have the capacity to 
self-renewal and differentiation, giving rise to heterogeneous tumor cell population. 
Various putative markers of breast cancer stem cells have been proposed, including 
aldehyde dehydrogenase-1 (ALDH1) activity, CD44+/CD24-, CD133, and ITGA6.7-10 
In particular, ALDH1 expression has shown promise as a clinically relevant prognostic 
marker.9, 11, 12 Moreover, various studies have shown that the subset of cancer stem cells 
is relatively resistant to chemo- and radiotherapy.13, 14 Thereby, the subpopulation of 
cancer stem cells can provide both an explanation and a therapeutic target for poor-
prognostic, treatment-resistant and recurrent breast cancer.
ALDH1 is a detoxifying enzyme responsible for the oxidation of intracellular 
aldehydes and thereby confers resistance to alkylating agents.12, 15 This detoxifying 
capacity might underlie the longevity of stem cells by protecting against oxidative stress. 
Moreover, ALDH1 may have a role in early differentiation of stem cells and stem cell 
proliferation through its role in oxidizing retinol to retinoic acid, a modulator of cell 
proliferation.15 ALDH1 expression is associated with unfavorable tumor characteristics 
in breast cancer, such as high grade, absence of hormone receptor expression, positive 
HER2 status and the basal-like molecular subtype.9, 16-18
To study whether the expression of the breast cancer stem cell marker ALDH1 
is associated with age and has an influence on clinical outcome, we analyzed the age-
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distribution of ALDH1 expression and its prognostic role in young and elderly patients 
using long-term follow-up data of a cohort of breast cancer patients primarily treated 
with surgery in our institution. 
mAteRIAl And metHods
study cohort
The patient population comprised all non-metastasized breast cancer patients 
primarily treated with surgery in the Leiden University Medical Center between 1985 
and 1994 with tumor material available (N = 574).19 Patients with bilateral tumors 
or a prior history of cancer, other than basal cell carcinoma or cervical carcinoma in 
situ, were excluded. The following data were known: age, tumor grade, histological 
type, TNM stage, local and systemic therapy, locoregional or distant tumor recurrence, 
survival, and expression of estrogen receptor (ER), progesterone receptor (PgR) and 
human epidermal growth factor receptor 2 (HER2). All tumors were graded according 
to current pathological standards by an experienced breast cancer pathologist (V.S.). 
Median follow-up was 17.9 years (range: 0.01 to 23.5). Approval was obtained from 
the Leiden University Medical Center Medical Ethics Committee. All samples were 
handled in a coded fashion, according to National ethical guidelines (“Code for Proper 
Secondary Use of Human Tissue”, Dutch Federation of Medical Scientific Societies).
Assessment of AldH1 expression
Mouse antibody against ALDH1 (611195, BD Biosciences) was used for 
immunohistochemistry. Tissue sections of 4 μm were cut from a previously constructed 
tissue microarray of formalin-fixed paraffin-embedded tumors of 574 patients from 
whom tumor material was available.19 Immunohistochemical staining was performed 
according to previously described standard protocols.19 Human liver tissue slides 
served as positive control. Negative controls were human liver tissue slides that did 
undergo the whole immunohistochemical staining without primary antibodies. 
Microscopic analysis of ALDH1 was assessed independently by two observers in a 
blinded manner. Absence and presence of ALDH1 activity was classified as 0% and 
1-100% staining of tumor cells, respectively (Figure 1A).9, 11 
statistical analysis
Statistical analyses were performed using the statistical packages SPSS (version 16.0 
for Windows, Spps Inc, Chicago, IL, USA) and Stata (version 10.0 for Windows, 
StataCorp, College Station, TX, USA). Cohen’s kappa coefficient was used to assess the 
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inter-observer agreement in quantification of ALDH1 expression. The χ² test was used 
to evaluate associations between various clinicopathological parameters and ALDH1 
expression. Relapse-free period was defined as the time from date of surgery until an 
event (locoregional recurrence and/or a distance recurrence, whichever came first). 
Relapse-free period is reported as cumulative incidence function, after accounting for 
death as competing risk.20 The Kaplan–Meier method was used for survival plotting 
and log-rank test for comparison of relapse-free period curves. Cox proportional 
hazard analysis was used for univariate and multivariable analysis for relapse-free 
period. Relative survival was calculated by the Hakulinen method as the ratio of the 
survival observed among the cancer patients and the survival that would have been 
expected based on the corresponding (age, sex, and year) general population. National 
life tables were used to estimate expected survival. Relative excess risks of death were 
estimated using a multivariable generalized linear model with a Poisson distribution, 
based on collapsed relative survival data, using exact survival times. 
Analyses were performed for all patients and stratified for age and systemic 
treatment. Age of 65 years at time of diagnosis was chosen as the cut-off point for age 
stratification.21 An interaction term with age and ALDH1 status was introduced in Cox 
proportional hazard model to assess the interaction in prognostic effects of ALDH1 
status for the age groups. Variables with a P-value of < .10 in univariate analysis were 
entered in multivariable analysis.
Results
AldH1 expression in patient cohort
Immunohistochemical data of ALDH1 expression were available for 496 of the 574 
patients (86.4%). Of these patients, 326 (65.7%) were < 65 years at diagnosis and 170 
(34.3%) were > 65 years at diagnosis. The Cohen’s kappa coefficient for inter-observer 
agreement was 0.81. Complete lack of expression of ALDH1 of any tumor cell was 
found in 40.4% of the tumors. The association between ALDH1 status and age is shown 
in Figure 1B. ALDH1 expression was inversely correlated with age (P = .0015) and was 
significantly higher in patients aged < 65 years (65.3%) than in patients aged > 65 years 
(48.2%; P < .001). The association of ALDH1 expression with classic patient, tumor 
and treatment characteristics is shown in Table 1. In patients aged < 65 years, ALDH1 
expression was significantly correlated with high histological grade and positive nodal 
status. In patients aged > 65 years, ALDH1 expression was significantly correlated with 
absence of estrogen receptor expression.
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Impact of AldH1 on survival
The association of ALDH1 status with relapse-free period and relative survival is 
shown in Figures 3 and 4, respectively. Analysis of relapse-free period showed a trend 
towards a significant association between ALDH1 status and clinical outcome for 
the whole population (P = .10; Figure 2A, D). In the group of patients aged younger 
than 65 years, a strong association was found between ALDH1 expression and poor 
clinical outcome (P = .01; Figure 2B). In the subgroup of younger patients who did 
not receive any systemic treatment, a comparable association was found (P = .009; 
Figure 2E). In this group, 52% of patients with ALDH1 positive tumors were relapse-
free at 10 years follow-up compared to 72% of patients with ALDH1 negative tumors 
(absolute difference = 20%). Conversely, in the elderly patients, no association was 
found between ALDH1 status and clinical outcome (P = .20; Figure 2C, F). Interaction 
analysis demonstrated a statistically significant difference in the prognostic effect of 
ALDH1 status in young and elderly patients (P = .007).
A 
B Logistic regression P = .015 ALDH1 absence 
ALDH1 presence 
Figure 1. ALDH1 expression and distribution over age groups. A. Representative photographs of tissue microarray 
punches of human breast cancer specimens immunohistochemically stained for ALDH1 with representative 
examples of strong staining (left panel), intermediate staining (middle panel) and no staining (right panel). Bar 
represents 100 μm. B. ALDH1 status according to age (N = 496). Logistic regression P-value is shown. 
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Table 1. Association of ALDH1 status with clinicopathological charateristics, stratified 
by age*















































































































































































Analysis of relative survival showed a similar pattern as for relapse-free period: 
a strong association between ALDH1 positive tumors and poor relative survival in the 
younger patient group (Figure 3B, E) and no association between ALDH1 status and 
relative survival for elderly patients (Figure 3C, F). In the subgroup of younger patients 
who did not receive any systemic treatment, the 10-year relative survival rate was 57% 
in patients with ALDH1 positive tumors compared to 83% in patients with ALDH1 
negative tumors (absolute difference = 26%, P = .008; Figure 3E). Interaction analysis 
demonstrated a statistically significant difference between the prognostic effect of 
ALDH1 status in young and elderly patients (P = .047).
Multivariable analyses were conducted for the patient groups that did not 
receive systemic treatment (276 young patients and 154 elderly patients). ALDH1 
status remained an independent prognostic factor in the young patient group for both 
relapse-free period (hazard ratio = 1.71, 95% CI = 1.09 to 2.68, P = .021; Table 2) and 
relative survival (relative excess risks of death = 2.36, 95% CI = 1.22 to 3.68, P = .016; 
Table 3).  
* Missing data not shown. N, number of patients; ALDH1, aldehyde dehydrogenase 1; ER, estrogen receptor; 
PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2
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dIsCussIon
In this study, we demonstrated that the presence of ALDH1 expression is significantly 
higher in young breast cancer patients than in elderly patients. Moreover, we 
demonstrated that ALDH1 expression is an independent risk factor for decreased 
survival in young breast cancer patients, but not in elderly patients.
To the best of our knowledge, we are the first to show that expression of ALDH1 
in tumors is age-dependent. A corresponding difference in the number of cancer stem 
cells might provide an explanation for known differences in survival between young 
and elderly breast cancer patients. A potential strength of our study is that it includes 
consecutive patients from one center, not biased by being part of a clinical trial. The 
age restriction of the majority of clinical trials prohibits inclusion of patients older 
than 70 year and, indeed, less than 10% of clinical trial participants is older than 65 
years.22 In our study, 34% of patients were 65 years or older at diagnosis of breast 
cancer. Therefore, our study was not hampered by lack of statistical power to analyse 
the effect of ALDH1 in the elderly.
We showed that ALDH1 expression has a qualitative age interaction effect. In 
our study, ALDH1 is a predictor of poor prognosis in young patients, but ALDH1 did 
not influence clinical outcome in elderly patients. Recently, Zhou et al. pooled the 
available data on the prognostic role of ALDH1 activity in breast cancer.18 Their meta-
analysis demonstrated that ALDH1 activity as assessed by immunohistochemistry was 
significantly associated with worse overall survival (unadjusted pooled relative risk, 
2.83, 95% CI = 2.16 to 3.67; four patient cohorts including 1,158 patients).18 However, 
the authors did not stratify for age. In other studies, no interaction was found between 
ALDH1 expression and age.9, 13, 17 However, in these studies, an age of 40 or 50 year was 
used as a cut-off for age stratification. We used 65 years as a cut-off point as this may 
better match with the bimodal age distribution of breast cancer, which suggests that 
breast cancer is characterized by early- and late-onset tumor types with modes near 
ages 50 and 70 years.4, 21 As argued by Anderson et al., these modal ages do not suggest 
a sharp division of distinctive tumor categories, but rather reflect central tendencies 
for the age distributions of biologically distinct cancer populations.4, 23 In line with this 
bimodal age distribution, a biological explanation of the qualitative age-interaction 
of the prognostic effect of ALDH1 expression might be that of a changing micro-
environment in elderly patients, which may result in hampered signal transduction 
between tumor stem cells and the micro-environment. Moreover, changes in metabolic 
processes might limit the role of tumor stem cells in elderly patients. Increasing 
evidence from the field of epigenetics demonstrates that hypermethylation-induced 
repression of genes required for stem cell differentiation is linearly associated with 
age.24 This suggests that, with increasing age, the role of tumor stem cells becomes 
more limited. Notwithstanding the need to clarify the underlying mechanism, this 
new finding on the age-dependent role of ALDH1 activity warrants further validation 
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and underlines the need of age stratification when assessing biomarkers and new 
therapies for breast cancer patients.  
In conclusion, we demonstrated that expression of the putative breast cancer 
stem cell marker ALDH1 and its prognostic effect are age-dependent in breast cancer 
patients. We demonstrate, for the first time, the different prognostic impact of a 
molecular marker in elderly, which suggests that fundamentally different biological 
mechanisms underlie age-related breast cancer prognosis. Our results support the 
hypothesis that breast cancer biology of elderly patients and their younger counterparts 
is distinct and emphasizes the importance of analyzing and reporting age-specific 
effects in breast cancer research.
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Alternatively spliced and full-length tissue 
factor reveal a non-identical relationship 
to clinicopathological parameters in a 
large cohort of human breast cancer
van den Berg JW1, Mieog JSD1, de Kruijf EM, Wang J, Sajet A, Kuppen PJK, van de 
Velde CJH, Reitsma PH, Osanto S, Bogdanov VY, Versteeg HH, Liefers GJ
1 Shared first authorship




Alternatively spliced tissue factor (asTF) - a soluble variant of TF - influences tumor 
growth and angiogenesis in an integrin-dependent fashion, while full-length TF 
(flTF) stimulates angiogenesis via protease-activated receptor-2 (PAR2). Therefore, we 
investigated how TF isoforms relate to clinicopathology in human breast cancer.
methods 
Tumor material and matched normal tissue of 574 breast cancer patients was obtained 
after primary surgery and assembled in tissue micro arrays, which were stained with 
antibodies specific for asTF and flTF. The percentage of positive tumor cells was 
independently scored by two observers. Patients in the first quartiles were deemed 
negative. Associations of TF expression with clinicopathological parameters and 
survival were calculated. Subcellular localization of asTF and flTF was investigated in 
transfected baby hamster kidney cells and human breast cancer sections.
Results
asTF and flTF expression was found in virtually all breast cancer samples (> 95%), 
whereas normal tissue showed limited expression (asTF = 4%; flTF = 38%). asTF 
positive tumors were associated with poor histological differentiation and large 
tumors. flTF positive tumors were associated with poor histological differentiation and 
expression of the breast cancer stem cell marker ALDH1. asTF and flTF positivity did 
not influence clinical outcome. However, co-expression of flTF and ALDH1 resulted 
in poor relapse-free survival in patients younger than 65 years (P = .004), whereas 
the opposite effect was noted in older patients (P = .08). Unexpectedly, nuclei stained 
positive for asTF and confocal microscopy and biochemical fractionation confirmed 
that asTF, but not flTF, was localized in the perinuclear region.
Conclusion
We demonstrated, in the largest cohort to date, expression of both TF isoforms to 
be common in human breast cancer and to be associated with unfavorable tumor 
characteristics. flTF and the VII:PAR2 pathway seems to play a role in breast cancer 
stem cell population. The differences in cellular localizations of asTF and flTF further 
support the notion that asTF acts through mechanisms distinct from flTF in cancer.
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IntRoduCtIon
In the mid-nineteenth century, activation of coagulation was already observed to 
be tightly interwoven with cancer progression.1 Patients suffering from various 
types of cancer frequently display Trousseau’s syndrome, which is characterized by 
venous thrombosis of the upper and lower extremities. This thrombotic tendency 
is putatively caused by tumoral overexpression of full-length tissue factor (flTF), a 
47 kDa transmembrane protein, on the surface of cancer cells.2 Under physiological 
circumstances, flTF expression is limited to the surface of extravascular cells. Upon 
damage of the endothelium, flTF becomes exposed to the bloodstream and binds the 
blood-borne zymogen factor VII (FVII) and subsequently factors Xa, thrombin and 
fibrin are formed, thus resulting in a blood clot.3 In a reciprocal manner, activation of 
coagulation also influences various stages of cancerous disease. The TF:FVIIa complex 
and thrombin have been implicated in tumor growth and metastasis.4 For instance, flTF 
expression in colon cancer is associated with an increased risk of hepatic metastasis.5 
flTF expression in both colon and breast cancer has been suggested to promote tumor 
growth through modulation of angiogenesis.6 Extensive research has uncovered that 
coagulation proteases activate so-called protease-activated receptors (PARs). The 
TF:FVIIa complex specifically activates PAR2 resulting in altered cell behavior such as 
proliferation, gene expression and migration.7 In a spontaneous murine breast cancer 
model, activation of PAR2 by the TF:FVIIa complex was shown to enhance primary 
tumor growth via activation of the angiogenic switch.
In 2003, a natural occurring splicing variant of TF, alternatively spliced TF 
(asTF), was described which lacks exon 5. Due to this exon skipping, a frame shift 
occurs and hence asTF lacks a transmembrane region, but has a unique C-terminus, 
rendering asTF soluble.8 Ever since its discovery, the role of asTF in coagulation has 
been debated,9-11 however, an increasing body of evidence indicates that asTF may be 
involved in determining tumor biology and angiogenesis. In cervical cancer samples, 
asTF has been detected both on protein and mRNA level.12 High levels of asTF mRNA 
confer an unfavorable outcome in non-small cell lung cancer,13, 14 but in esophageal 
cancer, asTF mRNA levels did not affect outcome nor clinicopathology.15 Experiments 
with murine cancer models revealed that tumor size of asTF-expressing tumors is 
larger and that those tumors display an enhanced number of tumor vessels.16 Recently, 
our group reported that asTF drives angiogenesis in a non-proteolytic, integrin-
ligating fashion. Human asTF activates α6β1 and αvβ3 integrins on endothelial cells, 
thereby contributing to enhanced cell alignment and migration, respectively, which are 
indispensable in angiogenesis. In summary, these results suggest that tumor-derived 
asTF ligates integrins on endothelial cells in a paracrine manner, thus contributing to 
tumor angiogenesis.12 
To date, clinical studies investigating the relation between asTF expression 
at protein level in tumor tissues and clinicopathological characteristics are lacking. 
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Furthermore, the relative contribution to cancer progression of the protease-mediated 
flTF axis and the integrin-mediated asTF axis is unclear. Apart from the contribution 
to tumor angiogenesis, previous studies showed that cancer stem cells are abundant in 
expression of flTF suggesting that the flTF:FVII:PAR2 axis in cancer stem cells fuels 
tumor growth and contributes to the maintenance of a chemotherapy resistant subset 
of tumor cells.17-19 However, the relationship between flTF and cancer stem cells has 
not been validated in large patient studies nor in human breast cancer. Moreover, 
whether asTF has a function in cancer stem cell biology has not been investigated. 
In this study, we employ a large cohort of human breast cancer samples with 
matched normal tissue and a long follow-up in order to clarify the relative contributions 
of TF isoforms to human breast cancer. Apart from classic clinicopathological 
parameters, we also investigated the relationship between TF isoforms and cancer stem 
cells. Moreover, we employed biochemical and microscopic techniques to characterize 
the tumoral and subcellular localization of asTF and flTF.
mAteRIAl And metHods
Reagents
Normal goat serum and envision anti-rabbit HRP conjugate was purchased from 
DAKO (Glostrup, Denmark). The specific rabbit polyclonal human asTF antibody used 
in this study has been previously described and characterized.8 A murine monoclonal 
anti human TF with an epitope against the AA encoded by exon 5 was purchased 
from American Diagnostica. RL-90 PDI and Histone 3 antibodies were purchased 
from AbCam (Cambridge, UK). Polyclonal goat-anti-human TF was a kind gift of Dr. 
W. Ruf (Scripps Institute, La Jolla, CA). Secondary antibodies directed against rabbit 
or mouse IgG with Alexa Fluor® fluorescent dyes were purchased from Invitrogen 
(Carlsbad, CA). Vectashield DAPI-containing mounting medium was purchased from 
Vector Labs (Burlingame, CA).
Cell lines and vectors
Baby hamster kidney cells were kindly provided by Dr. W. Ruf. MCF-7 and MDA-
MB-231 cells (ATCC, Manassas, VA) were cultured in DMEM (PAA GmbH, Pasching, 
Austria) supplemented with 10% fetal calf serum (Bodinco, Alkmaar, the Netherlands) 
and 50 μg/ml penicillin and 50 μg/ml streptomycin (PAA GmbH). ORFs for asTF 
(Baseclear) and flTF kind gift from Dr. W. Ruf were subcloned pcDNA3.1 (Invitrogen, 
Carlsbad, CA) vectors and used when appropriate. Transfections were performed with 
lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer’s 
protocol.
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study cohort
The patient population comprised all non-metastasized breast cancer patients 
primarily treated with surgery in the Leiden University Medical Center between 1985 
and 1994 with tumor material available (N = 574).20 Patients with bilateral tumors 
or a prior history of cancer, other than basal cell carcinoma or cervical carcinoma in 
situ, were excluded. The following data were known: age, tumor grade, histological 
type, TNM stage, local and systemic therapy, locoregional or distant tumor recurrence, 
survival, and expression of estrogen receptor (ER), progesterone receptor (PgR), 
human epidermal growth factor receptor 2 (HER2), and the breast cancer stem cell 
marker aldehyde dehydrogenase-1 (ALDH1). All tumors were graded according to 
current pathological standards. Of 371 patients (65%), normal mammary tissue was 
available for analysis. Median follow-up was 17.9 years (range: 0.01 to 23.5). Approval 
was obtained from the Leiden University Medical Center Medical Ethics Committee. 
All samples were handled in a coded fashion, according to National ethical guidelines 
(“Code for Proper Secondary Use of Human Tissue”, Dutch Federation of Medical 
Scientific Societies). 
Assessment of expression of astf and fltf 
Tissue sections of 4 μm were cut from a previously constructed tissue microarray of 
formalin-fixed paraffin-embedded tumors of 574 patients from whom tumor material 
was available and a tissue microarray of formalin-fixed paraffin-embedded normal 
corresponding mammary tissue of 371 patients. Immunohistochemical staining was 
performed according to standard procedures. Briefly, sections were deparaffinized, 
rehydrated and endogenous peroxidase activity was blocked with 0.3% H2O2 in 
MetOH. For asTF stainings, antigen retrieval was omitted whereas sections for flTF 
staining were subjected to antigen retrieval in sodium citrate buffer for 10 minutes at 
100 °C. Sections were blocked for 1 hour with 10% normal goat serum in PBS/BSA 
1% at room temperature. Then, sections were incubated overnight at 4 °C with 1 μg/
ml anti-asTF or 20 μg/ml anti-flTF. Sections were washed in PBS, incubated for 30 
minutes with Envision, washed and visualized in DAB solution. After counterstaining 
with hematoxillin, sections were dehydrated and covered. Human placenta tissue 
slides served as positive control, whereas placenta also served as a no primary control 
tissue for each staining procedure. The percentage of asTF and flTF positive tumor 
cells was scored by two observers in a blinded manner. Patients in the first quartiles 
were deemed negative.
Immunofluorescent detection of astf and fltf 
Tissue sections were processed and incubated with primary antibodies as mentioned 
above. After washing in PBS, sections were incubated with Alexa-488-labeled anti-
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rabbit IgG and Alexa-546-labeled anti-mouse IgG for asTF and flTF, respectively. 
Sections were washed and mounted with DAPI-containing mounting medium. 
Pictures of the slides were obtained with a confocal laser scanning microscope 
(LSM510; Carl Zeiss Meditec, Jena, Germany) in a multitrack setting in which the 
slide is scanned multiple times with a fixed laser–filter pair. Alexa-488 was excited 
at 488 nm and detected with a 505 to 530 nm band-pass filter. Alexa-546 was excited 
at 543 nm and detected with a 560 to 615 nm band-pass filter. DAPI was excited at 
358 nM and detected with a 455 to 470 nm band-pass filter. The computerized scans 
presented each fluorochrome signal with an artificial color: green for Alexa-488, red 
for Alexa-546 and blue for DAPI. All pictures were 512 × 512 pixels, 8-bit depth, and 
stack size 368.5 × 368.5 μm. A ×25 objective was used (PH2 Plan-NEOFluor 25×/0.80 
Imm Korr; Carl Zeiss Meditec). Images were viewed and saved as merged images or as 
a set of two separate panels in LSM files.
Cell fractionation
asTF- and flTF-transfected baby hamster kidney cells were grown to subconfluency, 
trypsinized and washed twice with PBS. 1.0 x 106 cells were pelleted by centrifugation 
for 10 minutes at 1200 RPM at room temperature. The cell pellet was resuspended in 
1 ml hypotonic buffer and cells were left on ice for 5 minutes. Then, 0.05% nonidet 
p-40 was added and cells were left on ice for 5 minutes for lysis of non-nuclear 
phospholipid membranes. The unlyzed nuclei were pelleted by centrifugation at 2000 
Figure 1. Representative photographs of tissue microarray punches of human breast cancer specimens 
(left panels) and matched normal mammary tissue (right panels) immunohistochemically stained for 
asTF (top panels) and flTF (bottom panels). A brown color indicates positive staining.
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rpm for 10 minutes at 4 °C and washed three times with nonidet p-40.  Proteins from 
the non-nuclear fraction were precipitated with 4 volumes of ice-cold acetone after 
which the obtained nuclear and non-nuclear pellets were resuspended in Laemmli 
buffer. Proteins were detected by western blot and purity of the fractions was assessed 
by blotting for protein disulfide isomerase (PDI) and Histone 3 as markers for the 
cytoplasmic and nuclear fractions, respectively.
statistical analysis
Statistical analyses were performed using the statistical packages SPSS (version 16.0 
for Windows, Spps Inc, Chicago, IL) and Stata (version 10.0 for Windows, StataCorp, 
College Station, TX). Cohen’s kappa coefficient was used to assess the inter-observer 
agreement in quantification of asTF and flTF expression. The Cohen’s kappa coefficient 
was 0.85 and 0.87 for asTF and flTF, respectively. The χ² test was used to evaluate 
associations between various clinicopathological parameters and asTF and flTF 
expression. Relapse-free period was defined as the time from date of surgery until an 
event (locoregional recurrence and/or a distance recurrence, whichever came first). 
Relapse-free period is reported as cumulative incidence function, after accounting for 
death as competing risk.21 Relative survival was calculated by the Hakulinen method 
as the ratio of the survival observed among the cancer patients and the survival that 
would have been expected based on the corresponding (age, sex, and year) general 
population. National life tables were used to estimate expected survival. Relative excess 
risks of death were estimated using a multivariable generalized linear model with a 
Poisson distribution, based on collapsed relative survival data, using exact survival 
times. The Kaplan–Meier method was used for survival plotting and log-rank test for 
comparison of curves. Analyses were performed for all patients and stratified for age 
and ALDH1 status. Age of 65 years at time of diagnosis was chosen as the cut-off point 
for age stratification.22 An interaction term with age and ALDH1 and flTF status was 
introduced in Cox proportional hazard model to assess the interaction in prognostic 
effects of ALDH1 status for the age groups. 
Results
astf and fltf are abundantly, but differentially expressed in breast cancer
Expression of asTF and flTF was found in virtually all breast cancer samples, whereas 
normal mammary tissue showed limited expression (asTF = 4%, flTF = 38%; Figure 1). 
At the first quartile, 60% and 95% of tumor cells expressed asTF and flTF, respectively 
(Figure 2). The association of asTF and flTF expression with clinicopathological 
characteristics is shown in Table 1. Patients with an asTF positive tumor had tumors 
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Figure 2. Bar chart indicating the number of positive tumor cells for each individual tumor for staining of asTF 
(top) and flTF (bottom). The red line marks the first quartile; these patients were deemed asTF or flTF negative.
with a higher histological grade compared to patients with an asTF negative tumor 
(odds ratio (OR) grade III vs. grade I = 3.88, 95% CI = 2.02 to 7.48, P < .001). Moreover, 
asTF positive tumors were larger in terms of tumor size (OR T3-4 vs. T1 = 2.18, 95% 
CI = 1.09 to 4.36, P = .002). Patients with a flTF positive tumor had tumors with a 
higher histological grade compared to patients with a flTF negative tumor (OR grade 
III vs. grade I = 3.12, 95% CI = 1.71 to 5.66, P < .001). However, flTF was not associated 
with tumor size (OR T3-4 vs. T1 = 1.6, 95% CI = 0.86 to 3.81, P = .26). flTF expression 
was highly associated with the expression of the breast cancer stem cell ALDH1 (P = 
.001), whereas asTF expression was not (P = .84). In addition, we unexpectedly noted 
a nuclear staining for asTF in breast cancer that was absent in placenta specimens and 
flTF-stained breast cancer specimens. As this unexpected staining pattern did not 
affect all nuclei, we regarded this to be a specific staining. High percentages of positive 
nuclei virtually coincided with high percentages of positive cytoplasm, which was 
reflected in a strong correlation (P = .001).
astf and fltf do not affect relapse-free period nor survival
The association of asTF and flTF status with relapse-free period and relative survival 
is shown in Figure 3. Analysis of relapse-free period showed no association between 
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asTF and flTF expression and clinical outcome (P = .38 and P = .23, respectively). 
In this cohort, 55% of patients with asTF positive tumors was relapse-free at 10 year 
follow-up compared to 61% of patients with asTF negative tumors (absolute difference 
= 6%, P = .38). 58% of patients with flTF positive tumors was relapse-free at 10 year 
follow-up compared to 63% of patients with flTF negative tumors (absolute difference 
= 5%, P = .23). Analysis of relative survival showed a similar pattern (Figure 3).
Age influences the prognostic role of fltf and AldH1 co-expression
To further study the relationship between the breast cancer stem cell marker ALDH1 
and the co- expression of flTF, the association of flTF status and ALDH1 status with 
relapse-free period was analyzed (Figure 4). Patients were grouped according to co-
expression of ALDH1 and flTF versus one of both marker overexpressed or none 
overexpressed. Relapse-free period showed a trend towards a significant association 
between ALDH1 and flTF co-expression and poor clinical outcome for the whole 
asTF, alternatively spliced tissue factor; flTF, full length tissue factor; T, tumor; N, Axillary lymph node; ER, 
estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor 2; ALDH1, aldehyde 
dehydrogenase 1
Table 1. Association of asTF and flTF with patient and tumor characteristics
total astf fltf
negative Positive P negative Positive P
n % n % n % n % n %
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population (P = .093; Figure 4A). In the group of patients aged younger than 65 years, 
a strong association was found between ALDH1 and flTF co-expression and poor 
relapse-free period (P = .004; Figure 4B) and 43% of patients with ALDH1 and flTF 
positive tumors was relapse-free at 10 year follow-up compared to 67% of patients 
without co-expressing tumors (absolute difference = 24%).
Conversely, in the group of patients aged older than 65 years, a trend towards 
an opposite effect of ALDH1 and flTF co-expression and improved clinical outcome 
was found (P = .084; Figure 4C). In this group, 71% of patients with ALDH1 and flTF 
positive tumors was relapse-free at 10 year follow-up compared to 53% of patients 
without co-expressing tumors (absolute difference = 18%; Figure 4C). Interaction 
analysis demonstrated a statistically significant difference in the prognostic effect of 
ALDH1 and flTF status in young and elderly patients (P = .003).
Figure 3. Expression of TF isoforms and association with relapse-free period (A, C) and relative survival (B, d). 
Log-rank P-values are shown in each graph.
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astf and fltf display different subcellular localizations
The observation of asTF specific positive staining nuclei in breast cancer specimen 
prompted us to confirm this unexpected localization of asTF. Confocal microscopy 
revealed that TF isoforms in human breast cancer show limited co-localization and 
rather have a different subcellular localization (Figure 5A). flTF as expected is located 
in the cytoplasm and on the cell membrane, whereas the asTF signal is most prominent 
adjacent to the cell’s nucleus. Although co-localization of both isoforms could be 
expected, the number of cells displaying co-localization is limited. In transfected baby 
hamster kidney cells, asTF similarly localized to the perinuclear areas (Figure 5B). We 
confirmed the findings with confocal microscopy by cellular fractionation of asTF- or 
flTF-transfected baby hamster kidney cells (Figure 5C). Indeed, asTF was detectable in 
the nuclear fraction at 40 kDa, which is the expected weight of fully glycosylated asTF, 
and at 36 kDa, which putatively represents underglycolyated asTF. 
Figure 4. Relapse-free period according to flTF and ALDH1 co-expression for all patients (A), for patients aged < 
65 years (B) and for patients aged > 65 years (C). Log- rank P-values are shown in each graph.
      both ALDH1 and flTF positive 
      rest of patients
All ages
> 65 years< 65 yearsB C
A
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dIsCussIon
Since its discovery, the role of asTF in coagulation has been a matter of debate. 
However, a role for asTF in cancer has been suggested on basis of both experimental 
and small-scale patient studies. Recently, our group confirmed that asTF bears an 
angiogenic potential that acts through a different mechanism when compared to flTF. 
Earlier small-scale clinical studies indicated a relation between asTF mRNA levels and 
clinical outcome for several cancer types. Here, to our best knowledge, we are the 
first to report on the clinicopathologic associations of asTF at protein level in breast 
cancer using a large patient cohort with a long follow-up. Further, we were able to 
distinguish between TF isoforms by use of two isoform-specific antibodies. Moreover, 
we investigated the relative contribution of TF isoforms to breast cancer stem cells 
identified by ALDH1 expression.
In concordance with some previous small-scale clinical studies, we found both 
TF isoforms to be abundantly expressed in human breast cancer. A comparison with 
matched normal tissue from the same patients, led us to conclude that this expression 
pattern is specific for cancerous epithelia, since expression of both isoforms was 
considerably lower in normal epithelia. Moreover, asTF expression was almost absent 
in normal epithelia, further underlining that epithelial asTF expression may be a 
general phenomenon in breast cancer. Despite the near omnipresence of TF isoforms 
in breast cancer, we were able to correlate increasing percentages of asTF or flTF 
positive tumor cells with histological grade. Tumor size was only correlated with asTF, 
possibly reflecting that asTF has a differential effect on tumor size when compared to 
flTF.
As previous reports described striking effects of TF isoforms in murine 
cancer models on survival, we expected that the aforementioned correlations with 
clinicopathologic characteristics would result in a poor relapse-free and/or overall 
survival. Indeed, we found an impaired survival for patients with asTF or flTF positive 
tumors (absolute difference at 10 year follow-up was 6% and 5%, respectively), however, 
this finding did not reach statistical significance. A likely explanation for this finding 
is that TF isoforms heavily contribute to tumor growth in early tumorigenesis and 
are involved in the angiogenic switch, as reported in mouse studies. However, in the 
current group of patients, who were all operated in the pre-screening era, the process 
of tumor growth was already passed the stage of the angiogenic switch. Therefore, 
future research should focus on patients with small, non-palpable breast lumps to 
further elucidate the role of TF isoforms in human breast cancer tumorigenesis.
Unexpectedly, we observed a specific nuclear staining for asTF. To date, flTF 
has only been detected on the cell membrane and in the cytoplasm. The latter may 
reflect a large intracellular stock that can be employed for trafficking of flTF to the cell 
membrane in (patho)physiological situations when flTF is rapidly needed.23 Further, 
the cellular secretion of asTF has been debated11 and, although secretion of asTF is 
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possible after proper stimuli,24 it is not excluded that asTF accumulates intracellularly 
and promotes processes other than ligation of extracellular integrins. Future studies 
may prove an intracellular role for asTF other than its extracellular function of integrin 
ligation.
In this study, we demonstrated that tumors expressing the breast cancer stem 
cell marker ALDH1 are correlated with overexpression of flTF and not with asTF 
overexpression. Cancer stem cells, defined as a small subset of tumor cells with stem 
cell-like features including epithelial-to-mesenchymal transition, have the capacity of 
self-renewal and differentiation, giving rise to heterogeneous tumor cell population. 
Various studies have shown that cancer stem cells are relatively resistant to chemo- 
and radiotherapy, which might provide opportunities for understanding treatment 
resistance and tumor dormancy.25, 26 The cancer stem cell marker ALDH1 expression 
has shown promise as a clinically relevant prognostic marker in breast cancer.27-29 The 
current finding of the relation of flTF and ALDH1 sheds new light on the interaction 
between the tissue factor/protease activated receptor (TF:VII:PAR2) pathway and 
Figure 5. subcellular localization of astf and fltf. A. Confocal microscopy of TF isoforms in human breast 
cancer. Limited co-localization of asTF and flTF is found. flTF is located in the cytoplasm and on the cell 
membrane. asTF signal is most prominent adjacent to the cell’s nucleus. B. In transfected baby hamster kidney 
cells, asTF is localized at the perinuclear areas. C. Western blot of cellular fractionated mock (left panel) and asTF 
(middle panel) and flTF (right panel) transfected baby hamster kidney cells demonstrates that asTF was detectable 
in the nuclear fraction and flTF in the cytoplasmic fraction. (40 kDa is expected weight of fully glycosylated asTF 
and 36 kDa is expected weight of underglycolyated asTF). Left lane, unfractionated cells. Middle lane, nuclear 
fraction. Right lane, cytoplasmic fraction. PDI, protein disulfide isomerase, marker of cytoplasmic fration. H3, 
histone 3, marker of nuclear fraction.
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the growth potential of the cancer stem cell subset. These observations are in line 
with others,17-19 however, to the best of our knowledge, we are the first to investigate 
this relationship in breast cancer. Moreover, we demonstrated that asTF expression 
was not associated with ALDH1 expression. This finding suggests that the role of 
the asTF/integrin-dependent pathway is of limited, if any, role in the formation and 
maintenance of the breast cancer stem cell subset. Interestingly, co-expression of flTF 
and ALDH1 was shown to have a strong synergistic prognostic effect, which implies 
that flTF:FVII:PAR2 signaling but not asTF-mediated integrin ligation contributes to 
stem cell function. Recently, we found evidence for a strong age-dependent role of 
tumor stem cells in breast cancer and this synergistic relation between flTF and stem 
cells is even more dramatic in breast cancer patients younger than 65 years, whereas 
this relation inverses above 65 years. How age, the flTF:FVII:PAR2 axis and tumor 
stem cells mechanistically further relate is unclear, but the strong hormonal influence 
on flTF and FVII expression is likely to play a major role. In summary, our data suggest 
that the flTF:FVII:PAR2 pathway is important for the cancer stem cell population 
in early breast cancer. Therefore, modulation of the activity of this pathway might 
interfere with the cancer stem cell subset, which may subsequently improve patient 
survival.
In conclusion, differential TF isoform expression in breast cancer relates to 
different patient characteristics, which may reflect the different mechanisms of how TF 
isoforms modulate cancer biology. Targeting both TF isoforms may prove beneficial 
in early stages of tumor biology by counteracting tumor angiogenesis, especially by 
targeting asTF since its expression is rather tumor specific. On the other hand, targeting 
of the flTF:FVII:PAR2 axis may also improve patient outcome since this axis seems to 
be involved in the small subset of cancer stem cells, which are relatively resistance to 
current chemotherapeutic and radiotherapeutic regimens. 
RefeRenCes
1. Trousseau A. Phlegmasia alba dolens. Clinique médicale de l’Hotel Dieu de Paris 3, 659-712. 
1865. Baillière, J.B.
2. Forster Y, Meye A, Albrecht S, et al. Tissue specific expression and serum levels of human tissue 
factor in patients with urological cancer. Cancer Lett 2003; 193:65-73.
3. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb 
Vasc Biol 2006; 26:41-8.
4. Versteeg HH, Ruf W. Emerging insights in tissue factor-dependent signaling events. Semin 
Thromb Hemost 2006; 32:24-32.
5. Seto S, Onodera H, Kaido T, et al. Tissue factor expression in human colorectal carcinoma: 
correlation with hepatic metastasis and impact on prognosis. Cancer 2000; 88:295-301.
6. Yu JL, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal 
cancer cells: implications for tumor progression and angiogenesis. Blood 2005; 105:1734-41.
7. Schaffner F, Versteeg HH, Schillert A, et al. Cooperation of tissue factor cytoplasmic domain 
and PAR2 signaling in breast cancer development. Blood 2010; 116:6106-13.
8. Bogdanov VY, Balasubramanian V, Hathcock J, et al. Alternatively spliced human tissue factor: 
a circulating, soluble, thrombogenic protein. Nat Med 2003; 9:458-62.
Thesis Mieog.indb   114 22-09-11   19:49
115Isoforms of tissue factor and breast cancer stem cells
9. Censarek P, Bobbe A, Grandoch M, et al. Alternatively spliced human tissue factor asHTF. is 
not pro-coagulant. Thromb Haemost 2007; 97:11- 4.
10. Szotowski B, Antoniak S, Rauch U. Alternatively spliced tissue factor: a previously unknown 
piece in the puzzle of hemostasis. Trends Cardiovasc Med 2006; 16:177-82.
11. Boing AN, Hau CM, Sturk A, et al. Human alternatively spliced tissue factor is not secreted and 
does not trigger coagulation. J Thromb Haemost 2009; 7:1423-6.
12. van den Berg YW, van den Hengel LG, Myers HR, et al. Alternatively spliced tissue factor 
induces angiogenesis through integrin ligation. Proc Natl Acad Sci USA 2009; 106:19497-502.
13. Goldin-Lang P, Tran QV, Fichtner I, et al. Tissue factor expression pattern in human non-small 
cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol 
Rep 2008; 20:123-8.
14. Rollin J, Regina S, Gruel Y. Tumour expression of alternatively spliced tissue factor is a 
prognostic marker in non-small cell lung cancer. J Thromb Haemost 2010; 8:607-10.
15. Ribeiro FS, Simao TA, Amoedo ND, et al. Evidence for increased expression of tissue factor and 
protease-activated receptor-1 in human esophageal cancer. Oncol Rep 2009; 21:1599-604.
16. Hobbs JE, Zakarija A, Cundiff DL, et al. Alternatively spliced human tissue factor promotes 
tumor growth and angiogenesis in a pancreatic cancer tumor model. Thromb Res 2007; 
120:S13-21.
17. Milsom C, Anderson GM, Weitz JI, Rak J. Elevated tissue factor procoagulant activity in 
CD133-positive cancer cells. J Thromb Haemost 2007; 5:2550-2.
18. Milsom C, Magnus N, Meehan B, et al. Tissue factor and cancer stem cells: is there a linkage? 
Arterioscler Thromb Vasc Biol 2009; 29:2005-14.
19. Garnier D, Milsom C, Magnus N, et al. Role of the tissue factor pathway in the biology of tumor 
initiating cells. Thromb Res 2010; 125:S44-S50.
20. van Nes JG, de Kruijf EM, Faratian D, et al. COX2 expression in prognosis and in prediction to 
endocrine therapy in early breast cancer patients. Breast Cancer Res Treat 2011; 125:671-85.
21. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state 
models. Stat Med 2007; 26:2389-430.
22. Anderson WF, Jatoi I, Devesa SS. Distinct breast cancer incidence and prognostic patterns 
in the NCI’s SEER program: suggesting a possible link between etiology and outcome. Breast 
Cancer Res Treat 2005; 90:127-37.
23. Mandal SK, Pendurthi UR, Rao LV. Cellular localization and trafficking of tissue factor. Blood 
2006; 107:4746-53.
24. Szotowski B, Antoniak S, Poller W, et al. Procoagulant soluble tissue factor is released from 
endothelial cells in response to inflammatory cytokines. Circ Res 2005; 96:1233-9.
25. Gong C, Yao H, Liu Q, et al. Markers of tumor-initiating cells predict chemoresistance in breast 
cancer. PLoS One 2010; 5:e15630.
26. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-
initiating cells to radiation. J Natl Cancer Inst 2006; 98:1777-85.
27. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant 
human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 
1:555-67.
28. Resetkova E, Reis-Filho JS, Jain RK, et al. Prognostic impact of ALDH1 in breast cancer: a story 
of stem cells and tumor microenvironment. Breast Cancer Res Treat 2010; 123:97-108.
 29. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by 
aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-
based chemotherapy for breast cancers. Clin Cancer Res 2009; 15:4234-41.
Thesis Mieog.indb   115 22-09-11   19:49
Thesis Mieog.indb   116 22-09-11   19:49
Part II
Image-guided surgery
Thesis Mieog.indb   117 22-09-11   19:49
Thesis Mieog.indb   118 22-09-11   19:49
Part IIA
Intraoperative tumor detection
Thesis Mieog.indb   119 22-09-11   19:49
Thesis Mieog.indb   120 22-09-11   19:49
Chapter 8
novel intraoperative near-infrared 
fluorescence camera system for optical 
image-guided cancer surgery
Mieog JSD, Vahrmeijer AL, Hutteman M, van der Vorst JR, Drijfhout van Hooff M, 
Dijkstra J, Kuppen PJK, Keijzer R, Kaijzel EL, Que I, van de Velde CJH, Löwik CWGM
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Current methods of intraoperative tumor margin detection using palpation and visual 
inspection frequently result in incomplete resections, which is an important problem 
in surgical oncology. Therefore, real-time visualization of cancer cells is needed to 
increase the number of patients with a complete tumor resection. For this purpose, 
near-infrared (NIR) fluorescence imaging is a promising technique. 
methods 
Here, we describe a novel hand-held intraoperative NIR fluorescence camera system 
equipped with a 690 nm laser and validated its utility in detecting and guiding resection 
of cancer tissues in two syngeneic rat models. The camera system was calibrated using 
an activated cathepsin-sensing probe (ProSense). 
Results
Fluorescence intensity was strongly correlated with increased activated-probe 
concentration (R2 = 0.997). During the intraoperative experiments, a camera exposure 
time of 10 ms was used which provided the optimal tumor-to-background ratio. 
Primary mammary tumors (N = 20 tumors) were successfully resected under direct 
fluorescent guidance. The tumor-to-background ratio was 2.34 using ProSense680 at 
10 ms camera exposure time. The background fluorescence of abdominal organs in 
particular liver and kidney was high, thereby limiting the ability to detect peritoneal 
metastases with cathepsin-sensing probes in these regions. 
Conclusion
In conclusion, using this new camera system, we demonstrated its technical 
performance and intraoperative utility in guiding resection of tumors.
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IntRoduCtIon
The main goal of surgical oncology is the complete and ‘en-bloc’ excision of tumors 
with adequate tumor-free margins whilst minimizing surgical morbidity. However, 
at present, intraoperative assessment of tumor margins is merely based on palpation 
and visual inspection, which frequently results in incomplete tumor resections (so-
called R1 resections). For example, up to 40% of breast cancer patients treated with 
breast-conserving surgery needs to undergo secondary surgery due to involved tumor 
margins.1 The local recurrence rate for primary or hepatic metastasis of colorectal 
carcinomas is 30-50% after curative intended surgery.2, 3 Breast and colorectal cancer 
are amongst the most commonly diagnosed types of cancer worldwide with each type 
responsible for more than a million new cases and half a million deaths annually.4 For 
patients suffering from these cancers, surgery is the cornerstone of curative intended 
therapy. It is therefore clear that new visualization techniques are needed to facilitate 
intraoperative assessment of the extent of the cancer tissue and to guide the subsequent 
surgical removal of these tumors with adequate margins. 
Optical imaging using near-infrared (NIR) fluorescence light has recently 
emerged as a promising technique to visualize cancer cells during surgery.5-9 Advantages 
of NIR fluorescence light (700-900 nm) include: high tissue penetration up to several 
centimeters deep, low autofluorescence providing sufficient signal-to-noise ratio, the 
current availability of NIR fluorescence probes and labels for conjugation to target 
tumor-specific molecules, and the insensitivity of human eyes to NIR wavelengths 
providing no interference with the surgical field.6 Nonetheless, only a small number 
of fixed-geometry or hand-held fluorescence imaging systems have been developed 
with surgical oncology in mind.10-15 These systems employ either a laser light source10, 
13 or light emitting diodes (LED)11, 12 for NIR fluorescence excitation. Gutowski et al.10 
assessed the technique of intraoperative immunophotodetection using a prototype 
device (BFP Electronique, France). In this device, a cooled laser diode emitted light at 
649 nm through a fiber-optic output. Ke et al.13 used a custom built imaging system for 
intraoperative tumor detection, which employed two laser diodes at 660 nm (0.7mW/
cm2) and 785 nm (1.6mW/cm2). Images were enhanced using an image intensifier 
tube. Kirsch et al.14 described the use of a handheld device (Siemens Medical Solutions, 
USA), for which they described the molar detection limit. The Photodynamic Eye 
(PDE, Hamamatsu Photonics, Japan) uses LEDs and is designed for the detection of 
the clinically available probe indocyanine green and has been used in several clinical 
studies on lymph node mapping12, 16, 17 and tumor imaging.9 The system provides 1 
mW/cm2 of 760 nm excitation light. The FLARE™ imaging system has been used in 
preclinical18-20 and clinical studies.15 This system employs high power, cooled LEDs at 
670 nm (4 mW/cm2) and 760 nm (14 mW/cm2) and also uses spectrally separate white 
light LEDs to illuminate the surgical field. This three-channel approach has the great 
advantage of displaying the NIR fluorescence signal in direct relation to the anatomical 
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landmarks by superimposing the NIR fluorescence image on the visible light image. 
However, the FLARE™ is significantly larger than other, hand-held systems.
All systems use charge-coupled devices (CCD) for signal registration. As the 
quantum efficiency of CCDs tends to diminish significantly in the NIR spectrum, 
the choice for a specific CCD is, besides excitation light and quality of optics, of 
importance for the detection limits of an imaging system. However, technical details 
such as illuminating power, detection capabilities of the camera, and resolving power 
are not clearly described for all of the above described camera systems. In order to 
determine an imaging system’s contribution to the field of NIR fluorescence image-
guided surgery, a system needs to be analyzed in a well-structured way for its technical 
capabilities (i.e. NIR excitation light production, detection limits) and its practical use 
(i.e. ergonomics, sterility). 
Here, we describe the Fluobeam®, a novel, hand-held, intraoperative fluorescence 
camera system. The minimal detection limits, resolving power and intraoperative 
utility are addressed in primary breast cancer and metastatic colorectal cancer in two 
syngeneic rat models. 
mAteRIAl And metHods
near-infrared fluorescence camera system 
The Fluobeam® system (Fluoptics, Grenoble, France) is composed of a class 3B 
continuous wave laser (100 mW) emitting at 690 nm (Power Technology, USA) and 
supplied by a mains supply box (Mascot, Norway) continuously delivering 9V output 
current with a maximum of 4.5 A. The light from the excitation source is scattered 
using a diffuser in order to produce a homogeneous lightened field (6-8 cm diameter, 
field homogeneity > 30%) with an illumination power of 2.6 mW/cm2. The animal is 
placed under the laser and illuminated by white light (Photonic Optics, China) filtered 
with a band-pass filter (350-650 nm) providing an irradiance of 7x103 lx at the animal 
level. The fluorescence signal is collected through a long pass filter (> 700 nm, OD-
value at 690 nm is 3.5) by a digital 12-bit CCD camera (PCO Imaging, Germany) 
using a fixed-focus objective (Schneider Optische Werke GmbH, Germany). Camera 
exposure times are adjustable between 1 to 1000 ms. Camera exposure times of 10 
ms and 20 ms provided the best contrast between tumor and background during 
surgical exploration for ProSense680 and ProSense750, respectively, and were used 
during both the in vitro and the in vivo part of this study. The spatial resolution of the 
Fluobeam is 0.17 mm/pixel at focus point. The resolving power of the system is 2.52 
line pairs per mm, as determined using the USAF 1951 Target. The laser, the filtered 
white light illumination and the camera are suspended on a multi-angle adjustable 
arm which is positioned 20 cm above the point of focus allowing sufficient space for 
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surgical maneuvers (Figure 1). The system is operated by a desktop computer and the 
fluorescence signal is displayed in real-time on the computer screen.
NIR fluorescence probe 
The NIR fluorescence probes ProSense680 and ProSense750 (VisEn Medical, Woburn, 
USA) with peak absorbance of 680 and 750 nm, respectively, were used for fluorescent 
imaging. ProSense is an autoquenched fluorescent probe that converts from a non-
fluorescent to a fluorescent state by proteolytic activation of lysosomal cysteine or 
serine proteases like cathepsin-B.21 
Calibration of camera system
For calibration of the Fluobeam camera system, 2 nmol Prosense (150 µl) was 
activated with 100 µl 0.25% trypsin-EDTA at 37 ºC for 1 h.14 The cleaved probe was 
diluted to a concentration of 128 nM and diluted 10 times on the ratio 1:2 in phosphate 
buffered saline and aliquoted into a 96 wells plate (Greiner Bio-one, #655090, suitable 
for fluorescent measurements). Subsequently, the samples were imaged with the 
Fluobeam at various camera exposure times. The experiment was performed for both 
ProSense680 and ProSense750. Phosphate buffered saline was used as negative control. 
In order to confirm the accuracy of dilution, the same samples were measured using 
the Odyssey NIR fluorescence scanning device (LI-COR Biosciences, USA). 
Figure 1 






Figure 1. The Fluobeam® intraoperative near-infrared camera system
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Cell line experiments
The syngeneic MCR86 breast cancer rat cell line and the syngeneic CC531 colorectal 
cancer cell line were used for cell line experiments.22, 23 Tumor cells were cultured in 
RPMI 1640 supplemented with 2 mM L-glutamine (Gibco, USA), 10% heat-inactivated 
fetal calf serum, 100 U/ml penicillin and 0.1 mg/ml streptomycin sulphate. Cells were 
harvested with a solution of 0.25% (w/v) EDTA and 0.25% (w/v) trypsin in HBSS 
(Sigma, St. Louis, MO, USA).
In order to determine the minimal number of tumor cells that could be detected, 
MCR86 and CC531 tumor cells were cultured in T75 culture flasks up to ¾ confluence 
and incubated in 20 ml medium with 10 nM ProSense680. After 24 h incubation with 
ProSense680, cells were washed, harvested as described above, washed in medium and 
adjusted to a suspension containing 1x106 tumor cells per ml. This suspension was 
diluted 7 times on the ratio 1:2 in medium and aliquoted in 1.5 ml tubes. Tubes were 
centrifuged at 13,000 rpm for 5 minutes to generate cell pellets. Subsequently, the cell 
pellets were imaged with the Fluobeam at 10 ms camera exposure time. Tumor cells 
incubated with medium only served as negative control. This experiment was repeated 
three times for both the MCR86 and CC531 cell lines. 
Animal models 
EMR86 breast cancer rat model 
The syngeneic transplantable EMR86 breast cancer model originated in a female WAG/
Rij rat bearing a subcutaneously implanted estrogen pellet and is related to the MCR86 
cell line. This model is developed by our research group.24 Tumors are only induced 
and maintained in rats carrying estrogen pellets, whereas tumors transplanted into 
non-estrogenized animals never grow out. Fresh EMR86 tumor fragments of 1 mm3 
were subcutaneously implanted into the mammary fat pads at four sites in 4-6 months 
old female WAG/Rij rats (Charles River, the Netherlands). Simultaneously, an estrogen 
pellet was implanted subcutaneously in the intrascapular region of the neck. The in-
house generated pellets consist of 2 by 3 mm silicone tubes containing 1.5 mg 17 beta-
estradiol on a 1:3 cholesterol/ paraffin basis. Tumor volumes were estimated using 
digital calipers by measuring three orthogonal diameters of the tumor and multiplying 
this product by pi/6. After four weeks, tumors had reached of volume of approximately 
1 cm3. 
CC531 colorectal cancer rat model 
In order to induce CC531 peritoneal metastases, CC531 cells were harvested as 
described above, washed three times in phosphate buffered saline and adjusted to a 
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suspension containing 2 x 106 viable (trypan blue exclusion test) tumor cells per ml. 
The peritoneal cavity was inoculated with 2 x 106 cells in 6-months old male WAG/Rij 
rats (Charles River, the Netherlands).25 Two weeks after inoculation, small metastases 
of approximately 2 mm in diameter have originated in the abdominal cavity.
Animal experiments
All animals were housed in the animal facility of the Leiden University Medical Center. 
Pellet food and fresh tap water were provided ad libitum. The weight of the animals was 
followed throughout the experiment to monitor their general health state. Throughout 
imaging and surgical procedures, the animals were anesthetized with 5% isoflurane for 
induction and 2% isoflurane for maintenance in oxygen with a flow of 0.8 L/min and 
placed on animal bed with integrated nose mask. The Animal Welfare Committee of 
the Leiden University Medical Center approved these studies.
Rats were injected with ProSense (i.v., 10 nmol per animal) 24 hours before 
imaging. Before injection, autofluorescence of tumors, surrounding tissue and 
abdominal organs was determined. Rats were shaved to reduce absorption of the 
optical signal by fur. Animals were anesthetized with isoflurane as described above. 
Ethanol 70% was used as a disinfectant. EMR86 mammary tumors were removed by 
making an incision ventrally of the tumor and carefully dissecting the tumor with 
direct guidance of the real-time fluorescent signal. For the detection of CC531 intra-
peritoneal metastases, a median laparotomy was performed followed by a systematic 
exploration of the small and large bowel along with the mesentery and peritoneal cavity. 
Metastases identified clinically or by fluorescence were carefully excised. Fluorescent 
intensity of tumors and abdominal organs was determined in vivo and ex vivo using 
the Fluobeam. Excised tumors were snap frozen in isopentane and stored at -80 °C or 
fixed in formaline and embedded in paraffin (FFPE) blocks. Frozen tissue sections of 
20 µm or FFPE tumor sections of 4 µm were air-dried and stained with hematoxylin 
and eosin.
statistical analysis
Fluobeam derived NIR fluorescence data were analyzed using the open-source 
software ImageJ by drawing regions of interest and measuring the fluorescent intensity 
of the 12-bit images.26 For determination of detection limits, the fluorescent intensity 
of test samples was divided by the fluorescent intensity of the negative control. A ratio 
higher then 2 was considered as discriminative. For the animal experiments, regions 
of interest were drawn at the tumor and at the surrounding tissue within a range of 
2 mm of the demarcation line of the tumor and the surrounding tissue. Statistical 
analysis and generation of graphs was performed using GraphPad Prism software 
(version 5.01, California, USA). Unless otherwise stated, mean fluorescent intensity 
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and associated standard deviations were reported. Pearson’s correlation coefficients 
R2 were used for the in vitro experiments. Unpaired and paired t-tests were used for 
testing differences of continuous variables between groups. Statistical tests were two-
tailed and P < .05 was considered significant. 
Results
Calibration of camera system
Trypsin-activated ProSense680 and ProSense750 were used to calibrate the Fluobeam 
camera system (Figure 2A). Fluorescent intensity was linearly correlated with the 
concentration of activated ProSense680 and ProSense750 (correlation coefficient 
R2 = 0.997 and 0.997, respectively). The dilution accuracy was confirmed using the 
Odyssey NIR fluorescence scanning device for both ProSense680 (R2 = 0.995) and 
ProSense750 (R2 = 0.995). At similar Fluobeam camera exposure times, fluorescent 
intensity of ProSense680 was on average 2.6 times higher than the fluorescent 
intensity of ProSense750. This reflects the better matching of the absorbance peak 
of ProSense680 with the 690 nm emitted by the laser of the Fluobeam. Therefore, 
ProSense680 was used in subsequent in vitro experiments. Camera exposure time was 
linearly correlated with fluorescent intensity (R2 ranged between 0.997 and 1 for the 
different concentrations), indicating linearity of the camera system. During the in vivo 
experiments, the optimal fluorescent signal for tumor identification without saturated 
pixels was obtained at 10 ms camera exposure time. Therefore, a 10 ms camera exposure 
time was used during subsequent in vitro experiments using ProSense680. In order to 
quantify the sensitivity of the camera system, the minimal detectable concentration of 
Figure 2 
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Figure 2. Calibration of the Fluobeam® camera system. A. The concentration of trypsin-activated ProSense680 
and ProSense750 is plotted against the mean fluorescent intensity at 10 and 20 ms camera exposure times. 
B. NIR fluorescence Fluobeam image showing 1.5 ml tubes containing cell pellets of various amounts of cells of 
the MCR86 breast cancer cell line after 24 h incubation with 10 nM ProSense680. Camera exposure time was 10 
ms. C. The number of MCR86 cells incubated with 10 nM ProSense680 is plotted against the total fluorescent 
intensity at 10 ms camera exposure time. 
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ProSense680 was determined at 10 ms camera exposure time, mimicking the in vivo 
situation. A signal-to-background ratio was calculated with phosphate buffered saline 
as background. A ratio of 2 was used as the cut-off. At these settings, the minimal 
detectable concentration of trypsin-activated ProSense680 was 9.3 ± 0.1 nM (Figure 
2A). Therefore, a concentration of 10 nM was used in subsequent cell line experiments. 
Cell line experiments 
In order to determine the minimal number of tumor cells that could be detected 
with the Fluobeam and ProSense680, cultured MCR86 and CC531 tumor cells were 
incubated in medium with 10 nM ProSense680. After 24 hours incubation, cells 
were aliquoted in 1.5 ml tubes at various cell concentrations, spun down and imaged 
with the Fluobeam (Figure 2B). The total fluorescence of the cell pellets was linearly 
correlated with the number of cells at 10 ms camera exposure time for both MCR86 
(R2 = 0.952; Figure 2C) and CC531 (R2 = 0.989; data not shown). To determine the 
minimal detection limit, a signal-to-background ratio was calculated with medium 
only as background. A ratio of 2 was used as the cut-off. At 10 ms camera exposure 
time, the minimal detection limit of the Fluobeam was 20,400 ± 9,200 MCR86 cells 
and 12,800 ± 2,700 CC531 cells (data not shown). Cell pellets containing 20,000 cells 
are approximately 0.2 mm3, reflecting sub-mm metastases.  
Figure 3 





























































Figure 3. Intraoperative NIR fluorescence guided resection of primary breast cancer using the Fluobeam® camera 
system. A. NIR fluorescence image showing the intraoperative view of a 3.5-mm EMR86 breast tumor in a female 
rat 24 h after administration of 10 nmol ProSense680. Camera exposure time was 10 ms. B. The mean fluorescent 
intensity of breast tumors is plotted for ProSense680 (N = 12 tumors, 3 rats) and ProSense750 (N = 8 tumors, 3 
rats). Camera exposure time was 10 ms. Horizontal lines represent mean ± SD. Fluorescent signal of the tumors 
was higher with ProSense680 than with ProSense750 (t = 4.33, P = .0004). C. The tumor-to-background ratio 
is plotted for both ProSense680 (N = 12 tumors, 3 rats) and ProSense750 (N = 8 tumors, 3 rats) for the camera 
exposure times that provided the optimal tumor-to-background ratio during surgery: 10 ms for ProSense680 
and 20 ms for ProSense750. Horizontal lines represent mean ± SD. Tumor-to-background ratio was significantly 
higher for ProSense680 when compared to ProSense750 (t = 2.53, P = .021).




The syngeneic EMR86 breast cancer rat model was used to test the intraoperative 
application of the Fluobeam camera system. Primary breast tumors were induced in six 
female rats in the mammary fat pad. Twenty tumors were induced varying in size from 
0.08 to 4.19 cm3 (mean = 0.77 cm3 ± 1.4). All tumors were successfully detected and 
resected under direct fluorescence guidance 24 hours after injection with ProSense680 
(N = 12 tumors) or ProSense750 (N = 8 tumors, Figure 3). In concordance with the in 
vitro data, the fluorescent signal of the tumors was higher with ProSense680 (mean = 
2552 ± 659.4) than with ProSense750 (mean = 1367 ± 489.9; t = 4.33, P = .0004; Figure 
3B) at a 10 ms camera exposure time. During surgery, an optimal fluorescent contrast 
between tumor (unsaturated signal) and surrounding mammary fat pad was obtained 
using a 10 ms camera exposure time for ProSense680 and 20 ms for ProSense750. The 




Figure 4. NIR fluorescence imaging of excised primary breast cancer using the Fluobeam® camera system. Shown 
are a color image (A), a NIR fluorescence image (B), and a pseudocolored green merge of the two images (C) 
of a sectioned 4-mm EMR86 breast tumor with surrounding mammary fat pad. The tumor was excised from a 
rat, which was injected with10 nmol ProSense680 24 h prior to imaging. Camera exposure time was 10 ms. D. 
H&E histological staining of a 20 µm frozen tissue section of the specimen from Figure 4C. Shown is the region 
indicated by the dashed square (25x magnification).
Thesis Mieog.indb   130 22-09-11   19:49
131Validation of intra-operative fluorescence camera system 
discussed above. Although the fluorescent intensity of tumor tissue was significantly 
higher than the surrounding mammary fat pad with both ProSense680 (paired t = 
12.52, P < .0001, N = 12 tumors) and ProSense750 (paired t = 6.29, P = .0004, N 
= 8 tumors) using these camera exposure times, the tumor-to-background ratio was 
significantly higher for ProSense680 (2.34 ± 0.35) when compared to ProSense750 
(1.91 ± 0.38; t = 2.53, P =.021; Figure 3C). 
Breast tumor margins
In order to visualize the fluorescence of tumor margins, excised breast tumors were 
sectioned, imaged with the Fluobeam and processed for histopathology. In Figure 4, 
a typical example of a 4 mm large excised breast tumor is presented. A distinctive 
difference in fluorescence of the tumor tissue and surrounding mammary fat pad is 
shown which is confirmed in a fresh frozen tissue section after hematoxylin and eosin 
staining.
Metastatic abdominal cancer
To assess if the use of a protease-activatable probe could be used in tumor types located 
in the abdominal cavity, the fluorescence intensity of abdominal organs relevant in 
cancer surgery was measured with the Fluobeam in three rats before and after injection 
with ProSense680. Figure 5 demonstrates that liver, kidney, spleen, small bowel and 
Figure 5 























































Figure 5. In vivo fluorescence intensity of EMR86 breast tumors and abdominal organs. Fluorescent intensity was 
measured using the Fluobeam® camera system in three rats bearing EMR86 breast tumors before and 24 h after 
administration of 10 nmol ProSense680. Camera exposure time was 10 ms. Bars represent mean ± SD. The 
signal for liver and kidney was saturated at 10 ms camera exposure times (dashed line). The plotted values are 
extrapolated from the non-saturated measurements at 5 ms camera exposure time. 
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bladder provide very high background fluorescence after injection of ProSense680. 
The fluorescent intensity of liver tissue was 69 times higher than in control rats (t = 
8.85, P = .003) reflecting the high intrinsic cathepsin B activity of hepatocytes.27 Also, 
the signal in the kidney was 32 times higher in the ProSense680 rats, particularly in 
the renal cortex, due to the intrinsic cathepsin B activity and the renal clearance of the 
probe (t = 6.06, P = .009).28 Similar results were obtained with ProSense750. 
These results suggest that protease-activatable probes are less useful for image-
guided surgery of abdominally located tumors or metastases regardless of the protease 
activity and associated fluorescent intensity of those tumors. 
To test the assumption that the use of ProSense in detecting abdominal tumors 
is limited, the syngeneic CC531 colorectal cancer rat model was used to induce intra-
peritoneal tumors. Figure 6 shows a typical example of a rat bearing intra-peritoneal 
CC531 metastases imaged with the Fluobeam after injection with ProSense750. 
Although small peritoneal metastases could be detected on the mesentery of the small 
bowel (Figure 6A-B), one can not be sure to detect metastases in all parts of the bowel 
and in particular at the liver and kidney due to the high background fluorescence, as 
illustrated in Figure 6C.
dIsCussIon
A highly promising new development in surgical oncology is image-guided tumor 
resection using NIR fluorescenc imaging. The extent of the primary tumor as well 
as sites of regional disseminated disease can be detected in real-time. Using this new 
information, the surgical procedure can directly be adapted. Moreover, this technique 
provides a direct assessment of the resection plane after tumor removal to detect any 
residual cancer tissue, thereby reducing the number of patients with incomplete tumor 







Mieog et al. 
A C B 
Figure 6. Intraoperative NIR fluorescence imaging of colorectal CC531 peritoneal metastases using ProSense and 
the Fluobeam® camera system. A. NIR fluorescence image showing a 3-mm fluorescent hotspot (arrow) located 
on the mesentery of the small bowel in a male rat injected with 10 nmol ProSense750. Camera exposure time 
was 20 ms. B. Corresponding H&E-stained formaline-fixed paraffine-embedded 4 µm tissue section confirms the 
presence of CC531 tumor cells (original magnification 25x). C. Intraoperative NIR fluorescence image showing 
the background fluorescence of the liver, kidney and small bowel in the same animal. Camera exposure time was 
20 ms. 
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been evaluated in humans. The main target of ProSense, the cysteine protease family (in 
particular cathepsin B) is upregulated in various human cancers including breast and 
colorectal cancer.29-32 In the current pre-clinical study, we described the performance 
of a novel hand-held, intraoperative NIR fluorescence camera system based on a 690 
nm laser and demonstrated its utility in detecting and guiding resection of primary 
and metastatic rat tumors using the cathepsin-activatable probe ProSense. Because 
the family of proteases is strongly conserved amongst mammals, it is expected that 
ProSense will be applicable for cancer patients.29
The efficacy of NIR fluorescence camera systems is determined by the 
interplay between the type of probe used, the probe concentration, tumor size and 
the camera exposure time. In this study, the cathepsin-activatable probe ProSense680 
and ProSense750 were used to test the 690 nm laser-based Fluobeam camera 
system. Because of the better matching of ProSense680 with the 690 nm laser, the 
fluorescent signal was significantly higher using ProSense680 (Figure 2A). During 
the intraoperative experiments, 10 ms camera exposure time was found to be optimal 
in terms of tumor-to-background ratio for ProSense680. When assessed in vitro, the 
minimal detectable ProSense680 concentration at 10 ms camera exposure time was 
approximately 10 nM (Figure 2A). The minimal detectable number of tumor cells with 
10 nM ProSense680 at 10 ms camera exposure time was approximately 20,000 for a 
breast cancer cell line and 13,000 for a colorectal cancer cell line. These cell numbers 
reflect sub-mm tumor depositions. When these settings were applied in the in vivo 
experiments, mammary tumors varying in size from 0.08 to 4.19 cm3 could be detected 
and subsequently resected under direct fluorescent guidance after administration of 10 
nmol ProSense680 with a clear demarcation of tumor margins (Figure 4). Fluorescence 
reflectance imaging is not inherently quantitative and quantification should always be 
performed relative to control tissue.5 In this study, a tumor-to-background ratio of 2.34 
was found for ProSense680. Tumor tissue was discriminated from the surrounding 
tissue by optimal thresholding without any further signal improvement techniques.33 
In general, the ratio of the fluorescent intensity between tumor and surrounding 
tissue determines the applicability of protease-activatable probes in NIR fluorescence 
image-guided cancer surgery. In order to assess the applicability of the cathepsin-
sensing probe in intraperitoneal metastases, the fluorescent intensity of abdominal 
organs were measured after the administration of ProSense680. In several abdominal 
organs the fluorescent intensity was markedly increased after injection of ProSense 
(Figure 5). For example, liver, kidney and intestine cells exploit an extensive cathepsin 
B activity and were highly fluorescent.27 Therefore, cathepsin-activatable probes seem 
less useful for image-guided surgery of abdominally located tumors, even if tumors 
express high levels of cathepsin-B (Figure 6). 
The currently available NIR fluorescence camera systems use either a laser13, 14 or 
light emitting diode (LED)11, 12, 19 illumination as a photon source for probe excitation. 
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The Fluobeam camera system is laser-based, which might possess logistic hurdles in 
terms of operator safety, although a distance of 18 cm away from the camera head 
is considered safe. However, LED illumination requires direct cooling at the camera 
head causing camera heads to be larger. Conversely, a fiber-guided laser source can 
be cooled outside the camera head, therefore the camera head can be smaller and a 
true hand-held system can be created. Direct comparison of various camera systems 
is necessary to test accuracy and efficacy parameters such as minimal detection limit, 
excitation power and signal-to-noise ratio in a standardized way, as presented here. 
Advantages of the Fluobeam system include its compact size, high resolving power 
and spatial resolution, user friendly and surgeon-oriented mode of operation, and the 
fact that the Fluobeam is commercially available. Moreover, the software incorporates 
the use of a dynamic threshold function, which could enhance the discrimination of 
tumor and normal tissue. Improvements of the Fluobeam could include the addition 
of a color video camera for visible light registration, as is already implemented in the 
LED-based FLARE™ system.15 
Several new developments in optical imaging, such as fluorescence lifetime 
imaging,34 frequency domain imaging and spatially modulated structured light35 
have the potential to increase tissue penetration and discriminatory power between 
fluorophores. These techniques are able to improve localization of an NIR fluorescence 
signal source and improve quantification of the fluorescence signal. These developments 
are expected to be integrated in intraoperative NIR fluorescence imaging devices 
within the next few years.
In conclusion, the ultimate goal of NIR fluorescence imaging is to provide 
surgical oncologists with a real-time tumor imaging technique to guide surgery for the 
complete and safe resection of cancer tissue. In this study, we described the technical 
details and performance of the Fluobeam intraoperative NIR fluorescence camera 
system. By using the Fluobeam and the activatable probe ProSense, we demonstrated 
that it is possible to resect tumors under fluorescence guidance. If these techniques will 
become available for clinical cancer treatment, surgical oncology will make a major 
step forward.
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Image-guided tumor resection using 
real-time near-infrared fluorescence in 
a syngeneic rat model of primary breast 
cancer
Mieog JSD, Hutteman M, van der Vorst JR, Kuppen PJK, Que I, Dijkstra J, Kaijzel EL, 
Prins F, Löwik CWGM, Smit VTHBM, van de Velde CJH, Vahrmeijer AL
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Tumor involvement of resection margins is found in a large proportion of patients 
who undergo breast-conserving surgery. Near-infrared (NIR) fluorescence imaging is 
an experimental technique to visualize cancer cells during surgery. 
methods
To determine the accuracy of real-time NIR fluorescence imaging in obtaining 
tumor-free resection margins, a protease-activatable NIR fluorescence probe and an 
intraoperative camera system were used in the EMR86 orthotopic syngeneic breast 
cancer rat model. 
Results
Influence of concentration, timing and number of tumor cells were tested in the 
MCR86 rat breast cancer cell line. These variables were significantly associated with 
NIR fluorescence probe activation. Dosing and tumor size were also significantly 
associated with fluorescence intensity in the EMR86 rat model, whereas time of 
imaging was not. Real-time NIR fluorescence guidance of tumor resection resulted in 
a complete resection of 17 out of 17 tumors with minimal excision of normal healthy 
tissue (mean minimum and a mean maximum tumor-free margin of 0.2 ± 0.2 mm 
and 1.3 ± 0.6 mm, respectively). Moreover, the technique enabled identification of 
remnant tumor tissue in the surgical cavity. Histological analysis revealed that the 
NIR fluorescence signal was highest at the invasive tumor border and in the stromal 
compartment of the tumor. 
Conclusion 
NIR fluorescence detection of breast tumor margins was successful in a rat model. The 
present study suggests that clinical introduction of intraoperative NIR fluorescence 
imaging has the potential to increase the number of complete tumor resections in 
breast cancer patients undergoing breast-conserving surgery.
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IntRoduCtIon
Incomplete tumor resections are an important clinical problem in breast cancer 
surgery. Tumor involvement of resection margins is found in 5-40% of patients who 
undergo breast-conserving surgery and these patients require additional surgery or 
intensified radiotherapy.1-4 Furthermore, additional biopsies of the surgical cavity after 
primary resection have been shown to contain residual disease in 10% of patients 
with tumor-free specimen margins.5 As a result, 5-year isolated local recurrences rates 
of 6.7-11% are reported in patients with tumor-free specimen margins treated with 
breast-conserving surgery and radiotherapy.6 The occurrence of local relapse reduces 
the 15-year breast cancer specific and overall survival.6 Consequently, increase of the 
radical resection rate will likely improve breast cancer outcome. Intraoperative real-
time visualization of cancer cells is a promising method to achieve that goal.7
Near-infrared (NIR) fluorescence imaging is an experimental technique that 
can be used to visualize cancer cells during surgery. In current surgical practice, 
surgeons can only rely on palpation and visual inspection. Therefore, the use of NIR 
fluorescence imaging can be of great value, as already demonstrated in patients with 
glioma and liver cancer.8-10 Advantages of NIR fluorescence light (700-900nm) include 
high tissue penetration (up to several centimeters deep) and low autofluorescence 
providing sufficient signal-to-background ratio.11 Moreover, as the human eye is 
insensitive to NIR wavelengths, the use of NIR light will not interfere with the surgical 
field. 
NIR fluorescence probes can target tumor cells through several mechanisms. 
For example, fluorophores can be conjugated to a tumor-specific antibody (e.g. 
directed to the Her-2/neu receptor), labeled to glucose derivates in order to visualize 
elevated metabolic rate, or autoquenched fluorophores can be activated by enzymatic 
cleavage in order to become fluorescent. The latter is of particular interest as certain 
enzyme systems are upregulated by a wide variety of cancer types, thus providing 
a more universally applicable NIR fluorescence probe. Proteolytic enzymes and 
in particular cathepsins from the cysteine protease family are a good candidate as 
they play essential roles in tumor growth, angiogenesis, resistance to apoptosis, 
and invasion.12, 13 A member of this family, cathepsin B, is commonly active in the 
tumor microenvironment in various human cancers including breast cancer.12, 14-16 
Upregulated expression of cathepsin B is found in tumor, endothelial and immune 
cells, in particular macrophages.13 Cathepsin B overexpression in human breast 
carcinomas is associated with poor differentiation, lymph node involvement, absence 
of estrogen receptor expression and impaired overall survival.17, 18 
The protease-activatable NIR fluorescence probe ProSense (VisEn Medical, 
Woburn, USA) has been shown to detect a variety of tumors in nude or transgenic 
mice.19-31 However, as tumor progression and metastasis are regulated by the 
surrounding microenvironment, it is important to use syngeneic animal models 
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that allow appropriate crosstalk at the invasive tumor border to study probes that are 
activated by proteolytic activity. Moreover, the use of a larger animal model such as the 
rat offers more challenges in terms of tissue penetration of NIR fluorescence probes. 
Therefore, the aim of this study was to assess the technique of NIR fluorescence 
imaging in a syngeneic breast cancer rat model using ProSense and to determine the 
accuracy of intraoperative tumor detection to obtain an adequate tumor-free resection 
margin.
mAteRIAl And metHods
Breast cancer cell line and culture conditions
The MCR86 cell line is a rapidly growing, syngeneic breast cancer cell line derived 
after subcutaneous transplantation of macroscopic lung tumors, which developed in 
a female WAG/Rij rat after intravenous inoculation of MCR83 breast cancer cells.32 
Tumor cells were cultured in RPMI 1640 supplemented with 2 mM L-glutamine 
(Gibco, Invitrogen Ltd, Carlsbad, USA), 10% heat-inactivated fetal calf serum, 100 U/
ml penicillin and 0.1 mg/ml streptomycin sulphate.
Breast cancer model and tumor induction 
The related EMR86 model is a transplantable, hormone-dependent, metastasizing 
mammary carcinoma that originated in a female WAG/Rij rat bearing a subcutaneously 
implanted estrogen pellet and is developed by our research group (Figure 1A).33 
Tumors are only induced and maintained in rats carrying estrogen pellets, whereas 
tumors transplanted into non-estrogenized animals do not grow out. Removal of the 
estrogen pellet induces apoptosis and tumor regression (Figure 1B). EMR86 tumors 
are histologically classified as high-grade invasive ductaltype adenocarcinomas, with 
both a  cribiform and a solid growth  pattern. In large tumors  areas, comedo type 
necrosis can be appreciated. Tumors have a stromal compartment of approximately 
30% depending on tumor size (Figure 1C). EMR86 tumor cells show strong nuclear 
expression of the estrogen and progesterone receptor in more than 90% of cells, but 
stain negative for HER2/neu receptor (Figure 1D-F). Therefore, EMR86 tumors closely 
resemble the luminal A molecular subtype – the most prevalent subtype of human 
breast cancer.34, 35 
For tumor induction, fresh EMR86 tumor fragments of 0.5-1 mm3 were 
implanted in the mammary fat pad at four sites of female WAG/Rij rats (Charles 
River, Maastricht, the Netherlands) aging 4-6 months. (A stable cell line from EMR86 
tumor has not yet been successfully established, therefore, tumor transplantation is 
used.) During the same session, an estrogen pellet was implanted subcutaneously in 
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the intrascapular region of the neck. The in-house generated pellets consist of 2 mm 
by 3 mm silicone tubes containing 1.5 mg 17 β-estradiol on a 1:3 cholesterol/paraffin 
basis. Tumor volumes were estimated twice weekly using digital calipers by measuring 
three orthogonal diameters of the tumor and multiplying this product by π/6. All rats 
were housed in the animal facility of the Leiden University Medical Center. Pellet food 
and fresh tap water were provided ad libitum. The weight of the animals was followed 
throughout the experiment to monitor their general health state. The Animal Welfare 
Committee of the Leiden University Medical Center approved the study. The study 
was conducted in concordance with the “Guidelines for the Welfare of Animals in 
Experimental Neoplasia” (Second Edition, 1997) available online at http://www.ncrn.
org.uk/csg/animal_guides_text.pdf.
nIR fluorescence probe
The commercially available, protease-activatable NIR fluorescence probes 
ProSense680 and ProSense750 were used (VisEn Medical). The probes consist of a 
synthetic graft polymer composed of poly-L-lysine that is sterically protected by 
multiple methoxypolyethylene glycol side chains and to which multiple fluorophores 
are attached.19 In this non-activated state, the fluorophores are positioned in close 
proximity to one another, which results in mutual energy transfer and thus inhibition 
of fluorescence emission. After enzymatic cleavage of the backbone, the fluorophores 
figure 1. description of a syngeneic rat model of hormone-dependent breast cancer. A. EMR86 breast tumors 
originate after transplantation of 0.5 mm3 fresh tumor fragments at the mammary fat path of female WAG/Rij 
rats. Shown is a tumor four weeks after transplantation. B. EMR86 tumors are only induced and maintained in 
rats carrying estrogen pellets. Removal of the estrogen pellet induces apoptosis and tumor regression (N = 16 
tumors, 4 rats). C. EMR86 tumors are histologically classified as high-grade invasive ductal carcinomas, with both 
a cribiform and a solid growth pattern. Tumors have a stromal compartment of approximately 30% depending on 
tumor size.  d-f. EMR86 tumor cells show strong nuclear expression of the estrogen and progesterone receptor 
in more than 90% of cells, but stain negative for HER2/neu receptor. Therefore, EMR86 tumors closely resemble 
the luminal A molecular subtype.
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are released and regain their fluorescent characteristics. A number of cysteine 
proteases are involved in this process. Cathepsin B, and to a lesser degree cathepsin K, 
L, and S, has been demonstrated to be a major contributor to cleavage and activation 
of ProSense.19 ProSense680 and ProSense750 have peak absorption of 680 nm and 750 
nm, respectively. ProSense680 was selected for intraoperative studies and fluorescence 
microscopy because of the better matching of the laser of the intraoperative camera 
system with the peak excitation of ProSense680. ProSense750 was used for cell line 
experiments and non-invasive animal experiments because of the better spectral 
separation of autofluorescence signal. 
Intraoperative nIR fluorescence camera system
The Fluobeam intraoperative NIR fluorescence camera system (Fluoptics, Grenoble, 
France) used in this study has been described previously by our group.36, 37 Briefly, the 
system is composed of a class 3B laser (100 mW) emitting at 690 nm resulting in an 
illumination power of 2.6 mW/cm2. Filtered white light (350-650 nm) provides an 
irradiance of 7x103 lx at the focus level. The emitted fluorescence is collected through 
a high pass filter (> 700 nm) by a 12 bits CCD camera resulting in a system spatial 
resolution of 0.17 mm/pixel. 
experimental design
Cell line experiments
For fluorescence measurements, tumor cells were harvested with a solution of 0.25% 
(w/v) EDTA and 0.25% (w/v) trypsin in Hanks’ Buffered Salt Solution (Sigma-Aldrich, 
St. Louis, USA), washed three times in 0.9% phosphate buffered saline and 200 µL 
complete medium suspensions were made and transferred on a 96-well acrylate 
plate (Greiner Bio-one, Alphen aan de Rijn, the Netherlands, #655090; suitable for 
fluorescence measurements) and kept at 37 °C and 5% CO2. At day 2, cells were washed 
and autoquenched ProSense750 (22.5 to 180 nM, 200 µl) was added. At day 3, cells 
were washed and 200 µl complete medium was added. Also, time-dependent studies 
were performed, during which ProSense750 was added at the indicated time-points 
(8 to 48 h). Fluorescence intensity was measured using the Odyssey NIR fluorescence 
scanning device (LI-COR Biosciences, Lincoln, USA). Overlying grids were drawn 
and fluorescence intensity was measured for each well using the Odyssey software 
(Version 2.1). 
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Animal experiments
Throughout injection, imaging and surgical procedures, rats were anaesthetized with 
inhalation of 2% mixture of isoflurane in oxygen. The rats were constantly monitored 
for the rate of the respiration and depth of anesthesia. Before imaging, rats were 
shaved to reduce absorption of the optical signal. A total of 20 rats bearing 77 primary 
mammary tumors varying in size from 0.01 to 1.8 cm3 were used in this study. 
In a dose- and time-dependent experiment, tumor-bearing rats (N = 9) were 
randomly assigned over three ProSense750 dose groups and intravenously injected 
with 2.5, 5 or 10 nmol ProSense750 (150 µl). Whole-body fluorescence was measured 
24 h and 48 h after administration of ProSense750 using the IVIS Spectrum (Caliper 
LifeSciences, Hopkinton, USA), which allowed separation of the ProSense750 signal 
from the background fluorescence by means of spectral unmixing.38 Acquisition 
settings were kept constant for the different dose groups and on the two consecutive 
days. Total photon counts per second were measured for each tumor using the Living 
Image software (Version 3.0, Caliper LifeSciences) and divided by the tumor volume 
as assessed by digital caliper measurement.
In an intraoperative experiment, tumor-bearing rats (N = 7) were operated 
under direct fluorescence guidance 24 h after intravenous administration of 10 nmol 
ProSense680 (150 µl). NIR fluorescence intensity of exposed tumors and surrounding 
tissues was measured with the Fluobeam intraoperative camera system. Tumor-to-
background ratios were calculated by drawing regions of interest at the tumor and 
at the surrounding tissue by visual interpretation and subsequent measurement of 
fluorescent intensity using the open-source software ImageJ.39 Merged visible light 
and NIR fluorescence light images were created using Adobe Photoshop CS3 Software 
(Version 10.0.1, Adobe Systems Inc., San Jose, USA). In order to determine sensitivity 
and specificity of the intraoperative NIR fluorescence technique, an attempt was made 
to completely remove all tumor tissue while removing as little as possible of the normal 
surrounding mammary fat pad tissue strictly based on the fluorescence signal in 5 of 
these 7 rats. Tumors were removed by sharp dissection. Excised tumors were inked 
with India ink, sliced in two or three parts depending on the size of the tumor and 
fixed overnight in 4% buffered formalin and embedded in paraffin (FFPE) blocks, 
mimicking the standard clinical workflow. After resection of the primary tumor, the 
surgical cavity was inspected with the Fluobeam to detect any remnant fluorescent 
tissue. After resection of all remnant fluorescent spots, random biopsies were taken 
of the surgical cavity from every quadrant in order to determine specificity of the 
technique. In one additional rat an irradical resection was performed intentionally to 
test the Fluobeam’s ability to detect remnant tumor tissue. All specimens were fixed in 
formalin as described above. FFPE tumor sections of 4 µm were air-dried and stained 
with hematoxylin and eosin (H&E). The tumor size, the minimum and maximum 
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tumor-free margin and the presence of tumor in the random biopsies were determined 
by an experienced breast pathologist (V.T.H.B.M.S.).
fluorescence microscopy
Cell line experiments 
Time-dependent microscopic analysis of ProSense680 activation by cultured MCR86 
cancer cells was performed using the LSM510 Zeiss confocal microscope (Jena, 
Germany, 40x/0,75w Ph2 ACHROPLAN objective). A 633 nm laser was used for 
fluorescence excitation and a 650 nm Long Pass for emission. Cells were cultured in 
3.5 cm petri dishes incubated with 33.3 nM ProSense680 in 3 ml medium. Cells were 
kept at 37 °C and imaged for 4.5 hours. 
Ex vivo tumor imaging 
Freshly excised tumors with a wide rim of surrounding normal mammary tissue of 
rats injected with 10 nmol ProSense680 (N = 3) were halved. From one half, a 2 mm 
section was analyzed using the Odyssey scanning device at 21 µm resolution. Tumor 
border was defined as the outer rim of the tumor and its width was approximately 15% 
of the tumor diameter. The other half was snap-frozen on dry ice and stored at -80 °C. 
Unfixed 20 µm sections were measured for fluorescence using the Odyssey scanning 
device at 21 µm resolution. Processing of sections was performed under reduced light 
conditions to prevent photobleaching. Subsequently, the tissue sections were stained 
with H&E. The fluorescence image and the H&E image were merged using Adobe 
Photoshop enabling detailed analysis of the NIR fluorescence distribution along with 
the histological context. 
statistical analysis
Statistical analyses and generation of graphs were performed using GraphPad Prism 
software (Version 5.01, La Jolla, USA). Continuous variables were analyzed using 
the (paired) t-test for comparison of two groups and one-way analysis of variance 
(ANOVA) for comparison of more than two groups. To test the effect of two 
independent variables two-way ANOVA was used. Trend analysis and one-tailed 
planned comparisons between adjacent groups were conducted. When the assumption 
of homogeneity of variance was violated (Levene’s test), the Brown-Forsythe F-ratio 
was reported. Pearson’s correlation coefficients R were calculated for correlation 
analyses. All statistical tests were two-tailed and P < .05 was considered significant.
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Results
In vitro activation of Prosense by breast cancer rat cell line
The autoquenched NIR fluorescence probe ProSense680 was activated by MCR86 
breast cancer cells within two hours. Microscopic analysis revealed an intracellular 
localization of activated ProSense680 (Figure 2A-B). Both incubation time (F(3, 36) 
= 1615, P < .0001) and concentration of ProSense750 (F(3, 36) = 3704, P < .0001) 
significantly influenced ProSense750 activation as measured by fluorescence intensity 
(two-way ANOVA, Fig. 2C). Also, there was an interaction between incubation time 
and ProSense750 concentration (F(9, 36) = 230.4, P < .0001), indicating that the 
difference in incubation time within ProSense750 concentration groups influenced 
ProSense750 activation. Furthermore, fluorescence intensity was highly correlated 
with number of MCR86 cells (F(4, 10.97) = 39.13, P < .0001, R = 0.904; Figure 2D).
figure 2. In vitro activation of Prosense by syngeneic breast cancer rat cell line. A,B. Fluorescence microscopy 
(LSM510 Zeiss confocal microscope, 40x objective) of a cluster of MCR86 cells, 1 minute (left panel) and 4.5 h 
(right panel) after incubation with ProSense680 (33.3 nM). C. ProSense750 concentration and incubation time 
both significantly influence NIR fluorescence intensity (4.000 MCR86 cells per well, two-way ANOVA, Odyssey 
scanner). Bars represent mean ± SEM (N = 4). d. NIR fluorescence intensity is positively correlated with number 
of MCR86 cells (45 nM ProSense750, 24 h incubation, R = 0.890, P < .0001, Odyssey scanner). Bars represent 
mean ± SEM (N = 8).
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In vivo activation of Prosense by syngeneic rat model of primary breast cancer
EMR86 breast tumors were successfully imaged percutaneously using the IVIS 
Spectrum after intravenous administration of ProSense750 (Figure 3A-B). To test the 
effect of ProSense750 dose and time of imaging on fluorescence intensity, nine rats (N = 
35 mammary tumors, mean volume = 0.38 ± 0.36 cm3) were randomly assigned to three 
ProSense750 dose groups and were imaged 24 h and 48 h post-injection. In concordance 
with the in vitro data, ProSense750 dose significantly influenced fluorescence intensity 
(F(2,32) = 3.56, P = .04, two-way ANOVA, Figure 3C). Of note, a substantial part of the 
tumors could not be identified in the 2.5 nmol dose group (24 h: 4 of 11 tumors, 48 h: 
7 of 11 tumors) and the 5 nmol dose group (24 h: 2 of 12 tumors, 48 h: 3 of 12 tumors), 
whereas in the 10 nmol dose group all tumors were identified. In contrast to the in 
vitro data, time of imaging did not influence fluorescence intensity (F(2,32) = 2.47, 
P = .13, two-way ANOVA, Figure 3C). Furthermore, there was no interaction between 
time of imaging and ProSense750 dose (F(2,32) = 1.06, P = .36), indicating that the dif-
ference in time of imaging within dose groups did not influence fluorescence intensity. 
Based on these results, a dose of 10 nmol was selected for further in vivo testing. 
Imaging 24 h after ProSense administration was selected for practical purposes. With 
these settings, fluorescence intensity was significantly correlated with tumor volume 
(R = 0.93, P < .0001; Figure 3D), which was in concordance with the in vitro data. 
Intraoperative nIR fluorescence-guided resection of primary breast cancer
Using the Fluobeam intraoperative camera system, all primary breast tumors (N = 26 
tumors, 7 rats) were successfully identified 24 h after intravenous administration of 10 
nmol ProSense680 (Figure 4A). The technique provided a clear demarcation of tumor 
and surrounding mammary fat pad tissue with a mean tumor-to-background ratio of 
2.35 ± 0.37 (paired t = 14.95, P < .0001, Figure 4B). To determine the accuracy of tumor 
margin detection of the intraoperative NIR fluorescence technique, 17 tumors (N = 
5 rats) were resected completely under direct, real-time NIR fluorescence guidance, 
while removing as little as possible of the normal surrounding mammary fat pad 
tissue and processed for histopathological analysis (Figure 4C). All 17 tumors were 
completely excised with a mean minimum and a mean maximum tumor-free margin 
of 0.2 ± 0.2 mm and 1.3 ± 0.6 mm, respectively (Table 1). Mean pathological tumor 
size was 5.0 ± 2.1 mm. In two cases, after resection of the primary tumor, remnant 
fluorescent tissue was detected in the surgical cavity with the Fluobeam (Table 1). 
One specimen contained a lymph node with metastatic involvement and the other 
contained a reactive lymph node with abundant macrophage influx but no tumor 
involvement. This false-positive finding can be explained by the fact that macrophages 
show high cathepsin B expression.13 After resection of all fluorescent spots, random 
biopsies were taken of the surgical cavity from every quadrant. None of the random 
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biopsies (N = 64, 5 rats) contained histologically any tumor cells. These results indicate 
an excellent accuracy of the technique. In one additional rat, an irradical resection 
was performed intentionally in order to show the Fluobeam’s ability to detect remnant 
tumor tissue (Supplementary Figure 1). Remnant tumor tissue could be detected and 
subsequently resected under direct NIR fluorescence guidance.
Ex vivo nIR fluorescence microscopy
In order to determine the histological localization of ProSense680, tumors were excised 
with a wide rim of normal mammary tissue 24 h after intravenous administration of 
10 nmol ProSense680 (N = 12 tumors, 3 rats; Figure 5A). Fluorescence imaging of 
2 mm thick, fresh tumor slices revealed that the NIR fluorescence intensity was 1.6 
± 0.3 times higher at the border of the tumor than at its center (paired t = 4.99, P = 
.0005, N = 12 tumors; Figure 5B). In order to obtain more detail about the histological 
localization of ProSense680, unfixed 20 µm frozen tissue sections were measured for 
figure 3. In vivo activation of Prosense by syngeneic rat model of primary breast cancer. A. Typical example 
of a spectral unmixed image of an EMR86 tumor-bearing female WAG/Rij rat, acquired 24 h after intravenous 
administration of 10 nmol ProSense750. Shown is the separation of the autofluorescence signal (pseudocolored 
green) and the ProSense750 signal (pseudocolored red; IVIS Spectrum). B. Emission curve plot of the spectrally 
unmixed fluorescence signals from A. demonstrates matching of the tumor signal (red line) with the predefined 
ProSense750 emission curve (blue line), confirming the localization of activated ProSense750 at the tumors. C. 
In a dose- and time-dependent experiment, nine tumor-bearing rats (N = 35 tumors) were randomized to three 
ProSense750 dose groups and imaged 24 h (grey bars) and 48 h (open bars) after intravenous administration of 
ProSense750 using the IVIS Spectrum. Bars represent mean ± SEM. d. Scatter plot of fluorescence intensity and 
tumor volume of the 10 nmol dose group imaged 24 h after intravenous administration of ProSense750 (R = 
0.934, P < .0001, N = 12 tumors from 3 rats).
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fluorescence using the Odyssey and subsequently stained with H&E (Figure 5C). These 
results showed that NIR fluorescence is mainly located in the stromal compartment of 
the breast tumors and in particular at the tumor border. 
dIsCussIon
In the current study, we demonstrated the feasibility of real-time intraoperative NIR 
fluorescence identification of breast tumors in a syngeneic orthotopic breast cancer rat 
model using the protease-activatable probe ProSense. In both the cell line and animal 
experiments, fluorescence intensity was strongly correlated with number of tumor 
cells, tumor size and ProSense dose. In contrast to the in vitro data, time of imaging (24 
h vs. 48 h after administration of ProSense) did not significantly influence fluorescence 
intensity of breast tumors. This is likely a result of the relatively long blood half-life 
of ProSense (half-life in mice 18 h, VisEn Medical website) and may provide flexible 
operation planning in future clinical applications. Histological analysis demonstrated 
that NIR fluorescence intensity of tumors was highest at the invasive tumor border. 
figure 4. Intraoperative nIR fluorescence-guided resection of primary breast cancer and pathological 
assessment. A. Intraoperative NIR fluorescence image showing a 6-mm EMR86 breast tumor in a female WAG/
Rij rat 24 h after intravenous administration of 10 nmol ProSense680 (Fluobeam camera system). Camera 
exposure time was 10 ms.  B. Tumor-to-background ratios were determined in vivo in rats 24 h after intravenous 
administration of 10 nmol ProSense680 (N = 26 tumors, 7 rats). Fluobeam camera exposure time was 10 ms. 
Horizontal lines represent mean ± SD. Mean tumor-to-background ratio was 2.35 ± 0.37. C. Ex vivo color image 
(left panel), NIR fluorescence image (Fluobeam, middle panel) of 3 slices of an EMR86 tumor after resection 
and inking using India ink. The tumor was excised from a rat 24 h after intravenous administration of 10 nmol 
ProSense680. Camera exposure time was 10 ms. Resection margin of the tumor is shown after H&E staining of a 
4 µm FFPE tissue section (right panel).
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Resection of tumors under real-time NIR fluorescence guidance showed excellent 
accuracy of the technique in the intraoperative detection of tumor margins. These 
results suggest that clinical introduction of intraoperative NIR fluorescence imaging 
using a protease-activatable probe such as ProSense has the potential to increase the 
number of complete tumor resections in breast cancer patients undergoing breast-
conserving surgery. 
Previous studies in which NIR fluorescent and protease-activatable probes were 
tested have utilized xenograft or transgenic mouse models.19-31 A limitation of many 
animal models of breast cancer is that, compared to the human situation, less normal 
mammary tissue is present in relation to tumor size. Therefore, these tumors are easily 
resected by removing all breast tissue. However, this approach does not resemble the 
principles underlying breast-conserving surgery. This study was performed using 
an orthotopic breast cancer model that is syngeneic to immunocompetent female 
WAG/Rij rats. In syngeneic models, tumors are grown in homologous species and 
in the strain in which the tumor has originated. Therefore, these models are more 
representative of the natural tumor-host interaction. Although no preclinical tumor 
model will contain all features of the complex biology of human cancer, this syngeneic 
model has several strengths, including its hormone-sensitivity, cribiform growth 
pattern and its ability to induce regression by estrogen pellet removal. Moreover, this 
model captures several important features of luminal A hormone-dependent, HER2/
neu negative human breast cancer, which is the most predominant subtype of breast 
cancer.34, 35 Another intrinsic limitation of animal models of surgical interventions is 
the potential occurrence of performance bias, because researchers carrying out the 
intervention can not be blinded to the allocated treatment. This form of bias may lead 
to flawed results.40 To surpass these limitations in our study, a one-arm study design was 
chosen using small breast tumors (5.0 ± 2.1 mm). Tumors were excised based on the 
NIR fluorescence signal and examined by a breast pathologist using standard clinical 
methodology. Using this approach, all tumors were completely resected with a mean 
maximum tumor-free resection margin of 1.3 ± 0.6 mm, indicating that a minimal 
amount of normal mammary tissue was resected. Although syngeneic models provide 
a relevant tumor-host interaction, their major drawback is that the tumor cells are 
rodent, and therefore express the rodent homologues of the desired targets. However, 
the main target of ProSense, the cysteine protease family (most particular cathepsin 
B) is strongly conserved amongst mammals.12 Upregulation of cathepsin B has been 
confirmed extensively in human breast cancer.12, 14, 15, 41 It is therefore expected that this 
kind of protease-activated NIR fluorescence probes will be applicable for intraoperative 
NIR fluorescence imaging in a large proportion of breast cancer patients.
Analysis of the histological localization of activated ProSense demonstrated 
that the invasive tumor border exhibited the most intense NIR fluorescence signal. 
This observation is in concordance with immunohistological analysis of cathepsin B 
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reported by others14, 24 and is in line with the pathophysiological role of cathepsins as 
reviewed by Gocheva.42 Cathepsins promote tumor invasion through several possible 
mechanisms. First, they can directly cleave components of the extracellular matrix 
and basement membrane, essentially clearing a path for the migration of tumor 
cells away from the primary tumor. Second, at the cell membrane, cathepsins can 
direct a proteolytic cascade in which they activate other proteases such as matrix 
metalloproteinases and urokinase plasminogen activator, which in turn promotes 
tumor invasion. Third, cleavage of the cell adhesion protein, E-cadherin, at the cell 
surface can disrupt adherens junctions and thus facilitate cancer cell migration and 
invasion.42 Apart from tumor border, NIR fluorescence was higher in the stromal 
compartment of the tumors. This finding is in concordance with Gounaris et al., who 
demonstrated that CD11+ tumor-infiltrating macrophages accounted for 75% of the 
ProSense signal at FACS analysis.29 In summary, as complete resection of breast tumors 
figure 5. Ex vivo nIR fluorescence microscopy of resected breast cancer. A. Ex vivo color image (top panel) 
and NIR fluorescence image (Fluobeam, bottom panel) of an excised EMR86 tumor with surrounding normal 
mammary fat pad. Fluobeam camera exposure time was 10 ms. The tumor was excised from a rat 24 h after 
administration of 10 nmol ProSense680. B. Quantification of NIR fluorescence measurements of tumor tissue 
slices showed that the fluorescence signal was 1.6 ± 0.3 times higher at the border of the tumor than at its center 
(Odyssey scanner, paired t  = 4.99, P = .0005, N = 12 tumors). C. Shown are a color image of H&E staining (left 
panel), a pseudocolored green NIR fluorescence image (middle panel; Odyssey scanner), and a merge of the two 
images (right panel) of a 20 µm frozen section of a 4-mm EMR86 breast tumor with surrounding mammary fat 
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requires adequate visualization of tumor margins, the increased activity of proteolytic 
enzymes at the invasive tumor border provides an excellent target for intraoperative 
NIR fluorescence-guided surgery.     
Future clinical studies will have to provide proof-of-principle of intraoperative 
NIR fluorescence tumor detection. Currently, a number of intraoperative NIR 
fluorescence imaging systems are clinically available and have already been used for 
sentinel lymph node mapping.43-45 It is expected that several tumor-targeting NIR 
fluorescent probes (such as ProSense) will receive regulatory approval within the next 
few years.
A therapeutic challenge of any new breast cancer imaging technology is the 
detection of occult tumor deposits in the breast. These tumor deposits could influence 
surgical decision making, but do not necessarily have a prognostic relevance, because 
postoperative radiation will eradicate these microscopic deposits in the vast majority 
of cases. For instance, in preoperative magnetic resonance imaging, the identification 
of additional tumor deposits is two to three times higher than the incidence of local 
recurrence, resulting in mastectomies that may not be beneficial to the patient.46 
Consequently, detection of tumor at the margins would be beneficial; detection of 
tumor deposits beyond the margins, below the cut edge of the lumpectomy cavity, 
could have the potential to increase surgical resection volume (or even mastectomy 
rates) without a benefit in survival. Since the maximum penetration depth for NIR 
fluorescence imaging is currently around 1 cm,47 it is unlikely that intraoperative NIR 
fluorescence imaging will detect occult lesions at several centimeters distance from the 
primary tumor. 
Sensitivity of NIR fluorescence is mostly dependent on photon absorption of 
the tissue, fluorescence excitation power of the light source and concentration of the 
NIR fluorophore in tissue. Required camera exposure times are inversely correlated 
with the amount of fluorescence signal. In the current study, camera exposure times 
of 2-20 ms were used. The field-of-view of the Fluobeam camera system is 7 cm of 
diameter. Therefore, the time needed to evaluate tumor margins and excision cavities 
is at most several seconds. Consequently, this real-time intraoperative technique is 
unlikely to prolong surgical time significantly. 
In conclusion, this study provides preclinical validation of an innovative 
technique in which NIR fluorescence light is used to visualize breast tumors and to 
provide real-time guidance during subsequent resection. Clinical translation of these 
results might be very promising because of high accuracy of the technique, flexible 
surgical planning, increased proteolytic activity at the tumor border and upregulation 
of cathepsin B in a large proportion of breast cancer patients. Therefore, this study 
warrants clinical validation of this technique, once NIR fluorescence probes become 
available for clinical testing, with the ultimate goal to increase the radical resection rate 
of patients undergoing breast-conserving surgery.
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suPPlementARy dAtA 
supplementary figure 1. Intraoperative nIR fluorescence detection of irradical resection of pirmary breast 
cancer. A. Intraoperative NIR fluorescence image of an intentionally irradical resection of an EMR86 tumor in 
a WAG/Rij rat 24 h after intravenous administration of 10 nmol ProSense680. B. A remnant fluorescent hotspot 
is readily visualized using intraoperative NIR fluorescence imaging. C. The identified fluorescent hotspot is 
resected under direct NIR fluorescence image-guidance. Camera exposure time was 10 ms. d. Resected hotspot 
is histologically confirmed as tumor tissue (H&E staining).
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Incomplete tumor resections occur frequently in patients undergoing breast-
conserving surgery. Intraoperative near-infrared (NIR) fluorescence imaging is a 
novel technique to assess the extent of disease during surgery. The current study aimed 
to investigate whether tumor-targeting monoclonal antibodies conjugated to a NIR 
fluorescence dye could detect primary breast carcinomas in a syngeneic rat model and 
be used for image-guided resection.
methods 
The monoclonal mouse antibody MG1, directed against epithelial rat tumor cells, was 
conjugated to the NIR fluorescent IRDye™800-CW (MG1-CW800) and purified to 
homogeneity. The isotype-matched irrelevant antibody UPC10 was used as a control. 
Tumor specificity of MG1-CW800 was assessed using the MCR86 rat breast cancer 
cell line. In vivo tumor targeting was assessed in female WAG/Rij rats carrying EMR86 
breast tumors. The Mini-FLARE imaging system was used for intraoperative image-
guided resection of EMR86 tumors.
Results
MG1-CW800 bound specifically to MCR86 tumor cells and could identify EMR86 
breast tumors in rats using NIR fluorescence. The tumor-to-background ratio (TBR) 
was highest 24 h after intravenous administration (2.81 ± 0.74). Although UPC10-
CW800 did not bound to MCR86 cells, clear tumor demarcation was observed after 
intravenous injection in EMR86 bearing rats (TBR = 2.95 ± 0.67). Using MG1-
CW800, all tumors could be resected under direct image-guidance. MG1-CW800 
signal corresponded with histological tumor demarcation.
Conclusion
This study demonstrated that tumor-targeted antibodies conjugated to NIR 
fluorescence dyes can identify breast tumors in a syngeneic rat model. However, as 
the control antibody obtained similar in vivo results, the ‘enhanced permability and 
retention effect’ may be an important factor. 
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IntRoduCtIon
During breast-conserving surgery, the surgeon has to rely on palpation and visual 
inspection to discriminate tumor tissue from normal tissue. The distinction between 
tumor and normal tissue is often not evident, resulting in irradical resections in 5 
to 40% of patients undergoing breast-conserving surgery, which requires additional 
resection or intensified radiotherapy regimens.1-3 Local recurrence rates following 
breast-conservative therapy of 6.7 to 11% are reported,4 which can be explained by 
remnant tumor tissue that is not identified during surgery. Loco regional recurrences 
are associated with a decrease in overall survival.4 Therefore, there is a need for a 
diagnostic tool that can discriminate tumor tissue from normal tissue in real-time 
during surgery.
Near-infrared (NIR) fluorescence imaging is a technique that has the potential 
to fulfill this need. NIR light (700 – 900 nm) can penetrate millimeters to centimeters 
into tissue without the use of ionizing radiation.5 Several imaging systems have 
recently become available that are capable of visualizing NIR fluorescence in real-
time (reviewed in 6). Besides these imaging systems, tumor-targeted NIR fluorescent 
contrast agents (“probes”) are necessary to visualize cancer cells. Various mechanisms 
are available for probes to target tumor cells: they can target increased metabolism,7 
upregulated enzymes,8-10 or specific cell surface markers.11 Besides these targeted 
strategies, a non-targeted approach has been suggested that exploits the so-called 
‘enhanced permeability and retention (EPR) effect’.12 The EPR effect is the phenomenon 
that macromolecules tend to accumulate in tumor tissue much more than they do in 
normal tissues, which is most probably due to fact that tumors have abnormal ‘leaky’ 
neovasculature having endothelial cells with wide fenestrations and lack of smooth 
muscle layer (Figure 1).
The current study focuses on the use of tumor-targeted antibodies for NIR 
fluorescence image-guided surgery. Ample clinical experience exists on the use of 
antibodies in breast cancer, which have been employed for diagnostic imaging,13, 14 
and therapeutic purposes.15, 16 Moreover, preclinical studies have successfully exploited 
antibody-based NIR fluorescence tumor targeting.17, 18 However, these studies were 
performed in transgenic animal models and lack an adequate isotype-matched control 
antibody. In this study, we used an antibody directed against epithelial rat tumors, 
which has been evaluated in a syngeneic rat model of colorectal cancer for the 
application of immunotherapy and radioimmunotherapy.19-21 The aim of the current 
study was to construct an NIR fluorescent tumor-targeted antibody and to validate 
the intraoperative use of this probe during tumor resection and to compare it with the 
performance of an isotype-matched irrelevant antibody to control for the EPR effect. 




All animals were housed in the animal facility of Leiden University Medical Center. 
Pellet food and fresh tap water were provided at libitum. The weight of the animals was 
followed throughout the experiment to monitor their general health state. Throughout 
imaging and surgical procedures, the animals were anesthetized with inhalation of 
2% mixture of isoflurane in oxygen. The Animal Welfare Committee of the Leiden 
University Medical Center approved the study. The study was conducted in concordance 
with the “Guidelines for the Welfare of Animals in Experimental Neoplasia” (Second 
edition, 1997) available online at http://www.ncrn.org.uk/csg/animal_guides_text.pdf.
The EMR86 model is a hormone-dependent, transplantable, metastasizing 
mammary carcinoma that originated in a female WAG/Rij rat bearing a subcutenously 
implanted estrogen pellet and has been described previously.9, 22 EMR86 tumor cells 
show strong nuclear expression of the estrogen and progesterone receptor, but stain 
negatively for the human epidermal growth factor receptor 2 (HER2/neu). Therefore, 
EMR86 tumors closely resemble the luminal A molecular subtype. Orthotopic breast 
tumors are induced after implantation of fresh EMR86 tumor fragments of 1 mm3 
into the mammary fat pad at four sites in 4 to 6 months old female WAG/Rij rats 
(Harlan, Horst, The Netherlands) with simultaneous implantation of an estrogen 
pellet in the intrascapular region of the neck. After four weeks, tumors reach a volume 
of approximately 1 cm3, at which time point the experiments were conducted.
Figure 1 
Hutteman and Mieog et al. 
figure 1. schematic representation of the ‘enhanced permeability and retention effect’.
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Immunohistochemistry and in vivo homing 
MG1 is an IgG2a mouse monoclonal antibody (Antibodies for Research Applications, 
Gouda, The Netherlands), which originated in Balb/c mice after immunization 
with CC531 colon adenocarcinoma cells that are syngeneic to WAG/Rij rats.23 MG1 
recognizes an 80 kDa cell surface antigen on rat cancer cells of epithelial origin, with 
minimal cross-reactivity with other tissues.23 To assess the specificity of MG1 for 
EMR86 breast tumors, 4 µm cryosections of snap frozen EMR86 tumors were stained 
with MG1 as described previously.23 The IgG2a mouse antibody UPC10 (Sigma Aldrich, 
Zwijndrecht, The Netherlands), which is directed against β-2-6-linked fructosan, was 
used as an isotype-matched irrelevant control antibody.24 
In vivo homing of MG1 to EMR86 tumors was tested by injection of 200 µg of 
MG1 or UPC10 antibody in 500 µL PBS in the tail vein of EMR86 tumor bearing rats 
(N = 6 rats, 24 tumors). 24 h after injection, rats were sacrificed and tumors and organs 
were harvested and snap-frozen on dry ice. Frozen tissue was sectioned and stained as 
described above, with the exception that no primary antibody was applied.
Construction of nIR fluorescence probes
The NIR fluorescent IRDye 800CW-NHS (LI-COR, Lincoln, NE) was purchased as 
a dry powder and resuspended to 10 mM in anhydrous dimethyl sulfoxide (DMSO; 
Sigma Aldrich) under reduced light conditions and stored at -80 °C until used for 
conjugation.
Preservatives were removed from the solution containing MG1 antibodies 
using gel filtration chromatography with Zeba spin desalting columns with a cut-off 
of 7 kDa (Thermo Fisher Scientific, Etten-Leur, The Netherlands). The purified sample 
was then concentrated using Vivaspin columns (Sigma Aldrich) with a cut-off of 30 
kDa and was reconstituted in phosphate-buffered saline (PBS) at pH 7.8. Antibody 
concentration was estimated using absorbance spectrometry (UltroSpec, Amersham, 
UK; e280nm = 180,000 M
-1 cm-1).
IRDye 800CW-NHS was added dropwise to the purified MG1 solution, while 
maintaining a pH of 7.8. The reactant was gently shaken for 4 h at room temperature. 
Unreacted dye was separated from conjugated antibodies (MG1-CW800) by gel 
filtration chromatography with Zeba spin desalting columns with a cut-off of 7 kDa. The 
labeling ratio of the purified sample was then analyzed using absorbance spectrometry, 
using the extinction coefficients of MG1 (e280nm = 180,000 M
-1 cm-1) and CW800 (ε785nm 
= 240,000 M-1 cm-1) in PBS, with correction for 6.5% of measured absorbance at 280 
nm of CW800: Ratio = (Abs785nm / e785nm) / ((Abs280nm – 0.065 * Abs785nm) / e280nm). The 
same protocol was applied to construct UPC10-CW800. 
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In vitro confirmation of specificity of mG1-Cw800
In vitro cell binding of the newly constructed NIR fluorescent probe MG1-CW800 
was tested in the rat breast cancer cell line MCR86, which is recognized by MG1.23 
The characteristics of the cell line and the culture conditions as well as the methods 
for fluorescence measurements have been described previously.9 In short, cultured 
tumor cells were harvested, washed and transferred to a 96-well acrylate plate (Greiner 
Bio-one, Alphen aan de Rijn, The Netherlands, #655090; suitable for fluorescence 
measurements). For the binding experiments, 16,000 cells were transferred per 
well, unless stated otherwise. After 24 h of incubation, cells were washed and MG1-
CW800 (6.7 nM to 26.7 nM, 200 µl) was added. In a competitive blocking experiment, 
unconjugated MG1 was mixed with a fixed MG1-CW800 concentration in order to 
obtain concentrations of 6.7, 26.7 and 53.4 nM of unconjugated MG1 and 6.7 nM of 
MG1-CW800, and 200 µl of the mixtures was added to the cells. After incubation of 1 
h, cells were washed and fluorescence intensity was measured using the Odyssey NIR 
fluorescence scanning device (LI-COR, Lincoln, NE). Overlying grids were drawn and 
integrated intensity was calculated for each well using the Odyssey software (Version 
2.1; LI-COR, Lincoln, NE) and corrected for baseline fluorescence signal. UPC10 and 
UPC10-CW800 were used in a negative control experiment. 
In vivo tumor targeting 
Tumor bearing rats (N = 14 rats, 55 tumors) were injected into the tail vein with 200 
µg of MG1-CW800, UPC10-CW800 or unconjugated IRDye 800CW carboxylate (LI-
COR). Rats were imaged at 24 h, 48 h and 120 h after injection of the NIR fluorescent 
probe using the IVIS Spectrum multispectral imager (Caliper LifeSciences, Hopkinton, 
MA), which allowed separation of the 800 nm signal from the rat’s autofluorescence by 
means of spectral unmixing. Signal intensity of tumors and surrounding tissue were 
measured in vivo.
Intraoperative nIR fluorescence imaging
Real-time intraoperative NIR fluorescence imaging was performed using the Mini-
FLARE imaging system, which has been described previously.25 Briefly, the system 
consists of two wavelength isolated light sources: a “white” light source, generating 
22,600 lx of 400-650 nm light and a “near-infrared” light source, generating 7.7 mW 
cm-2 of 760 nm light. Color video images and NIR fluorescence images are acquired 
simultaneously and displayed in real-time using custom optics and software. The 
system provides the surgeon with real-time images of color video, NIR fluorescence 
and a pseudocolored merge of the two for anatomical reference.
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Image-guided resection
Directed by time optimization experiments, EMR86 tumor bearing rats (N = 6 rats, 
24 tumors) were injected with 200 µg of MG1-CW800 via tail vein injection and 
imaged 24 h thereafter. The Mini-FLARE was positioned at 30 cm above the animal. 
Guided by the NIR fluorescence images, a skin incision was made and the fluorescent 
hotspots were resected with a margin of approximately 0.5 cm non-fluorescent tissue. 
The surgical cavity was inspected for any remnant fluorescence, which, if present, was 
resected. NIR fluorescence intensity of organs was assessed in vivo for biodistribution 
analyses. Excised tumors were sliced in two parts and snap frozen on dry ice. Tumors 
were sectioned at 10 µm and air-dried. NIR fluorescence signal was measured using 
the Odyssey, after which the sections were stained with hematoxylin and eosin.
statistical analyses
Statistical analyses and generation of graphs were performed using GraphPad Prism 
software (Version 5.01, La Jolla, CA). Continuous variables were analyzed using the 
(paired) t-test for comparison of two groups. Homogeneity of variance was assessed 
using Levene’s test. Pearson’s correlation coefficients R were calculated for correlation 
analyses. All statistical tests were two-tailed and P < .05 was considered significant. 
Figure 2 





figure 2. Immunohistochemical confirmation of specificity of mG1 antibodies for emR86 breast cancer 
tumors. Incubation of frozen EMR86 sections with MG1 (upper left panel) and UPC10 antibodies (lower left 
panel). In a homing experiment, rats were intravenously infected with 200 µg MG1 or UPC10 antibody 24 h prior 
to resection of EMR86 tumors. Staining of frozen sections of these tumors showed presence of MG1 antibodies 
(upper right panel) and absence of UPC10 antibodies (lower right panel). Bars represent 100 µm. 
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Results
specificity of mG1 antibody for emR86 breast tumors
Cryosections of EMR86 tumors showed clear staining with MG1 after immuno-
histochemistry and no staining with the UPC10 control antibody (Figure 2). Limited 
cross-reactivity with other tissues was observed (data not shown), similar to previous 
results in colorectal cancer.23 To determine the in vivo binding capabilities of MG1 to 
EMR86 breast tumors, six tumor-bearing rats (N = 24 tumors) were i.v. injected with 
200 µg of MG1 or UPC10 antibodies. The tumors were excised 24 h after injection. 
Immunohistochemical analyses showed adequate homing of the MG1 antibody to the 
tumors and no homing of the UPC10 antibody (Figure 2). 
Construction and in vitro testing of nIR fluorescent probes
To construct a NIR fluorescent probe, MG1 antibodies were conjugated to the NIR 
fluorescent IRDye 800CW. The resulting fluorescent antibody (MG1-CW800) was 











































































Figure 3. In vitro characterization of MG1-CW800. A. Absorbance and fluorescence spectra of MG1-CW800. 
Concentration and labeling ratio were determined using Beer-Lambert’s law, as shown in the table. B. 
Fluorescence intensity was significantly correlated with the number of MCR86 breast cancer cells (R = 0.98, P < 
.0001). C. Fluorescence intensity was significantly correlated with the concentration of MG1-CW800 added to a 
fixed number of MCR86 cells (16,000 cells, R = 0.95, P < .0001). D. Specific binding was demonstrated by linear 
decrease of fluorescence intensity by adding increasing amounts of unlabeled MG1 (R = -0.73, P = .003).
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separated from reaction products by gel filtration chromatography. The average number 
of fluorophores per antibody (labeling ratio) as estimated by absorbance spectrometry 
was 1.6 ± 0.4 (Figure 3A). To test if the binding capacities of MG1-CW800 were retained, 
cell line experiments were conducted (Figure 3B-D). UPC10-CW800 was used a 
control NIR fluorescent probe. Fluorescence intensity was significantly associated 
with number of cells (R = 0.98, P < .0001; Figure 3B) and the concentration of MG1-
CW800 (R = 0.95, P < .0001; Figure 3C). Blocking of MG1-CW800 binding to MCR86 
tumor cells was performed by adding escalating concentrations of unconjugated MG1. 
Fluorescence intensity was inversely correlated with the concentration of unconjugated 
MG1 (R = -0.73, P = .003; Figure 3D). UPC10-CW800 showed no binding with MCR86 
cells (Figure 3B-D). These results demonstrated that the specific binding capacities of 





























figure 4. In vivo nIR fluorescence detection of emR86 tumors after intravenous injection of mG1-Cw800 
or uPC10-Cw800. A. In vivo imaging EMR86 tumor-bearing female WAG/Rij rats, 24 h after intravenous 
administration of 200 µg MG1-CW800 (left), 200 µg UPC10-CW800 (middle panel) or 2 nmol unconjugated 
IRDye 800CW carboxylate (right panel). Shown is the image after spectral unmixing (IVIS Spectrum). B. Tumor-
to-background ratios were determined in vivo at t = 0, 24 h, 48 h and 120 h after administration of MG1-CW800, 
UPC10-CW800 and IRDye 800CW carboxylate using the IVIS Spectrum (N = 3 rats in each group).
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In vivo tumor targeting nIR fluorescent antibody mG1-Cw800
The tumor-targeting properties of the NIR fluorescent antibody MG1-CW800 were 
tested in the EMR86 breast cancer rat model using the IVIS Spectrum imaging system 
(Figure 4). Both UPC10-CW800 and unconjugated IRDye 800CW carboxylate were 
used as a negative control. The tumor-to-background ratio’s (TBR) were assessed 
at 24 h, 48 h and 120 h after injection (Figure 4B). The TBR of rats injected with 
MG1-CW800 peaked at the 24 h time point and the mean TBR was 2.81 ± 0.74. No 
significant difference was observed between the 24 h and 48 h time point (t = 1.11, 
P = .82). Imaging after 120 h resulted in a significantly lower TBR compared to the 
24 h time point (t = 4.30, P = .001). Rats injected with UPC10-CW800 showed clear 
identification of tumors with a mean TBR at 24 h of 2.95 ± 0.67. Rats injected with 
unconjugated IRDye 800CW carboxylate showed no tumor demarcation. Based on 
these results, imaging 24 h after administration of fluorescent probe was selected for 
practical purposes. 
figure 5. Intraoperative and ex vivo tumor identification with nIR fluorescence. Image-guided resection of an 
EMR86 breast tumor in a rat, 24 h after intravenous administration of 200 µg MG1-CW800 (upper row). Shown 
are a color image (left panel), NIR fluorescence image (middle panel) and a pseudocolored merge of the two 
(right panel) as shown in real-time during surgery (Mini-FLARE). Ex vivo NIR fluorescence analysis using the 
Mini-FLARE of resected specimens shows a clear demarcation of the tumor (T) from the surrounding mammary 
tissue (M; middle row). H&E staining and NIR fluorescence measurement (Odyssey) of cryosections of resected 
specimens reveal that MG1-CW800 localization corresponds with tumor areas (T = primary tumor, * = tumor 
satellites) as determined by histology. Surrounding mammary tissue (M) shows no NIR fluorescence (lower row).
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Intraoperative nIR fluorescence-guided resection of primary breast cancer
Using the Mini-FLARE intraoperative imaging system, all primary breast tumors (N 
= 24 tumors, 6 rats) were successfully identified 24 h after intravenous administration 
of 200 µg MG1-CW800 (Figure 5A). The technique provided a clear demarcation of 
tumor from surrounding mammary fat pad tissue (t = 9.95, P < .0001), with an average 
tumor-to-background ratio of 2.78 ± 0.74. After resection of the primary tumor under 
direct NIR fluorescence-guidance, no remnant fluorescence hotspots were detected. 
Histological analyses and fluorescence microscopy (at 800 nm) confirmed that the 
NIR fluorescent signal of MG1-CW800 corresponded with the presence of tumor 
cells (Figure 5B-C). In addition, immunohistochemical analysis confirmed that MG1 
antibody was present at the cell surface of EMR86 tumor cells (data not shown). Next, 
the biodistribution of MG1-CW800 was assessed in vivo by quantifying the NIR 
fluorescence signal in selected organs of 6 rats 24 h after intravenous administration 
of 200 µg MG1-CW800 (data not shown). Because of the renal clearance of the NIR 
fluorescent probe, the kidney and the bladder showed attenuated fluorescent signal. 
Most organs, however, showed low fluorescent intensities. Conversely, the liver showed 
high fluorescence intensity.
dIsCussIon
The current study demonstrated the construction of a NIR fluorescent tumor-targeted 
antibody (MG1-CW800) and its validation in a syngeneic rat model of breast cancer. 
In vitro characterization showed a linear increase of NIR fluorescence signal with 
increasing MG1-CW800 concentration and increasing cell concentration. Specificity 
of the binding was shown in vitro by blocking of the NIR fluorescence signal by 
addition of unlabeled antibody. During the in vivo experiments, all breast tumors 
could be clearly identified by NIR fluorescence after intravenous injection of MG1-
CW800. Tumor demarcation as identified by intraoperative NIR fluorescence imaging 
corresponded to the histological findings.
In vivo, however, animals injected with the NIR fluorescent-labeled UPC10-
CW800 isotype control antibody, showed similar tumor uptake as MG1-CW800. As 
UPC10-CW800 showed no specific binding in vitro, the in vivo tumor uptake can be 
attributed to the enhanced permeability and retention effect.12 Previous studies using 
radiolabeled UPC10 demonstrated no tumor uptake.24 The NIR fluorophore used in 
this study has a molecular weight of 1091 Da, whereas the radiolabel 111Indium has a 
molecular weight of 111 Da. A recently published study on novel NIR fluorophores 
has demonstrated the influence of the negative net charge of IRDye 800CW on 
biodistribution.26 Future research should focus on the exploiting the effect of size and 
charge on tumor uptake, whilst minimizing background uptake.
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Antibodies are a promising entity to provide contrast during NIR fluorescence 
image-guided surgery. In contrast to, for example, enzymatic targeting,27, 28 an antibody 
targeting the correct antigen will target tumor cells itself, instead of surrounding tissue. 
Indeed, MG1 has been shown to stain virtually all tumor cells,23 and similar results have 
been reported for antibodies against human targets.29, 30 Several antibodies are available 
for clinical application,15, 31, 32 with a multitude in the process of clinical approval. As the 
first fluorophores, including IRDye 800CW, are in the process of clinical approval,33 it 
is expected that combining such a novel fluorophore with an already clinically available 
tumor-targeting agent (for example trastuzumab, bevacizumab and cetuximab) will 
encounter less roadblocks from bench to bedside.34 Moreover, as these antibodies 
are already employed for novel adjuvant treatment options, as immunotherapy,15, 31 
radioimmunotherapy,35 or pretargeted radioimmunotherapy,36, 37 these antibodies have 
the potential to be used for both intraoperative tumor visualization and perioperative 
treatment of residual disease.
For an optimal tumor demarcation using NIR fluorescence probes, tumor 
binding needs to be maximized, while minimizing background uptake.38 Therefore, 
an optimal tumor-targeting NIR fluorescent probe has a high affinity for the targeted 
ligand, has low non-specific uptake in non-targeted tissue, and unbound molecules 
are cleared rapidly from the body.39 Antibodies as MG1 have a molecular weight of 
approximately 150 kDa and are therefore macromolecules, which have a relatively 
long blood half-life of 330 minutes.40 In the current study, a high NIR fluorescence 
signal was observed in the liver, which could be caused by specific binding of the 
Fc region of the antibody and subsequent degradation of the immune complex by 
Kuppfer cells,41 or aspecific binding by the liver parenchyma due to the surface charge 
and hydrodynamic diameter of MG1-CW800. Although the uptake in the liver would 
not directly hamper the ability to demarcate breast tumors (as opposed to intra-
abdominal tumors, where this could be a significant impairment42), lower aspecific 
uptake will decrease the required dose and reduce potential side effects. Therefore, 
future studies will have to focus on smaller tumor-targeted entities (e.g. peptides,43, 44 
peptidomimetic molecules,45-47 or antibody fragments48) that should be combined with 
optimized fluorophores, with minimal background uptake, to optimize biodistribution 
and clearance properties in order to maximize contrast with minimal dosing.39
In conclusion, this study shows the tumor-targeting capabilities of a newly 
constructed NIR fluorescent antibody and its use for intraoperative tumor demarcation 
of breast tumors, in a preclinical animal model. An aspecific isotype control antibody 
demonstrated similar in vivo tumor uptake, indicating the influence of the enhanced 
permeability and retention effect. The use of an antibody based tumor-targeting 
strategy permits the use of currently clinically available molecules, could enable 
combined use for visualization and treatment and therefore has the potential to be 
translated to the clinic in the foreseeable future.
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Near-infrared (NIR) fluorescent sentinel lymph node (SLN) mapping in breast cancer 
requires optimized imaging systems and lymphatic tracers. 
methods
A small, portable version of the FLARE™ imaging system, termed Mini-FLARE™, 
was developed for capturing color video and two semi-independent channels of NIR 
fluorescence (700 nm and 800 nm) in real-time. Initial optimization of lymphatic tracer 
dose was performed using 35-kg Yorkshire pigs and a 6-patient pilot clinical trial. More 
refined optimization was performed in twenty-four consecutive breast cancer patients. 
All patients received the standard of care using 99mTechnetium-nanocolloid and patent 
blue. In addition, 1.6 mL of indocyanine green adsorbed to human serum albumin 
(ICG:HSA) was injected directly after patent blue at the same location. Patients were 
allocated to one of eight escalating ICG:HSA concentration groups from 50 to 1000 
µM. 
Results
The Mini-FLARE™ system was positioned easily in the operating room and could be 
used up to 13” from the patient. Mini-FLARE™ enabled visualization of lymphatic 
channels and SLNs in all patients. A total of 35 SLNs (mean = 1.45, range 1-3) were 
detected: 35 radioactive (100%), 30 blue (86%), and 35 NIR fluorescent (100%). 
Contrast agent quenching at the injection site and dilution within lymphatic channels 
were major contributors to signal strength of the SLN. Optimal injection dose of 
ICG:HSA ranged between 400 and 800 µM. No adverse reactions were observed. 
Conclusions
We describe the clinical translation of a new NIR fluorescence imaging system and 
define the optimal ICG:HSA dose range for SLN mapping in breast cancer.
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IntRoduCtIon
Sentinel lymph node (SLN) mapping, as introduced for the management of breast 
cancer by Giuliano et al,1 is currently regarded as the standard of care for staging of the 
axilla.2 In general, a combination of radioactive colloid and blue dye is used. However, 
this exposes patients and caregivers to ionizing radiation, and blue dyes cannot be seen 
through skin and fatty tissue. Nonetheless, in recent trials, SLN identification rates of 
95-97% are achieved when using this combination, and use of only one agent results in 
significantly lower identification rates.3-6
Recent preclinical and clinical data have demonstrated that near-infrared 
(NIR) fluorescence imaging using the NIR fluorescence agent indocyanine green 
(ICG) enables real-time transcutaneous and intraoperative visualization of lymphatic 
channels and detection of the SLN.7-14 Therefore, NIR fluorescence imaging could 
provide an alternative for, or an addition to, conventional techniques used for SLN 
mapping. However, to date, clinical data are lacking a direct comparison of NIR 
fluorescence to the combination of radioactive tracer and blue dye. Also, even though 
ICG is the only fluorescent agent currently available in the clinic, it is not an optimal 
lymphatic tracer. Previous preclinical work has demonstrated that adsorption of ICG 
to human serum albumin (HSA, complex is ICG:HSA) increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection and 
better retention in the SLN.15 
Recently, first-in-human clinical testing of ICG:HSA was performed.14 The 
Fluorescence-Assisted Resection and Exploration (FLARE™) imaging system, 
developed by our group14, 16 and used in the trial, is a general-purpose optical imaging 
platform that provides the surgeon with two independent NIR fluorescence channels 
(centered at 700 nm and 800 nm) to see otherwise invisible structures within the 
surgical field. The first generation of FLARE™ was large, expensive to build, and had a 
heavy imaging head that required a specially-designed articulated arm.14 This prevented 
shipment of FLARE™ to researchers around the world, and therefore impeded efficient 
scientific investigation. During the first-in-human clinical testing of FLARE™, it also 
became apparent that contrast agents for SLN mapping were not yet optimal. The goals 
of the present study were to develop a miniaturized version of FLARE™, termed Mini-
FLARE™, and to determine optimal lymphatic tracer dosing for SLN mapping in breast 
cancer.




A detailed description of the Mini-FLARE™ imaging system and in vitro characterization 
is available online at http://www.springerlink.com/content/r4712247933613tv/. For 
sterile usage in the operating room, a 0.118” thick acrylic splash shield having 95% 
optical transmission at 800 nm was hermetically bonded to a clear plastic drape and 
sterilized (Medical Technique, Inc., Tucson, USA). 
Preparation of indocyanine green adsorbed to human serum albumin
ICG (25-mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 
mM) stock solution. Various amounts of this stock solution were transferred to a 50 
cc vial of Cealb (20% human serum albumin (HSA) solution; Sanquin, Amsterdam, 
The Netherlands) to yield ICG in HSA (ICG:HSA) at a final concentration of 50 µM, 
100 µM, 200 µM, 400 µM, 500 µM, 600 µM, 800 µM, or 1000 µM. To obtain a final 
concentration of 800 µM and 1000 µM, ICG was resuspended in 5 cc of sterile water, 
to yield a 6.4-mM stock solution prior to dilution.
A
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figure 1. The mini-flARe™ portable near-infrared fluorescence imaging system. A. Imaging system 
composed of electronics/monitor cart and counter-weighted imaging system pole. B. Sterile drape/shield attached 
to the imaging head with other major parts identified. C. Excitation and emission light paths, and filtration for the 
Mini-FLARE™ imaging system. DM = 650 nm dichroic mirror. 
B
C
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Pre-clinical characterization
Animals were studied under the supervision of approved institutional protocol. 
Female Yorkshire pigs (E. M. Parsons and Sons, Hadley, USA) averaging 35 kg were 
induced with 4.4-mg/kg intramuscular Telazol (Fort Dodge Labs, Fort Dodge, USA), 
intubated, and maintained with 2% isoflurane (Baxter Healthcare, Deerfield, USA). 
Vital signs were monitored continuously. Excitation fluence rate for white light and 
800-nm excitation light were 26,600 lux and 7.7 mW/cm2, respectively. One hundred 
microliters of the specified ICG:HSA solution was injected intradermally. ICG 
concentration of the ICG:HSA complex was systematically increased from 10 µM 
to 500 µM to explore the counteracting effects of NIR fluorophore quenching at the 
injection site and NIR fluorophore dilution within the lymphatic channels. 
dose-optimization clinical trial
A 24-patient dose-escalation clinical trial was approved by the Medical Ethics 
Committee of the Leiden University Medical Center and was performed in accordance 
with the ethical standards of the Helsinki Declaration of 1975. All patients that had 
planned to undergo a SLN procedure for invasive breast cancer or extensive high-risk 
carcinoma in situ were eligible for participation in the study. Patients had clinically 
negative axillary nodes as assessed by palpation and ultrasonography. Exclusion 
criteria were pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine 
green. 
Twenty-four consecutive patients were included. All patients gave informed 
consent and were anonymized. Patients received the standard-of-care SLN procedure. 
For our institution, this implies one periareolar injection of approximately 100 MBq 
99mTechnetium-nanocolloid (mean ± S.D. = 99.6 ± 5.8 MBq) the day before surgery. 
Before the start of the operation, one mL of patent blue V was injected peritumorally 
or periareolarly. Choice of the injection site was left to the surgeon. Directly after 
patent blue injection, 1.6-mL ICG:HSA was administered as four injections at the 
same location as the patent blue injections. After surgical scrub and sterile covering of 
the operation field, NIR fluorescence imaging was performed with the imaging head of 
the Mini-FLARE™ at approximately 30 cm distance to the surgical field. 
The surgical technique consisted of percutaneous assessment of NIR fluorescent 
signal in the breast and the axilla prior to skin incision. The location and length of 
the axillary skin incision was determined by the surgeon. Assessment of the surgical 
field using NIR fluorescence was applied continuously throughout the SLN procedure 
and surgical exploration. If the SLN was not easily detected by NIR fluorescence, the 
gamma probe was used to provide direction for surgical exploration. Camera exposure 
was between 5 to 250 msec as indicated. A SLN exhibiting a signal-to-background 
ratio (SBR) ≥ 1.1 in situ was considered positive by NIR fluorescence. Background 
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was chosen as an area within the surgical field, directly adjacent (within 1-2 cm) to 
the SLN.
Routine histopathological frozen analysis of SLNs was performed during surgery. 
If the patient participated in the After Mapping of the Axilla Radiotherapy or Surgery 
(AMAROS) trial and was randomized to the radiotherapy arm, no intraoperative 
frozen analysis was performed. SLNs were fixed in formalin and embedded in paraffin 
for routine hematoxylin, eosin, and immunohistopathological staining for AE1/AE3 at 
three levels, with an interval of 150-250 µm, according to the Dutch guidelines for SLN 
analysis. Patients underwent an axillary lymph node dissection if the SLN was found 
to contain metastases, except for those patients who participated in the radiotherapy 
arm of the AMAROS trial. If isolated tumor cells (ITCs) were found (< 0.2 mm), no 
axillary lymph node dissection was performed.
table 1. Mini-FLARE™ imaging system specifications
Category Specification Description
Physical Size Mobile Cart: 24” W x 24” D x 29” H; Mast Height: 76.5”
Weights
             
Cart: 272 lbs, including all electronics
Arm: 95 lbs, including, stand, gooseneck, and imaging head
Imaging Head: 8.8 lbs.
Arm and Stand Flexible Arm; Reach: 27” – 64” from floor, 42” from center of 
stand. Center of stand up to 11 linear feet from cart
Electrical Voltage and Plug 120 V AC, 60 Hz; single NEMA 5-15 120 V/15 A AC plug
Current 5 A max
Grounding Isolation transformer for all components; redundant chassis 
grounding
Leakage Current < 300 µA (per AAMI/IEC #60601)
Sterility Shield Disposable acrylic shield with ≥95% transmission
Drape Disposable, custom-fit plastic drape bonded to shield 
Light Source Housing Anodized aluminum with integrated liquid cooling 
Elements Custom 25 mm circular LED arrays w/ integrated linear drivers
Electronics Custom control board with embedded microcontroller
Fluence Rates 26,600 lux white light (400-650 nm), 1.08 mW/cm2 of 700 nm 
(656-678 nm) excitation light, 7.70 mW/cm2 of 800 nm (745-779 
nm) excitation light
Optics Working Distance 4” (10 cm) to 13” (32 cm) from patient (reverse telephoto)
Field-of-View 12 cm W  x 9 cm H at 13” working distance
Emission/
Reflectance Channels
Color Video (400-650 nm), 700 nm fluorescence (689-725 
nm), 800 nm fluorescence (800-848 nm), all with simultaneous 
acquisition
Pixel Resolution 640 x 480 for each camera
System Resolution 320 x 320 µm (x,y)
Display Refresh Up to 15 Hz simultaneous acquisition on both cameras
NIR Exposure Time Adjustable from 100 µsec to 8 sec
Hands-Free Optics Automatic focus
Control 6-pedal footswitch
Monitors Number 3 cart-mounted 20”: 2 for operator and 1 for surgeon 
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statistical analysis
For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, 
USA) was used. Graphs were generated using GraphPad Prism Software (Version 
5.01, La Jolla, USA). To compare the SBR between concentration groups, a one-
way analysis of variance (ANOVA) was performed with pairwise comparison with 
least square difference (LSD) adjustment for multiple testing. When the assumption 
of homogeneity of variance was violated (Levene’s test), a log10 transformation was 
applied. All statistical tests were two-tailed and P < .05 was considered significant.
Results
design of the mini-flARe™ imaging system and in vitro characterization
The Mini-FLARE™ imaging system (Figure 1A) is composed of a small portable 
electronics cart and a counter-weighted pole stand that supports the imaging head. 
Unlike FLARE™, Mini-FLARE™ utilizes a flexible gooseneck arm, which permits 
positioning of the imaging head at extreme angles virtually anywhere over the surgical 
field. The only consumable for Mini-FLARE™ is a specially designed acrylic splash 
plate that is hermetically sealed to a plastic drape. Using sterile technique, the shield/
drape is inserted into the imaging head, locked into place, and the drape is unfolded 
to encase the imaging head and imaging system pole stand (Figure 1B). Optical light 
paths for white light (i.e., color video images) and the two semi-independent NIR 
fluorescence channels, one centered at 700 nm emission and the other at 800 nm 
emission, are shown in Figure 1C. 
Technical specifications of Mini-FLARE™ are detailed in Table 1. Of note, the 
working distance is up to 13” away from the patient, with field-of-view adjustable 
from 4.7” (12 cm) to 2” (5 cm) simply by moving the device toward or away from the 
surgical field. The cart occupies a volume of only 9.7 cu ft, and weighs only 272 lbs. A 
6-pedal footswitch and autofocus circuit permit hands-free operation. The cost of all 
parts is ≈ $40,000.
Pre-clinical optimization of nIR fluorescent lymphatic tracers
Our group has previously reported that ICG (and ICG:HSA) exhibits intense 
quenching (i.e., reduction of fluorescence emission) as its concentration is increased.15 
That is, increasing concentration actually decreases fluorescence, so there would 
theoretically be no benefit to injecting high concentration for SLN mapping. This 
effect is demonstrated vividly in Figure 2 (left panel), where the injection site becomes 
dramatically less fluorescent as concentration increases. As a general rule, if the 
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concentration is high enough to see green color at the injection site, ICG fluorescence 
is severely quenched.
 Importantly, we have recently discovered that dilution of the injected 
NIR fluorophore as it travels through the lymphatic system and mixes with lymph 
counteracts the effect of quenching and results in signal in the SLN that increases with 
concentration, even when the injection site is barely fluorescent (Figure 2, right panel). 
This suggests that there will be an “optimal” concentration of injected NIR fluorophore 
such that final signal in the SLN is as high as possible. 
optimization of ICG:HsA dose in breast cancer patients undergoing sln mapping
This study aimed to test the feasibility of NIR fluorescence in SLN detection, using 
ICG:HSA and the Mini-FLARE™, in direct comparison with the conventional 
lymphatic tracers radiocolloid and patent blue. Twenty-four consecutive breast cancer 
figure 2. optimization of ICG:HsA dose as a function of the complex tradeoff between fluorescence 
quenching at the injection site and dilution of fluorophore in lymphatic channels. Pre-clinical studies in 
Yorkshire pigs. Subcutaneous injection sites (left; white arrows) showing quenching and resected SLNs (right) 
showing NIR fluorophore dilution for increasing concentrations of ICG:HSA. For each are displayed color video 
(left columns) and 800 nm NIR fluorescence (right columns) images obtained using 760 nm excitation light at 7.7 
mW/cm2. All camera exposure times were 45 msec. Data are representative of N = 3 pigs. 
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patients underwent standard-of-care SLN mapping with the addition of preoperative 
ICG:HSA injection and subsequent intraoperative NIR fluorescence imaging. Patient 
and tumor characteristics are provided in Table 2. Use of the Mini-FLARE™ during 
surgery did not interfere with the standard of care. Average time between ICG:HSA 
injection and skin incision was 16 ± 3 minutes (Table 3). In all patients (N = 24), NIR 
fluorescence imaging enabled visualization of the SLN (Figure 3). A total of 35 SLNs 
were identified, which were all radioactive and NIR fluorescent (Table 3). Five SLNs 
from four patients did not have blue staining from patent blue. In all patients, the NIR 
fluorescence signal in the SLN was detected before patent blue. Average time between 
skin incision and resection of the first SLN was 17 ± 5 minutes. After resection of 
all nodes detected using NIR fluorescence, the axilla was systematically inspected for 
any remaining radioactivity. No additional radioactive nodes were identified that were 
not detected by NIR fluorescence. No adverse reactions associated with the use of 
ICG:HSA or the Mini-FLARE™ occurred. Two patients experienced a wound infection 
requiring antibiotics and one patient underwent surgical re-exploration because of an 
expanding hematoma following axillary lymph node dissection (Table 3). 
A second objective of this trial was to determine the optimal concentration 
of injected ICG:HSA for NIR fluorescence SLN mapping, i.e. which concentration 
provides the highest SBR in the SLN. Because ICG and ICG:HSA exhibit intense 
quenching as their concentrations are increased (typically above 50 μM), there would 
be theoretically no advantage of injecting higher doses of ICG:HSA. However, dilution 
of the lymphatic tracer occurs upon injection in the breast and uptake by the lymphatic 
system counteracting the quenching effect. To assess the relationship between the 
figure 3. Real-time nIR fluorescence imaging during sentinel lymph node mapping in women with breast 
cancer. Shown are typical intraoperative results from a subject injected with 600 µM ICG:HSA demonstrating 
visualization of lymphatic channels (white arrowhead) of the breast running into the axilla from the partially 
covered periareolar injection site (top row) and detection of the sentinel lymph node (white arrow) in the axilla 
(bottom row). Camera exposure times were 67 msec (top row) and 20 msec (bottom row). 760 nm excitation 
fluence rate was ≈ 7.7 mW/cm2 for all images. 
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concentration of injected NIR fluorescent lymphatic tracer and final SBR in the SLN, 
patients were allocated to eight ICG:HSA concentration groups ranging from 50 μM 
to 1000 μM. The concentration of ICG:HSA influenced the SBR and showed a normal 
distribution (Figure 4). The variances of the concentration groups were not equal 
(Levene’s test, P = .02). A log10 transformation of the data could account for part 
of the unequal variances (Levene’s test, P = .05). A one-way ANOVA with pairwise 
table 2. Patient and tumor characteristics
Characteristic N %
Age (median, range) 59.5 (33-81)
Menopausal state
- Premenopausal 5 21
- Postmenopausal 19 79
Body Mass Index (median, range) 25 (18-38)
Skin type
- II 4 17
- III 20 83
Previous breast surgery a 3 13
Multifocality 4 17
Tumor side
- Left 14 58
- Right 10 42
Tumor localization
- Central 5 21
- Lower inner 1 4
- Lower outer 1 4
- Upper inner 6 25
- Upper outer 11 46
Type of operation
- Ablation 9 38
- Wide Local Excision 15 63
Pathological tumor size (median, range) 15 (3-35)
Histological type
- Infiltrating ductal adenocarcinoma 18 75
- Infiltrating lobular adenocarcinoma 2 8
- Ductal carcinoma in situ 4 17
Histological grade
- I 3 13
- II 13 54
- III 8 33
Receptor status b
- ER+ HER2- 16 67
- ER+ HER2+ 3 13
- ER- HER2- 1 4
- Missing c 4 17
a Previous breast surgery (N = 3): silicone breast implantation, breast reduction and re-excision. 
b HER2 status was determined using the chromogenic in situ hybridization (CISH) kit of Zymed 
(Invitrogen, Carlsbad, CA) 
c Not applicable in four patients with ductal carcinoma in situ. 
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comparison with LSD adjustment for multiple comparison showed that the SBRs of 
the 400, 500, 600, and 800 µM concentration groups were significantly higher than of 
the 50, 100, 200, and 1000 µM concentration groups (200 vs. 400, P = .001; 200 vs. 500, 
P = .001; 200 vs. 600, P < .0001; 200 vs. 800, P = .001; 1000 vs. 400, 500, 600 and 800, all 
P < .0001). The SBRs of the 400, 500, 600, and 800 µM concentration groups were not 
significantly different, although a trend was found favoring the 600 µM concentration 
group (500 vs. 600, P = .06). The decline of the SBR in the 1000 µM concentration 
group was caused by decreased NIR fluorescence signal of the SLN (800 vs. 1000, P = 
.001), which suggests that quenching of ICG indeed occurred in the SLN.
dIsCussIon
Near-infrared (NIR) fluorescent light in the wavelength range of 700 to 900 nm is 
invisible to the human eye. It is also capable of penetrating millimeters into living 
tissue and is not obscured by autofluorescence. For these reasons, NIR fluorescent 
light is ideal for image-guided surgery. Indeed, several NIR fluorescence surgical 
imaging systems are already FDA-approved or are in the process of obtaining approval 
(reviewed in 17). The Mini-FLARE™ camera system used in this study is capable of 
displaying NIR fluorescence signal in relation to the surgical anatomy and illuminates 
the surgical field with white light. This enabled the surgeon to perform surgery under 
direct image guidance.
figure 4. optimization of ICG:HsA concentration for breast cancer sln mapping. Signal-to-background 
ratio (mean ± S.D.) of the SLNs (ordinate) as a function of injected concentration of ICG:HSA (abscissa) in 
women undergoing SLN mapping for breast cancer. Statistical comparisons are as follows: 200 µM vs. 400 µM, P 
= .001; 200 µM vs. 500 µM, P = .001; 200 µM vs. 600 µM, P < .0001; 200 µM vs. 800 µM, P = .001; 1000 µM vs. 400, 
500, 600 and 800 µM, all P < .0001). The SBRs of the 400, 500, 600 and 800 µM concentration groups were not 
significantly different, although a trend was found favoring the 600 µM concentration group (500 vs. 600, P = .06).
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NIR fluorescence optical imaging using Mini-FLARE™ offers the advantages of 
real-time, continuous, high-resolution, and high sensitivity detection of SLNs, without 
the need for ionizing radiation. Because NIR light is invisible, there is no staining of 
the surgical field as with blue dyes, and the class of chemicals in which ICG belongs 
has a remarkable safety record in humans. ICG:HSA adds approximately $150 to the 
cost of a case, but if future studies show that the blue dye and/or Tc-99m sulfur colloid 
can be eliminated when using NIR fluorescence, a much larger savings will offset this 
cost. And, the surgeon can perform the injection procedure only minutes before SLN 
identification and resection. Although a technologist was used in this first-in-human 
study, Mini-FLARE™ is equipped with hand-free operation and there is virtually no 
learning curve because unlike other SLN techniques, the lymphatic tracer can be 
visualized in real-time throughout the procedure.
table 3. SLN identification results
Characteristic N %
Injection site patent blue and ICG:HSA
- Periareolar 20 83
- Peritumoral 4 17
SLN detection
- Number of SLNs identified 35
- Average number of SLNs identified (range) 1.45 (1-3)
Method of detection
- Radioactive  35 100
- Blue 30 86
- Near-infrared fluorescence 35 100
Average time between injection of ICG:HSA and skin incision (S.D.) 16 minutes ± 3
Average time between skin incision and SLN resection (S.D.) 17 minutes ± 5
Histology
- Negative 26 74
- Isolated tumor cells 3 9
- Micrometastases 0 0
- Macrometastases 6 17
Axillary treatment
- None 16 67
- Axillary lymph node dissection 5 21
- Axillary radiotherapy 3 13
Complications
- No 21 87
- Yes 3 a 13
Abbreviations: ICG:HSA = indocyanine green adsorbed to human serum albumin, SLN = 
sentinel lymph node, S.D. = standard deviation 
a Two patients experienced postoperative wound infection requiring treatment with antibiotics 
and one patient underwent surgical re-exploration because of an expanding hematoma following 
axillary lymph node dissection.  
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 An important objective of the study was to optimize NIR fluorescent contrast 
agent dose for breast cancer SLN mapping. The only clinically available NIR fluorescent 
lymphatic tracer, albeit approved for other indications, is ICG.7, 11, 13, 18, 19 We have 
previously proposed simple mixing of ICG and HSA (ICG:HSA) prior to injection14, 15 
because ICG is a small molecule and like blue dyes can pass through SLNs, and exhibit 
a relatively low quantum yield in aqueous environments.15 Indeed, the product insert 
for ICG notes that it rapidly binds albumin when injected intravenously, so pre-mixing 
merely improves kinetics. Importantly, though, pre-mixing increases quantum yield 
(i.e., brightness) 3-fold and also results in a final hydrodynamic diameter (≈ 7 nm) that 
is better retained in the SLN.15 
NIR fluorescent signal in the SLN is a complex function of the concentration 
of the injected NIR lymphatic tracer, the distance between the injection site and the 
SLN, the volume of ultra-filtrate within the lymphatic channels encountered by the 
NIR fluorophore, and retention of the NIR fluorophore by the SLN. Of these, only 
the injection concentration can be controlled. Our study suggested that an optimal 
ICG:HSA concentration is in the range 400 μM and 800 μM. In the 1000 μM 
concentration group, the fluorescence intensity of the SLN and the SBR decreased 
rapidly, most likely due to quenching. Furthermore, since lymphatic vessels could 
be visualized percutaneously and directly after incision, particularly in the optimal 
dose range groups, a more efficient identification of SLNs was facilitated. This is of 
particular benefit for lymph nodes located deeper in the axilla, which exceed the 1-2 
cm depth limit of the technology. These nodes could often be located by following the 
NIR fluorescent signal of the afferent lymphatic tract.
The accuracy of SLN identification using ICG fluorescence was similar to 
that using conventional radioisotope scanning, as both techniques identified all 
SLNs and no additional fluorescent lymph nodes were identified. However, blue dye 
identification was not successful in 5 of 35 (14%) SLNs. These results suggest that 
patent blue staining can be replaced by NIR fluorescence using ICG:HSA. Replacing 
patent blue has the additional advantage of absent tattooing of the breast and visual 
alteration of the surgical field. Moreover, the intrinsic dark color of patent blue dye 
can obscure the fluorescence intensity of any fluorescent lymphatic tracer. Indeed, in 
vitro tests using a fixed ICG:HSA concentration showed that addition of patent blue 
dye decreased NIR fluorescence of ICG:HSA (data not shown). An as yet unanswered 
question is whether radioisotope scanning can be omitted from the SLN procedure. A 
larger trial to address whether NIR fluorescence imaging alone can replace blue dyes 
and/or radiocolloids is ongoing. 
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In summary, this study demonstrated feasibility and accuracy of NIR 
fluorescence imaging using ICG:HSA and the Mini-FLARE™ imaging system for SLN 
mapping in breast cancer patients. The optimal dose of injected ICG:HSA lies between 
400 µM and 800 µM and can be chosen based on local preparation preferences. For 
example, in the United States, a dose of 500 µM is most convenient since it requires 
minimal manipulation of albumin volumes.
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Near-infrared (NIR) fluorescence imaging has the potential to improve sentinel lymph 
node (SLN) mapping in breast cancer. Indocyanine green (ICG) is currently the only 
clinically available fluorophore that can be used for SLN mapping. Preclinically, 
ICG adsorbed to human serum albumin (ICG:HSA) improves its performance as a 
lymphatic tracer in some anatomical sites. The benefit of ICG:HSA for SLN mapping 
of breast cancer has not yet been assessed in a clinical trial. 
methods
We performed a double-blind, randomized study to determine if ICG:HSA has 
advantages over ICG alone. The primary endpoint was the fluorescence brightness, 
defined as the signal-to-background ratio (SBR), of identified SLNs. Clinical trial 
subjects were 18 consecutive breast cancer patients scheduled to undergo SLN biopsy. 
All patients received standard of care using 99mTechnetium-nanocolloid and patent 
blue. Patients were randomly assigned to receive 1.6 mL of 500 µM ICG:HSA or ICG 
that was injected periareolarly directly after patent blue. The Mini-Fluorescence-
Assisted Resection and Exploration (Mini-FLARE) imaging system was used for NIR 
fluorescence detection and quantitation. 
Results
SLN mapping was successful in all patients. Patient, tumor and treatment characteristics 
were equally distributed over the treatment groups. No significant difference was 
found in SBR between the ICG:HSA group and the ICG alone group (8.4 vs. 11.3, 
respectively, P = .18). In both groups, the average number of detected SLNs was 1.4 ± 
0.5 SLNs per patient (P = .74). 
Conclusion
This study shows that there is no direct benefit of premixing ICG with HSA prior to 
injection for SLN mapping in breast cancer patients, thereby reducing the cost and 
complexity of the procedure. With these optimized parameters that eliminate the 
necessity of HSA, larger trials can now be performed to determine patient benefit.
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IntRoduCtIon
Sentinel lymph node (SLN) mapping is currently regarded as standard of care in staging 
of the axilla in breast cancer patients with clinically negative axillary lymph nodes.1 In 
general, a combination of radioactive colloid and blue dye is used for SLN mapping. 
Using this combination, identification rates of 95% to 97% are achieved.2-5 The use of 
only one of these two detection methods results in significantly lower identification 
rates.2-5 Both detection methods possess certain disadvantages. Radioactive colloids 
require involvement of a nuclear medicine physician, can be difficult to localize with a 
handheld gamma probe, and the time-window for SLN identification is limited due to 
the short half-life (6 hours) of 99mTechnetium. Blue dyes cannot be seen through skin 
and fatty tissue, and permit only limited visualization of afferent lymphatic vessels and 
the SLN. 
Optical imaging using the near-infrared (NIR) fluorescence lymphatic tracer 
indocyanine green (ICG) enables real-time transcutaneous and intraoperative 
visualization of lymphatic channels and SLNs.6-13 Therefore, NIR fluorescence imaging 
could provide an alternative for, or an addition to, conventional techniques used for 
SLN mapping. Recently, our group has demonstrated that NIR fluorescence performed 
equally well as the combination of radioactive colloid and blue dye in SLN mapping of 
breast cancer patients.14 
ICG is currently the only clinically available NIR lymphatic tracer. However, 
due to its relatively low fluorescence brightness and its small hydrodynamic diameter, 
which permits flow through the SLN to higher tier nodes, it is not an optimal lymphatic 
tracer. Preclinical work has demonstrated that adsorption of ICG to human serum 
albumin (HSA, complex is ICG:HSA), by simply mixing it, increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection 
and better retention in the SLN in certain anatomical sites, such as the intestine.15 
Another parameter that must be considered when using ICG or ICG:HSA is the effect 
of fluorescence quenching, which results in a decrease in fluorescence intensity as the 
concentration of ICG (or ICG:HSA) is increased above 50 μM. The use of 50 μM ICG 
for SLN imaging, however, is suboptimal, because ICG will be diluted once taken up by 
the lymphatic system. To assess the magnitude of this in vivo dilution effect, our group 
has conducted a dose-finding study to demonstrate that the optimal concentration of 
ICG:HSA for NIR-based SLN mapping in breast cancer patients lies between 400 µM 
and 800 µM.14 
A theoretical disadvantage of the use of ICG alone is poor retention of the 
lymphatic tracer in the SLN, which as a consequence results in fluorescent staining 
of higher tier nodes and background staining of the axilla. Although not compared 
directly, studies using ICG alone reported a higher average number of identified SLNs 
(range = 1.8-5.4; aggregate average = 3.4),6-10 than with the use of ICG:HSA (aggregate: 
1.5).11, 14 However, comparison of these data is difficult because the concentration of 
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ICG used was significantly higher (typically 6.4 mM) than in the trials using ICG:HSA 
(10 µM to 1000 µM). 
Although we have obtained good results with the use of ICG:HSA for SLN 
mapping in breast cancer patients, the use of albumin adds cost and complexity to 
the procedure. Moreover, the use of human blood products, such as HSA, poses 
regulatory hurdles in certain countries, such as the United States. Therefore, the use 
of ICG alone would be favorable. After intravenous administration, ICG binds rapidly 
and completely to plasma proteins.16 Lymph fluid has a similar protein constitution 
as serum, albeit in a lower concentration (20.6 g/L for lymph fluid versus 73.7 g/L for 
plasma).17 After intradermal or subcutaneous injection, ICG could theoretically bind 
to these proteins, eliminating the need for premixing ICG and HSA. We therefore 
hypothesized that ICG alone could render the same fluorescence intensity in SLNs as 
ICG:HSA, and tested this hypothesis in a double-blind randomized trial.
mAteRIAl And metHods
Preparation of indocyanine green adsorbed to human serum albumin
ICG (25 mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) 
and was resuspended in 10 cc of sterile water for injection to yield a 2.5 mg/ml (3.2 
mM) stock solution. To obtain a 500 µM dilution, 7.8 mL of the 3.2 mM ICG solution 
was diluted in 50 cc vial of sterile water for injection or 50 cc vial of Cealb (20% human 
serum albumin, Sanquin, Amsterdam, The Netherlands) for the preparation of ICG 
alone or ICG:HSA, respectively. Prior to the addition of ICG, 7.8 mL was drawn from 
the 50 cc vials. In a previous study, we determined that the optimal dose of ICG:HSA 
lies between 400 µM and 800 µM.14 A dose of 500 µM was chosen because it requires 
minimal manipulation of ICG and albumin volumes. 
Intraoperative near-infrared imaging system (mini-flARe)
SLN mapping was performed using the Mini-Fluorescence-Assisted Resection and 
Exploration (Mini-FLARE) image-guided surgery system as described in Chapter 11. 
Briefly, the system consists of two wavelength isolated light sources: a “white” light 
source, generating 26,600 lx of 400-650 nm light, and a “near-infrared” light source, 
generating 7.7 mW/cm2 of 760 nm light. Color video and NIR fluorescence images are 
simultaneously acquired and displayed in real-time using custom optics and software 
that separate the color video and NIR fluorescence images. A pseudo-colored (lime 
green) merged image of the color video and NIR fluorescence images is also displayed. 
The imaging head is attached to a flexible gooseneck arm, which permits positioning 
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of the imaging head at extreme angles virtually anywhere over the surgical field. For 
intraoperative use, the imaging head and imaging system pole stand are wrapped in a 
sterile shield and drape (Medical Technique Inc., Tucson, USA).
Clinical trial
The double-blind, randomized, single-institution, non-inferiority trial comparing 
ICG:HSA with ICG alone was approved by the Medical Ethics Committee of the 
Leiden University Medical Center and was performed in accordance with the ethical 
standards of the Helsinki Declaration of 1975. All patients planning to undergo a 
sentinel lymph node procedure whether for invasive breast cancer or for high-risk 
carcinoma in situ were eligible for participation in the study. Patients had clinically 
negative axillary nodes as assessed by palpation and ultrasonography. Exclusion 
criteria were pregnancy, lactation or an allergy to iodine, shellfish, or indocyanine 
green.
All patients gave informed consent and were anonymized. Patients were 
randomized by the Department of Clinical Pharmacy. Treatment allocation was 
performed by block randomization. Patients received the standard-of-care sentinel 
lymph node procedure. For our institution, this implies one periareolar injection of 
approximately 100 MBq 99mTechnetium-nanocolloid (mean ± S.D. = 96.6 ± 14.7 MBq, 
no difference between treatment groups [P = .47]) the day before surgery. Before the 
start of the operation, one mL of patent blue V was injected. Directly after patent blue 
injection, the surgeon injected a total of 1.6 mL of 500 µM ICG:HSA or ICG alone. 
Both dyes were injected intradermally and periareolarly at four sites. Gentle pumping 
pressure was applied to the injection site for 1 min. After surgical scrub and sterile 
covering of the operation field, NIR fluorescence imaging was performed with the 
imaging head of the Mini-FLARE at approximately 30 cm distance to the surgical field. 
Camera exposure times were between 5 to 200 msec. A SLN exhibiting a signal-to-
background ratio (SBR) ≥ 1.1 in situ was considered positive by NIR fluorescence. 
Both the surgeon and the Mini-FLARE operator, who was responsible for analyzing 
the data, were blinded to the treatment allocation.
Routine histopathological frozen analysis of SLNs was performed during 
surgery. SLNs were fixed in formalin and embedded in paraffin for routine hematoxylin 
and eosin staining and immunohistopathological staining for AE1/AE3 at three levels, 
with an interval of 150 to 250 µm, according to the Dutch guidelines for SLN analysis. 
Patients underwent an axillary lymph node dissection if the SLN was found to contain 
metastases. If isolated tumor cells were found (< 0.2 mm), no axillary lymph node 
dissection was performed.
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Power calculation and statistical analysis
A power calculation based on data from our previous study14 revealed that 18 patients 
are needed to achieve 91% power to detect non-inferiority using a one-sided, two-
sample t-test (α = 0.025) with a margin of equivalence of 5.0 while assuming no 
difference between the SBRs of ICG:HSA and ICG alone. For statistical analysis, SPSS 
statistical software package (Version 16.0, Chicago, USA) was used. Graphs were 
generated using GraphPad Prism Software (Version 5.01, La Jolla, USA). To compare 
the SBR and the number of SLNs identified between ICG:HSA and ICG alone, a one-
sided, two-sample t-test was performed. A P-value < .05 was considered significant.
Results
Eighteen consecutive breast cancer patients undergoing standard-of-care SLN mapping 
were randomized to ICG:HSA or ICG alone for NIR fluoresence SLN imaging. Patient, 
tumor and treatment characteristics were equally distributed over the treatment 
groups (Table 1). Use of the Mini-FLARE during surgery did not interfere with the 
standard of care. Average time between lymphatic tracer injection and skin incision 
was 15.6 ± 2.2 minutes (Table 2). In all patients (N = 18), NIR fluorescence imaging 
enabled visualization of one or more SLNs (Figure 1). In the ICG:HSA group (N = 8 
subjects), a total of 11 SLNs were identified (average per patient = 1.4 ± 0.5); 9 (82%) 
were radioactive, 8 (73%) were blue and 11 (100%) were NIR fluorescent. In the ICG 
alone group (N = 10 subjects), a total of 14 SLNs were identified (average per patient 
= 1.4 ± 0.5); 14 (100%) were radioactive, 10 (71%) were blue and 14 (100%) were 
NIR fluorescent. The average number of SLNs identified was not significantly different 
between both groups (P = .74). 
The primary endpoint of this study was the average brightness of the SLN in 
both groups, expressed in signal-to-background ratio (SBR). The results are presented 
in Table 2. The average SBR of ICG:HSA (8.4 ± 3.6) and ICG alone (11.3 ± 4.8) was 
not significantly different (P = .18). However, in the ICG alone group, the afferent 
lymphatics were significantly better visualized percutaneously compared to the 
ICG:HSA group (P = .004; Table 2 and Figure 1).
In all patients, the NIR fluorescence signal in the SLN was detected earlier 
in the procedure than patent blue staining. Average time between skin incision and 
resection of the first SLN was 11.0 ± 4.1 minutes and was not different between both 
groups (P = .74). No adverse reactions associated with the use of ICG, ICG:HSA, or 
Mini-FLARE occurred.
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ICG:HSA = indocyanine green adsorbed to human serum albumin  
 
Skin type = American Academy of Dermatology Skin Types I-VI: 
I. Pale, white skin: always burns easily; never tans (Celtic, Scandinavian, and infants)  
II. White: usually burns easily; tans minimally (Northern European)  
III. White (average): sometimes burns; tans gradually to light brown (Central European)  
IV. Beige or lightly tanned: burns minimally; always tans to moderately brown (Mediterranean, Asian)  
V. Moderate brown or tanned: rarely burns; tans well (South American, Indian, Native American)  
VI. Dark brown or black: never burns; deeply pigmented (African, African-American, Aborigine)
table 1. Patient and tumor characteristics
         ICG:HSA (N = 8)           ICG alone (N = 10)
Characteristic N % N % P
Age (median, range) 59.5 (38-72) 57.5 (40-73) 0.99
Menopausal state 0.74
- Premenopausal 3 37.5 3 30
- Postmenopausal 5 62.5 7 70
Body Mass Index (median, range) 26 (20-41) 23.5 (21-30) 0.26
Skin type 0.40
- II 2 25 1 10
- III 6 75 9 90
Previous procedure of breast 0.12
- Breast implants 1 0
- Breast reduction 0 1
- Lumpectomy 2 0
- Radiotherapy 0 1
- Neoadjuvant chemotherapy 1 0
Multifocality 0 0 1.00
Tumor side 0.81
- Left 2 25 3 30
- Right 6 75 7 70
Tumor localization 0.23
- Upper outer 6 75 4 40
- Lower outer 0 0 1 10
- Lower medial 1 12.5 2 20
- Upper medial 0 0 3 30
- Central 1 12.5 0 0
Type of operation 0.15
- Mastectomy 3 37.5 1 10
- Wide Local Excision 4 50 9 90
- SNB only 1 12.5 0 0
Pathological tumor size (median, range) 7 (5-11) 12 (8-15) 0.13
Histological type 0.62
- Infiltrating ductal adenocarcinoma 7 87.5 7 70
- Infiltrating lobular adenocarcinoma 0 0 1 10
- Ductal carcinoma in situ 1 12.5 1 10
- Other 0 0 1 10
Histological grade 0.15
- I 1 16.7 3 33.3
- II 2 33.3 5 55.6
- III 3 50 1 11.1
Thesis Mieog.indb   197 22-09-11   19:50
198 Chapter 12
figure 1. nIR fluorescence imaging during sentinel lymph node mapping in breast cancer patients. 
A. ICG:HsA. In the upper panel, the periareolar injection site (arrow) is shown, but percutaneously, no lymphatic 
channel can be visualized. In the lower panel, identification of the SLN (arrow) and an afferent lymphatic channel 
(open arrowhead) with NIR fluorescence imaging is demonstrated 27 min after injection of 1.6 mL of 500 µM 
ICG:HSA. Camera exposure times were 60 msec (top row) and 150 msec (bottom row). Scale bars represent 1 cm. 
B. ICG alone. In the upper panel, the periareolar injection site (arrow) and a lymphatic channel (arrowhead) are 
clearly visualized. In the lower panel, identification of the SLN (arrow) and an afferent lymphatic channel (open 
arrowhead) with NIR fluorescence imaging is demonstrated 28 min after injection of 1.6 mL of 500 µM ICG. 




The use of NIR fluorescence for SLN mapping has several advantages over conventional 
methods, such as better tissue penetration when compared to blue dyes, and lack of 
ionizing radiation and real-time visualization when compared to radiotracers. A 
number of clinical studies have been published on the use of NIR fluorescence in the 
SLN procedure in breast cancer, all of which use ICG, which is currently clinically 
available.6, 9, 11, 12, 14 Preclinical studies indicated that adsorption of ICG to human serum 
albumin (HSA, complex is ICG:HSA), by simply mixing it, increases the fluorescence 
intensity and the hydrodynamic diameter, thereby providing improved detection and 
better retention in the SLN.15 Our group has subsequently conducted a dose-finding 
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study and demonstrated that the optimal concentration of ICG:HSA for NIR-based SLN 
mapping in breast cancer patients lies between 400 µM and 800 µM.14 Indeed, above 
800 µM ICG:HSA, the fluorescent intensity dropped due to quenching. Based on these 
results a concentration of 500 µM ICG:HSA, which requires minimal manipulation 
of albumin volumes and uses only one vial of ICG, was chosen for further studies to 
identify whether premixing with albumin indeed increases the fluorescent intensity of 
the node in a clinical setting. In the current study, SLN mapping after ICG or ICG:HSA 
injection was successful in all patients. ICG showed a comparable or even slightly 
increased (though not significantly) brightness than ICG:HSA while identifying 
an equal average number of SLNs. Although no macrometastases in the SLNs were 
observed in the current study, our previous study showed that tumor-positive SLNs 
were also detected by NIR fluorescence, signifying ICG uptake.14 However, lymph node 
macrometastases continue to be a contraindication for SLN mapping and preoperative 
staging of the axilla remains pivotal to minimize false negatives SLN mapping.
The results of our study are discordant with preclinical work in intestine, which 
suggested an improvement in fluorescent brightness and retention in the SLN by 
premixing ICG with HSA.15 Although the current study was powered to determine 
non-inferiority in SBR of ICG alone when compared to ICG:HSA, it was not formally 
powered to assess the secondary endpoint, average number of SLNs identified. 
However, power analysis using data from our previous study14 demonstrated that a 
difference of at least one additional SLN identified per patient could be detected with 
90% power with the current sample size. The discrepancy between the current clinical 
results and these preclinical experiments could be caused by the increased distance 
that the injected dye has to travel, as the preclinical studies were performed in the 
bowel of healthy pigs.15 Lymph fluid contains a high concentration of albumin, among 
other proteins; therefore, a longer traveling distance could aid ICG in adsorbing to 
albumin or other proteins, as it would after intravenous injection,18 diminishing the 
need for premixing ICG with HSA. This observation implies that premixing might 
prove to be useful in other cancer types (such as colon cancer, for example), where 
ICG is less likely to completely adsorb to proteins before the SLN is reached. Therefore, 
the use of ICG:HSA or ICG alone should be formally tested for every anatomical site.
Although the fluorescent brightness did not differ significantly between both 
groups, ICG alone showed significantly improved percutaneous visibility of lymphatic 
channels when compared to ICG:HSA (Figure 1). It has been shown that in plasma, ICG 
preferably binds to α1-lipoprotein and γ-globulin, despite the higher concentration of 
albumin.19 Previous experiments have shown a higher increase in quantum yield when 
ICG is mixed with serum, in comparison to HSA.15 Therefore, the observed differences 
in visualization of lymphatics could likely be attributable to the protein constitution of 
lymph fluid. The high albumin content (20%) of ICG:HSA could also be a contributing 
factor, as the increased hydrodynamic diameter and higher viscosity could diminish 
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N % N % N %
Number of SLNs identified 25 11 14
Number of SLNs identified per patient 0.91
- One SLN 11 61 5 63 6 60
- Two SLNs 7 39 3 37 4 40
Average number of SLNs identified ± S.D. 1.4 ± 0.5 1.4 ± 0.5 1.4 ± 0.5 0.92
Method of detection
- Radioactive  23 92 9 82 14 100 0.18
- Blue 18 72 8 73 10 71 1.00
- NIR fluorescent 25 100 11 100 14 100 1.00
Signal-to-background ratio 10.0 ± 4.4 8.4 ± 3.6 11.3 ± 4.8 0.18
Percutaneous NIR fluorescent lymph drainage 
visualization 0.004
- Yes 10 56 1 13 9 90
- Partiallya 3 17 3 38 0 0
- No 5 28 4 50 1 10
Average time between injection and skin 
incision ± S.D. (minutes) 15.6 ± 2.2 15.3 ± 1.7 15.9 ± 2.6 0.55
Average time between skin incision and SLN 
resection ± S.D. (minutes) 11.0 ± 4.1 10.6 ± 5.1 11.3 ± 3.3 0.74
Histology 0.44
- Negative 24 96 10 91 14 100
- Isolated tumor cells 1 4 1 9 0 0
- Macrometastases 0 0 0 0 0 0
Axillary lymph node dissection 1.00
- No 18 100 8 100 10 100
- Yes 0 0 0 0 0 0
 
ICG:HSA = indocyanine green adsorbed to human serum albumin; S.D. = standard deviation; SLN = sentinel 
lymph node; NIR = near-infrared. 
a Partial percutaneous visualization was noted when lymphatic channels could be visualized percutaneously 
from the injection site, but did not reach the axilla.
ICG uptake in lymphatic channels. It should be noted that the anatomical variation 
(amount of tissue overlying the lymphatic channels) is also a major influencing factor 
and may be primarily responsible for the observed difference.
An optimal lymphatic tracer is non-toxic, has a high quantum yield (i.e., 
brightness), migrates quickly to the SLN, and does not migrate to higher tier nodes. 
If a tracer migrates to higher tier nodes, non-sentinel lymph nodes could incorrectly 
be identified as SLNs, causing more nodes than necessary to be resected. ICG is far 
from optimal; in aqueous solution the quantum yield is relatively low and due to its 
small hydrodynamic diameter, it can flow to higher tier nodes, as is the case with blue 
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dyes. The synthesis and clinical introduction of an optimal probe will be the subject of 
future studies and will greatly help to confirm the clinical benefit of NIR fluorescence 
imaging in the SLN procedure.15, 20 
In the current study, NIR fluorescence after ICG injection could consistently be 
visualized before blue dye staining could be observed, which is consistent with earlier 
findings.14 Therefore, NIR fluorescence imaging has the potential to replace blue dyes 
in SLN mapping of breast cancer patients. Furthermore, as NIR fluorescence light 
penetrates relatively deep into tissue, it can potentially replace radiocolloids in SLN 
mapping in a selected group of patients, for example those with a low body mass index. 
A clinical trial on omitting blue dyes and using NIR fluorescence without the need for 
radiocolloids is currently ongoing (NTR2674).
In conclusion, this double-blind, randomized trial showed no advantage of 
ICG:HSA in comparison to ICG alone for the SLN procedure. To reduce the cost and 
complexity of the procedure, a dose of 500 µM ICG alone (1.6 ml) is recommended 
for NIR fluorescence SLN mapping in breast cancer patients. Therefore, this study has 
determined the optimal parameters that can be used to validate this technique in a 
larger series in order to investigate patient benefit.
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This thesis consists of two parts. In part I, we have demonstrated that preoperatively 
administrated systemic (neoadjuvant) therapy is a feasible treatment strategy in early 
stage breast cancer to achieve improved surgical options and to assess tumor response. 
We also demonstrated that overexpression of the breast cancer stem cell marker 
aldehyde dehydrogenase-1 in early stage breast cancer patients is inversely associated 
with age and is of prognostic importance. In part II, we have demonstrated proof-of-
principle of intraoperative tumor detection and image-guided tumor resection by using 
the novel technique of near-infrared fluorescence imaging. We have performed two 
clinical trials to optimize the use of indocyanine green as a near-infrared fluorescence 
lymphatic tracer for the sentinel lymph node procedure in breast cancer patients.
PARt I: neoAdjuvAnt systemIC tHeRAPy
The meta-analysis described in Chapter 2 demonstrated that neoadjuvant chemo-
therapy results in equivalent overall and disease-free survival rates and permits more 
breast-conserving therapies, while not significantly hampering loco regional control. 
An international expert panel recently recommended that all patients with a clear 
indication for adjuvant chemotherapy can be offered chemotherapy preoperatively.1 
However, neoadjuvant therapy is still underutilized in many countries. Also, 
in the Netherlands, an apparent barrier exists for the routine administration of 
neoadjuvant strategies in the treatment of early stage breast cancer patients that might 
benefit from this approach. This is in spite of the obvious advantages associated with 
the use of neoadjuvant therapy, while little disadvantages exits (Table 1). Moreover, 
the compliance of patients to neoadjuvant therapy is high, thanks to the motivating 
decrease in tumor size that breast cancer patients can assess themselves by palpation. 
Even more, the indications for neoadjuvant strategies have broadened due to an 
increase in the availability of more tailored regimens, e.g. hormonal, chemo- and 
targeted therapies.
table 1. Advantages and disadvantages of neoadjuvant chemotherapy 
Advantages Disadvantages
Tumor down staging: more breast conserving surgery Delay of adequate surgery in the case of tumor resistance
Nodal down staging: less axillary lymph node 
dissection Loss of information on pretreatment nodal status
In vivo assessment of tumor resistance or sensitivity
Tumor response as surrogate prognostic marker  
Rapid screening of efficiency of new drugs
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Although the routine use of neoadjuvant therapy could be extended, an 
encouraging increase in the number of included patients in Dutch neoadjuvant 
studies is witnessed over the last years, as demonstrated in the recently closed INTENS 
study (BOOG 2007-02) and the lately started NEO-ZOTAC study (BOOG 2010-01). 
However, another national study, the TEAM-IIA trial (BOOG-2006-04a), in which the 
duration of neoadjuvant hormonal therapy is investigated, suffers from slow inclusion. 
Therefore, further research and propagation on the use of neoadjuvant systemic 
therapy as a powerful tool in the treatment of early stage breast cancer patients is still 
warranted. 
Neoadjuvant hormonal therapy is an attractive alternative to neoadjuvant chemotherapy 
in treating women with estrogen receptor (ER) positive breast cancer because of the 
low toxicity of hormonal therapy and the low response rate in ER positive breast cancer 
(especially lobular cancer) treated with neoadjuvant chemotherapy. Neoadjuvant 
hormonal therapy was directly compared with neoadjuvant chemotherapy in one study 
demonstrating equal response rates (64%) and lower adverse events in the hormonal 
group.2 Currently, the randomized NEOCENT study is underway to compare 6 cycles 
of neoadjuvant chemotherapy with 18-23 weeks of the aromatase inhibitor letrozole. 
Three randomized trials have compared 3-4 months of neoadjuvant tamoxifen with 
aromatase inhibitors and showed superiority of aromatase inhibitors in clinical 
response rate and breast conservation rate (RR, 1.36; 95% CI, 1.16- 1.59).3 The tumor 
response to neoadjuvant hormonal therapy is slow, but sustained. To address the issue 
of the optimum duration of neoadjuvant hormonal therapy, several phase II studies 
have investigated the prolonged use of neoadjuvant hormonal therapy beyond 3-4 
months and demonstrated response rates up to 80%. Even more, reductions in tumor 
volume were achieved up to 2 years of treatment.4 For elderly women with a limited 
life expectancy, neoadjuvant hormonal therapy without surgery provided long-term 
disease control. So, these data suggest that a further reduction in tumor size can be 
achieved with prolonged treatment and that even surgery can be withheld for elderly 
women on continuing hormonal treatment. However, the optimum duration of 
neoadjuvant hormonal therapy remains to be established.
Several surgical aspects are associated with the use of neoadjuvant therapy. Chapter 2 
demonstrated that the major benefit of neoadjuvant chemotherapy is the down sizing 
effect on the primary tumor allowing for a breast conservative approach in selected 
patients. In addition, the total volume of excised breast tissue is significantly decreased 
in patients with tumors already suitable for breast-conserving surgery.5 However, 
defining the optimal selection criteria for breast conservation remains a clinically 
relevant area of research, as breast tumors respond in a heterogeneous fashion to 
neoadjuvant chemo- and hormonal therapy and distinct types of regression can be 
recognized (Figure 1). After concentric shrinkage, the residual tumor can easily be 
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completely resected. However, tumors that regressed in a patchy fashion leaving 
scattered microscopic disease over the original tumor bed volume may predispose to 
a higher breast cancer recurrence rate when surgery is directed only at the ‘center’ of 
the residual tumor.6 
figure 1. Regression patterns to neoadjuvant therapy. Adapted from 7, 8.
Conventional imaging modalities have demonstrated poor correlation between 
the radiological and the pathological tumor size after neoadjuvant chemotherapy.9 
Chapter 2 demonstrated that the local recurrence rate in the neoadjuvant arm is greatly 
reduced after excluding studies in which patients received exclusive radiotherapy 
and no surgery after clinical complete tumor regression. These data emphasize the 
importance of incorporating surgery in the loco regional treatment after neoadjuvant 
chemotherapy. Otherwise stated, the current clinical assessment of tumor response 
is insufficiently sensitive to safely withhold surgery. Therefore, surgical planning and 
execution should take into account the size of the original tumor and the response to 
neoadjuvant chemotherapy.1 Placement of radiopaque clips within breast lumps at the 
time of biopsy provides localization for subsequent surgical removal has been associated 
with better local control.10 In order to improve risk assessment of a loco regional 
recurrence following breast-conserving surgery after neoadjuvant chemotherapy, 
a prognostic index has been developed, which includes four factors: clinical N2-3 
disease, residual pathologic tumor size larger than 2 cm, a multifocal pattern of 
residual disease, and lymphovascular space invasion.11 The index was able to predict 
loco regional recurrence in a retrospective study,12 and may be useful in selecting type 
of surgical treatment for patients treated with neoadjuvant chemotherapy; however, 
confirmation in prospective patient series is warranted.
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Sentinel lymph node (SLN) mapping provides the possibility of assessing the 
axillary lymph node status after neoadjuvant therapy. If the SLN becomes negative 
following neoadjuvant therapy in patients with proven nodal metastases prior to 
treatment, an axillary dissection could be prevented. Though, concerns exist on the 
accuracy of SLN mapping after neoadjuvant chemotherapy because the proposed 
alteration of the lymphatic network. However, scintigraphy data from patients before 
and after neoadjuvant chemotherapy demonstrated that the location of the SLN was 
the same in 99.2% of patients.13 Moreover, a meta-analysis on SLN mapping after 
neoadjuvant chemotherapy reported a SLN identification rate of 91% and a false 
negative rate of 11%;14 these rates are comparable in patients naïve to chemotherapy.15 
In patients with proven axillary metastases, the SLN becomes negative in approximately 
one-third of the cases and the SLN identification rate and false negative rate are 85% 
and 11%, respectively.13 These results suggest that SLN mapping after neoadjuvant 
chemotherapy is feasible in node-positive patients with complete clinical response 
in order to avoid an axillary dissection. Currently, the prospective, multicenter 
SENTINA trial is accruing patients to evaluate the accuracy of the SLN procedure in 
both clinically node-negative and node-positive patients.
In Chapter 3, data are presented from the neoadjuvant chemotherapy trial EORTC 
10902 that suggest that expression of the tumor suppression protein p53 is of 
predictive significance in anthracycline-containing chemotherapy regimens. To 
assess the value of p53 to predict sensitivity of anthracycline and taxane containing 
neoadjuvant chemotherapy regimens, the phase III randomized EORTC 10994/BIG 
00-01 trial has been conducted using a functional yeast assay to detect biologically 
important mutations of p53. The final results of this trial were recently published and 
demonstrated that although p53 was highly prognostic, p53 status was not a predictive 
factor of sensitivity or resistance to taxanes or anthracyclines.16
In Chapter 4, the effect of chemotherapy in relation to ER status was studied in 
very young breast cancer patients. Patients with ER positive tumors had an improved 
overall survival compared to their ER negative counterparts. However, in the subgroup 
of patients treated with chemotherapy, no difference in overall survival was shown. 
These data suggest that young patients with ER positive tumors benefit less from 
chemotherapy than patients with ER negative tumors. Moreover, these results suggest 
that chemotherapy alone cannot be considered optimal adjuvant systemic treatment in 
very young breast cancer patients with hormone receptor positive tumors. 
In Chapter 5, the impact of established prognostic factors was tested in very 
young breast cancer patients. Tumor size, nodal status and molecular subtype were 
independent prognostic factors. In the node negative patient group, molecular subtype 
was the sole prognostic factor for overall survival. These data support the use of 
established prognostic factors and in particular molecular subtype to plan systemic 
treatment strategies in these very young patients. 
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In Chapter 6, the prognostic effect of the breast cancer stem cell marker aldehyde 
dehydrogenase-1 (ALDH1) has been analyzed. ALDH1 expression was inversely 
associated with age. In elderly patients, ALDH1 status was not associated with clinical 
outcome. Alternatively, in young patients, ALDH1 expression was associated with poor 
outcome. These results support the hypothesis that breast cancer biology is different in 
elderly patients compared to their younger counterparts, which may be explained by 
differences in cellular pathways involved in cancer stem cell activity.  
In Chapter 7, the association was studied between ALDH1 expression and the 
coagulation protein tissue factor (TF) and its alternatively spliced (asTF) isoform. 
Expression of both TF isoforms was very common in human breast cancer cells and 
was associated with poor histological grade. Expression of TF was associated with 
ALDH1 expression, whereas expression of asTF was not.  Moreover, co-expression 
of TF and ALDH1 was strongly correlated with poor relapse-free period in patients 
younger than 65 years, whereas in older patients the inverse effect was demonstrated. 
These results provide new insights on the interaction between the tissue factor/
protease activated receptor (TF/PAR) pathway and the growth potential of the cancer 
stem cell subset and suggest that the TF/PAR pathway is important for the cancer 
stem cell population in early breast cancer.17, 18 Therefore, modulation of the activity of 
this pathway might interfere with survival of the cancer stem cell subset, which may 
subsequently improve patient survival.
Selective survival of cancer stem cells might be responsible for treatment failure 
witnessed in early stage breast cancer. Regrowth of tumors from this intrinsically 
chemotherapy-resistant subpopulation has been termed the ‘dandelion hypothesis’.19 
Neoadjuvant systemic therapy offers an excellent model to test the dandelion hypothesis 
in breast cancer patients. By comparing the cancer stem cell content of the pretreatment 
specimens with the posttreatment specimens, an increase in the relative proportion of 
cancer stem cells is expected after neoadjuvant systemic therapy. Targeting with novel 
therapies of the residual cells with stem cell self-renewal properties may provide a 
specific approach to prevent cancer recurrence and improve long-term survival.20 
PARt II: ImAGe-GuIded suRGeRy
In Chapter 8, a novel near-infrared (NIR) fluorescence imaging system, the Fluobeam®, 
was tested both in vitro and in vivo. This study demonstrated the technical performance 
of this new imaging system and its intraoperative utility in guiding resection of tumors 
using a protease-activatable NIR fluorescent probe. Also, this study has provided 
several methods for the validated testing of new NIR fluorescence imaging system.
In Chapter 9, the accuracy was determined of real-time NIR fluorescence imaging 
in obtaining tumor-free resection margins in a rat model of primary breast cancer using 
a protease-activatable NIR fluorescence probe. Real-time NIR fluorescence guidance 
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of tumor resection resulted in a complete resection of all tumors with minimal excision 
of normal healthy tissue (mean minimum and a mean maximum tumor-free margin 
of 0.2 ± 0.2 mm and 1.3 ± 0.6 mm, respectively). Histological analysis revealed that the 
NIR fluorescence signal was highest at the invasive tumor border and in the stromal 
compartment of the tumor, which correlates with the mechanism of action of protease 
activity.
In Chapter 10, the performance was assessed of antibody-based detection of 
breast tumor margins in the same breast cancer rat model as described in Chapter 
9. The monoclonal antibody MG1, directed against epithelial rat tumor cells, was 
conjugated to a NIR fluorophore. All breast tumors were identified and under direct 
image-guidance, all tumors could be resected with a clear margin. The fluorescence 
signal corresponded with histological tumor demarcation. Interestingly, the control 
experiment with a non-targeted antibody demonstrated equal fluorescent intensity 
and signal-to-background ratio. This observation can be explained by the ‘enhanced 
permeability and retention’ effect, by which the conjugated antibodies passively 
accumulate in the tumor due to the ‘leaky vessels’; the characteristic large pores seen 
in neovascularization. This observation may provide a simple and effective targeting 
strategy for NIR imaging of solid tumors.
Chapter 8, Chapter 9, and Chapter 10 demonstrated that NIR fluorescence 
detection of breast tumor margins was successful in a rat model. These studies suggest 
that clinical introduction of intraoperative NIR fluorescence imaging has the potential 
to increase the number of complete tumor resections in breast cancer patients 
undergoing breast-conserving surgery. 
In Chapter 11, the clinical translation of a new, portable NIR fluorescence imaging 
system, the Mini-FLARETM, is described in a dose optimization study of SLN mapping 
in breast cancer using indocyanine green (ICG) absorbed to human serum albumin 
(ICG:HSA) as a lymphatic tracer. The imaging system, which was developed for 
capturing color video and two channels of NIR fluorescence (700 nm and 800 nm), 
enabled visualization of lymphatic channels and SLNs in all patients. Mean number 
of identified SLNs was 1.45. All SLNs were NIR fluorescent. Optimal injection dose of 
ICG:HSA ranged between 400 and 800 μM. 
In Chapter 12, the effect of premixing ICG to HSA for SLN mapping in breast 
cancer was determined in a double-blind, randomized study. No significant differences 
were found in signal brightness and number of detected SLNs between the ICG:HSA 
group and the ICG alone group. This study has demonstrated that there is no direct 
benefit of premixing ICG with HSA prior to injection for SLN mapping in breast 
cancer patients, thereby reducing the cost and complexity of the procedure. 
Chapter 11 and Chapter 12 describe the optimization of NIR fluorescence SLN 
mapping using ICG in breast cancer and have paved the way for larger trials that can 
determine patient benefit of this technique.
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The recent introduction of NIR fluorescence image guidance has provided new 
opportunities in cancer surgery. Several NIR fluorescence imaging systems have 
been designed for intraoperative clinical use.21 Two of these imaging systems have 
been described in Chapter 8 and Chapter 11, respectively. Although differing in their 
technical specifications, all of these systems provide the surgeon with an image of the 
NIR fluorescence signal that would otherwise be invisible to the human eye (Table 
2). To permit precise localization of the NIR fluorescent signals in the context of 
surgical anatomy, several imaging systems acquire color video and NIR fluorescence 
emission simultaneously and provide overlay images.22-24 The development of new 
imaging systems will further improve NIR fluorescence image-guided surgery. NIR 
fluorescence laparoscopic imaging systems are currently being developed, and a 
commercial system is already available, which will allow NIR fluorescence guided-
surgery in a minimally invasive setting.25, 26 Various techniques are being evaluated 
to correct photon scattering and thereby enhance the depth at which NIR fluorescent 
signal can be detected.27-29 
Table 2. Clinically available NIR fluorescence imaging systems






PDE LED 805 nm,  power NS 15 - 25 cm NS No No
SPY Laser 806 nm,  2.0 W 30 cm 56 cm
2 No No
Fluobeam® Laser 780 nm, 10mW/cm2 22 cm 80 cm2 Yes No
HyperEye LED 760 nm,  power NS 30 - 50 cm 78.5 cm
2 Yes Yes
FLARETM LED 745-779 nm,14 mW/cm2 45 cm
3.7 cm2 - 169.5 
cm2 Yes Yes
Mini-FLARETM LED 760 nm,  8.6 mW/cm2 30 cm 100 cm
2 Yes Yes
FDPM imager Laser 785 ± 10 nm,  < 1.9 mW/cm2 <76.2 cm Max 900 cm
2 No No
Munich prototype Laser 750 nm,  300 mW 21 cm
1,5 cm2 -  
107 cm2 Yes Yes
PDE, Photodynamic Eye; LED, Light emitting diode; NS, not specified; FLARE, Fluorescence-Assisted 
Resection and Exploration; FDPM, Frequency Domain Photon Migration
Besides NIR fluorescence imaging systems, exogenous NIR fluorescent 
contrast agents are necessary to visualize specific tissues. The only NIR fluorescent 
contrast agents currently registered by the FDA and EMA for clinical applications are 
indocyanine green (ICG; peak emission ≈ 820 nm) and methylene blue (peak emission 
≈ 700 nm).30 ICG has preferable fluorescent characteristics because it provides a higher 
signal-to-background ratio as the autofluorescence is lower and tissue penetration is 
increased at 820 nm wavelength compared to 700 nm and ICG has a higher “brightness” 
(quantum yield). 
Thesis Mieog.indb   212 22-09-11   19:50
213Summary and general discussion
ICG is a negatively charged, amphiphilic, water-soluble, tricarbocyanine with a 
molecular mass of 776 Da. ICG has been registered for several decades to determine 
cardiac output, hepatic function, and ophthalmic perfusion. ICG has a very favorable 
safety profile, as the number of allergic reactions, the most important side-effect, is 
very low (1: 10,000, as reported by manufacturer).31 ICG is currently utilized in NIR 
fluorescence cancer surgery for four indications: sentinel lymph node (SLN) mapping, 
endoscopic marking of colorectal tumors,32 intraoperative identification of certain 
solid tumors,33 and angiography during reconstructive breast surgery.34 
Sentinel lymph node mapping with NIR fluorescence imaging using ICG as 
described in Chapter 11 and Chapter 12 has demonstrated accuracy and percutaneous 
visualization of the lymphatic channels. Thereby, it can reduce time of surgery and 
improve localisation of the SLN so that surgical exploration can be minimized, 
while maintaining a high identification rate. It should be noted, however, that NIR 
fluorescence detection is currently in the millimetre to centimetre range, far less 
than radioactive tracers, which requires caution when interrogating thick tissues, 
for instance in patients with high body mass index. In Chapter 11 and Chapter 12, it 
was demonstrated that NIR fluorescence using ICG could consistently be visualized 
before the blue dye could be observed. Therefore, NIR fluorescence imaging has the 
potential to replace blue dyes in SLN mapping of breast cancer patients. Whether NIR 
fluorescence could also replace radiocolloids is subject of an ongoing clinical trial, 
which is conducted by our group (NTR2674).
Intraoperative NIR fluorescence imaging tumor detection in cancer patients is 
currently limited because both ICG and methylene blue are so-called non-targeted 
probes as they cannot be conjugated to tumor-specific targets. Novel, non-toxic NIR 
fluorophores have been developed, such as IRDye CW800 (LI-COR Biosciences, 
Lincoln, USA), VivoTag family (PerkinElmer, Waltham, USA) and the 800 nm 
zwitterionic heptamethine indocyanine ZW-800-1 (John V. Frangioni, Center for 
Molecular Imaging, Boston, USA), with improved fluorescence properties for higher 
tissue penetration and with the ability to be conjugated to tumor-targeting ligands. 
Several academic and industry groups are translating these fluorophores to the clinic 
and the first toxicity results have been reported.35 Once these fluorophores have 
obtained regulatory approval, the logical next step would be the conjugation of these 
fluorophores to already clinically available monoclonal antibodies, such as trastuzumab 
(directed to the HER2/neu receptor, which is overexpressed in 20% of breast cancer 
patients), cetuximab, or bevacizumab. Thereafter, novel tumor-targeting approaches 
should be exploited. Various mechanisms are available for tumor targeting, including 
the conjugation of NIR fluorophores to tumor-specific antibody, to glucose derivates 
in order to visualize elevated metabolic rate, and autoquenched fluorophores that can 
be activated by tumor-specific enzymatic cleavage in order to become fluorescent. An 
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important strategy is the conjugation of fluorophores to a tumor-specific antibody or 
ligand directed to markers overexpresed by tumors, such as the follicle-stimulating 
hormone receptor, which is selectively expressed by endothelial cells at the periphery 
in a layer of approximately one cm of a wide range of tumors.36 Multiple targeted probes 
have already been developed, some of which are commercially available, and have 
successfully been tested in animal studies and this thesis also has provided examples 
of this in Chapter 9 and Chapter 10. Translating these preclinical results to the clinical 
setting in order to improve breast cancer outcome remains a major challenge for the 
next decades.
NIR optical spectroscopy is a technique to non-invasively monitor tumor response 
to neoadjuvant therapy. The technique utilizes the differences in absorption and 
scattering spectra of endogenous compounds. Therefore, no contrast agents are 
necessary. For the breast, the major absorption chromophores are oxyhemoglobin, 
deoxyhemoglobin, lipids and water, which are altered by angiogenesis, tumor cell 
proliferation and hypoxia.37, 38 The Softscan® (ART, Montreal, Canada) is an optical 
breast imaging device, which uses pulsed time domain optical spectroscopy to obtain 
3D images of the breast.39 Current imaging modalities for tumor response assessment 
(mammography, ultrasound, MRI) are mainly based on size measurements. However, 
it is expected from tumor biology data that physiological changes in the tumor can be 
noted long before any changes in size can be observed.40 As the Softscan measurements 
are based on tissue physiology, it should theoretically be able to assess early changes 
in the tumor, which could indicate a good response to neoadjuvant therapy. Indeed, a 
small clinical trial has demonstrated that the Softscan can discriminate responders from 
non-responders after one cycle of neoadjuvant chemotherapy.41 Our group is currently 
conducting a larger clinical trial with the Softscan to study the predictive value of 
early tumor response assessment to neoadjuvant therapy within the framework of the 
NEOZOTAC and TEAM-IIa studies. Another application of NIR imaging could be the 
in vivo monitoring of the response of axillary metastases, either by optical spectroscopy 
or by NIR fluorescence contrast agents either targeting apoptotic42 or viable tumor 
cells. As discussed above, if axillary metastases are regressed after neoadjuvant therapy 
and this can be confirmed by fluorescent imaging, an axillary lymph node dissection 
can be prevented.
In summary, near-infrared fluorescence imaging has the potential to revolutionize 
human cancer surgery by providing sensitive, specific, and real-time intraoperative 
visualization of normal and malignant tissues, to optimize surgical removal of tumors 
and their (local or lymph node) metastases.
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Borstkanker is de meest voorkomende kankersoort bij vrouwen en veroorzaakt 
de grootste kankergerelateerde sterfte onder vrouwen. Hoewel de incidentie van 
borstkanker nog steeds stijgt, is het sterftecijfer de laatste decennia afgenomen 
voornamelijk als gevolg van verbetering van systemische therapie. Desondanks blijft 
chirurgisch ingrijpen de hoeksteen van de curatieve behandeling van borstkanker. 
De chirurgische behandeling van borstkanker heeft de afgelopen eeuw een sterke 
verandering doorgemaakt, waarbij deze steeds minder uitgebreid is geworden en 
daardoor patiëntvriendelijker. In 1907 werd door de Amerikaanse chirurg William 
S. Halsted een serie patiënten beschreven die dankzij een radicale mastectomie een 
uitstekende lokale controle kende. Bij deze operatie werden de borstklier, beide 
pectoralisspieren en alle relevante lymfklierstations en bloc verwijderd hetgeen gepaard 
ging met een grote morbiditeit. Om de morbiditeit te verminderen werd de radicale 
mastecomie gemodificeerd naar een operatie waarbij de pectoralisspieren gespaard 
bleven, de gemodificeerde radicale mastectomie. In de jaren zeventig van de vorige 
eeuw werd borstsparende chirurgie in combinatie met radiotherapie geïntroduceerd. 
Dit leidde tot een betere cosmetische uitkomst en een verbetering van het zelfbeeld 
van de patiënt. In 1994 werd de schildwachtklierprocedure geïntroduceerd waardoor 
een okselklierdissectie slechts bij patiënten met een positieve schildwachtklier wordt 
uitgevoerd. In deze paradigmaverschuiving naar een meer conservatieve chirurgische 
benadering past het concept van preoperatieve systemische (ook wel neoadjuvante) 
therapie, omdat hierbij de systemische therapie voorafgaand aan de operatie wordt 
gegeven om de tumor te verkleinen en daarmee de chirurgische mogelijkheden tot 
minder invasief opereren vergroot. 
De belangrijkste uitdaging bij de chirurgische behandeling van borstkanker is 
het volledig verwijderen van het tumorweefsel met in achtneming van een adequate 
tumorvrije marge en een acceptabel cosmetisch resultaat. Echter, de chirurg moet 
vertrouwen op zijn zicht en gevoel om een onderscheid te maken tussen tumor- en 
normaal weefsel. Bij borstsparende operaties is dit bijzonder lastig, getuige het feit dat 
een onvolledige (irradicale) resectie in 5-40% van de gevallen voorkomt. Irradicale 
resecties kunnen leiden tot lokale terugkeer van de ziekte, hetgeen geassocieerd is met 
een slechtere overleving. Een techniek die tijdens de operatie specifiek tumorcellen 
visualiseert om de chirurg te helpen de optimale resectievlakken te kiezen zou daarom 
van grote meerwaarde kunnen zijn. Fluorescente beeldvorming met nabij-infrarood 
licht is een techniek die voor dit doel zeer geschikt lijkt.
Dit proefschrift bestaat uit twee delen. In deel I werd de effectiviteit van neoadjuvante 
therapie en de aanvullende waarde van het meten van de tumorrespons beoordeeld. 
Bovendien werd onderzocht of kankerstamcellen van invloed zijn op de prognose van 
borstkankerpatiënten. In deel II werd de techniek van de nabij-infrarode fluorescente 
beeldvorming preklinisch gevalideerd en geïntroduceerd in de kliniek.
Thesis Mieog.indb   218 22-09-11   19:50
219Nederlandse samenvatting
deel I: neoAdjuvAnte tHeRAPIe, tumoRResPons en 
kAnkeRstAmCellen
Hoofdstuk 1 geeft  een algemene inleiding op dit proefschrift. In Hoofdstuk 2 werd 
in een meta-analyse van gerandomiseerde studies aangetoond dat neoadjuvante 
chemotherapie vergeleken met adjuvante chemotherapie resulteert in een gelijke 
overleving en een toename van het aantal borstsparende operaties, terwijl de lokale 
controle gelijk blijft. Derhalve is in internationale richtlijnen geadviseerd om 
neoadjuvante chemotherapie toe te passen voor alle patiënten waarbij voorafgaand 
aan de operatie duidelijk is dat zij in aanmerking komen voor chemotherapie. 
Dankzij neoadjuvante therapie kan uitstekend het biologisch gedrag van de 
tumor in vivo geanalyseerd worden. Immers de tumor is nog in het lichaam aanwezig 
en hierdoor kan de respons van de tumor op de systemische therapie direct bepaald 
worden. Dit in tegenstelling tot de adjuvante situatie, waarbij de therapie ‘blind’ 
wordt gegeven; de tumor is reeds verwijderd en de reactie van de tumor tijdens de 
behandeling kan niet worden bepaald. Hierdoor is het nog grotendeels onbekend 
welke vrouwen het meeste baat hebben van welke specifieke systemische therapie. 
In Hoofdstuk 3 werd binnen een gerandomiseerd onderzoek van neoadjuvante 
chemotherapie bepaald welke tumormarkers een goede tumorrespons voorspellen. 
Hierbij bleek het tumorsuppressoreiwit p53 de gevoeligheid voor een anthracycline-
bevattende chemotherapieschema goed te voorspellen. 
In Hoofdstuk 4 werd het effect van chemotherapie in relatie tot de 
hormoonreceptorstatus onderzocht in een grote groep jonge borstkankerpatiënten 
(< 40 jaar). Uit eerdere neoadjuvante studies is gebleken dat hormoonreceptornegatieve 
borstkanker beter reageert op chemotherapie dan tumoren met overexpressie van de 
hormoonreceptoren. Echter, borstkanker op jonge leeftijd is relatief zeldzaam (~ 5% 
van de gevallen), waardoor er weinig onderzoeksresultaten bekend zijn voor deze 
groep. Bovendien is door de slechtere overleving van deze patiëntengroep in de huidige 
richtlijnen jonge leeftijd als absolute indicatie voor het geven van chemotherapie 
opgenomen ongeacht de status van de hormoonreceptoren. Hierdoor bestaat de zorg 
van overbehandeling bij deze jonge (fertiele) patiëntengroep. De meta-analyse van 
Hoofdstuk 4 toont aan dat jonge vrouwen met hormoonreceptorpositieve borstkanker 
minder baat hebben bij chemotherapie dan die met hormoonreceptornegatieve 
borstkanker. 
Hoofdstuk 5 laat zien dat de overleving van jonge vrouwen sterk afhankelijk is van 
het moleculaire subtype borstkanker en dat jonge patiënten met een gunstig subtype 
een uitstekende lange-termijn overleving hebben. Deze resultaten benadrukken dat 
tumorspecifieke prognostische kenmerken moeten worden meegenomen in het 
behandelingsplan van jonge borstkankerpatiënten. 
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Ondanks de recente verbeteringen in systemische en lokale behandeling ontwikkelt 
een substantieel deel van de borstkankerpatiënten een lokaal recidief of metastasen 
op afstand. Vaak ontstaan deze na een aanzienlijke follow-up tijd; soms pas 20 jaar na 
de operatie. Uit recent onderzoek is gebleken dat de kankerstamceltheorie dit falen 
van de behandeling kan verklaren. Binnen deze hypothese worden kankerstamcellen 
gezien als een kleine subpopulatie van tumorcellen met stamcelachtige kenmerken, 
zoals het overgaan van epitheel naar mesenchym, aanzetten tot differentiatie, 
het overleven van chemotherapie en bestraling door onder andere specifieke 
transporteiwitten en reparatie van DNA-schade. Expressie van het ontgiftende enzym 
aldehyde dehydrogenase-1 (ALDH1) wordt als één van de meest karakteristieke 
kenmerken van borstkankerstamcellen gezien. De kankerstamceltheorie zou ook een 
verklaring kunnen bieden voor de leeftijdsspecifieke verschillen in overleving van 
borstkanker, waarbij vroeg-optredende tumoren (< 65 jaar) vaak agressiever zijn en 
snel metastaseren, terwijl laat-optredende tumoren (> 65 jaar) meer indolent zijn. 
Het onderzoek in Hoofdstuk 6 toont aan dat de expressie van ALDH1 omgekeerd 
evenredig is met de leeftijd bij diagnose van borstkanker. Bij patiënten jonger dan 
65 jaar was ALDH1 expressie sterk geassocieerd met een slechtere overleving, terwijl 
bij patiënten ouder dan 65 jaar ALDH1 status geen effect had op de overleving. 
Dit onderzoek onderstreept de verschillen in borstkankerbiologie tussen jonge en 
oude patiënten, hetgeen deels verklaard kan worden door verschillen in cellulaire 
mechanismen betrokken bij kankerstamcelactiviteit. 
In Hoofdstuk 7 werd de rol van het stollingseiwit tissue factor (TF) en zijn 
alternatief-gesplitste variant (asTF) bij de formatie en groei van borstkankerstamcellen 
onderzocht. Beide eiwitten worden tot expressie gebracht in een groot aantal 
tumortypen. De activiteit van TF verloopt via een protease activated receptor-2 
(PAR2) pathway, terwijl de activiteit van asTF via een integrine-afhankelijke pathway 
verloopt. De resultaten van Hoofdstuk 7 tonen aan dat ALDH1 expressie sterk 
geassocieerd is met TF expressie en niet met asTF expressie, hetgeen suggereert dat 
de TF-PAR2 pathway van belang is voor de activiteit van borstkankerstamcellen. Het 
specifiek beïnvloeden van deze pathway door nieuwe medicijnen zou theoretisch de 
kankerstamcellen kunnen aanpakken, hetgeen zou kunnen leiden tot verbetering van 
overleving van borstkankerpatiënten. 
deel II: ImAGe-GuIded suRGeRy
In deel II van dit proefschrift werd de intraoperatieve beeldvormende techniek van 
nabij-infrarood (NIR) fluorescentie onderzocht. Nabij-infrarood (NIR) licht heeft een 
golflengte tussen de 700 en 900 nm, hetgeen voor het menselijk oog niet zichtbaar is. 
Het grote voordeel van NIR licht is dat het minder wordt geabsorbeerd door weefsel, 
waardoor de weefselpenetratie groter is (tot enkele cm’s) dan dat van zichtbaar licht. 
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Daarnaast is de techniek veilig en vindt de beeldacquisitie in milliseconden plaats, 
waardoor het ‘real-time’ toegepast kan worden. Bovendien wordt het operatieveld 
niet beïnvloed door het NIR licht, omdat het niet zichtbaar is voor het menselijk oog. 
Voor de intraoperatieve detectie van tumoren zijn tumorspecifieke, NIR fluorescente 
contrastmiddelen (probes) nodig en camerasystemen om deze stoffen zichtbaar te 
maken.
In Hoofdstuk 8 werd een nieuw, ‘hand-held’, intraoperatief NIR fluorescentie 
camerasysteem getest. Met nieuw ontwikkelde methodes werd zowel in vitro als in vivo 
de minimale detectielimieten, resolutie en intraoperatieve toepasbaarheid bepaald 
met behulp van een protease-geactiveerde NIR fluorescente probe en twee syngene 
ratmodellen.
In Hoofdstuk 9 werd dit camerasysteem gebruikt om in een syngeen 
borstkankerratmodel orthotope borsttumoren te detecteren met een protease-
geactiveerde NIR fluorescente probe. Op geleide van het NIR fluorescente beeld 
werden alle tumoren compleet gereserceerd met een minimale hoeveelheid normaal 
weefsel (gemiddelde minimale en maximale tumorvrije marge van respectievelijk 0.2 
± 0.2 mm en 1.3 ± 0.6 mm).
In Hoofdstuk 10 werd het gebruik van monoclonale antilichamen gekoppeld 
aan een NIR fluorescente kleurstof uitgetest in hetzelfde syngeen ratmodel. Dit 
onderzoek toonde aan dat zowel de specifieke als de aspecifieke antilichamen een 
adequate detectie van borsttumoren faciliteerden, waardoor alle tumoren compleet 
gereserceerd konden worden. Het feit dat ook de aspecifieke antilichamen een goed 
contrast gaven, kan verklaard worden door het zogenaamde ‘enhanced permeability 
and retention effect’. Hierbij concentreren de stoffen zich in de tumor door passieve 
accumulatie. 
Deze preklinische onderzoeken toonden de potentie van NIR fluorescente 
beeldvorming aan voor de intraoperatieve detectie en succesvolle resectie van tumoren 
in een borstkankerratmodel. Zodra de NIR fluorescente probes goedgekeurd worden 
voor klinische toepassing kan de waarde van NIR fluorescente beeldvorming bij de 
operatieve behandeling van borstkankerpatiënten bepaald worden.
Naast de intraoperatieve tumordetectie biedt NIR fluorescente beeldvorming de 
mogelijkheid om de schildwachtklierprocedure te verbeteren. De schildwachtklier is 
de eerste lymfeklier waar een tumor op draineert. Als deze klier geen tumorcellen 
bevat is de kans zeer groot dat de andere lymfeklieren ook geen metastasen bevatten, 
waardoor een ingrijpende okselklierdissectie achterwege kan worden gelaten. Om de 
schildwachtklier te vinden wordt tegenwoordig een radioactieve stof en een blauwe 
kleurstof rondom de borsttumor ingespoten. NIR fluorescente beeldvorming kan met 
de klinisch goedgekeurde NIR probe indocyaninegroen (ICG) een aanvulling vormen 
op de huidige schildwachtklier-procedure of zelfs de huidige modaliteiten vervangen. 
Preklinisch onderzoek heeft laten zien dat als ICG aan humaan serum albumine (HSA) 
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gekoppeld wordt de eigenschappen als lymfetracer verbeterd worden door een betere 
retentie in de schildwachtklier en een verhoogde fluorescentie.
 In Hoofdstuk 11 werd een nieuw, intraoperatief camerasysteem gebruikt 
dat zowel het normale kleurenbeeld als het NIR fluorescente beeld registreert, om 
de geïnjecteerde dosis ICG:HSA te optimaliseren bij borstkankerpatiënten. De 
schildwachtklier werd bij alle patiënten succesvol geïdentificeerd. De optimale dosis 
ICG:HSA lag tussen 400 en 800 μM. Bovendien werden de lymfebanen en in sommige 
gevallen de schildwachtklier percutaan gevisualiseerd.
 In Hoofdstuk 12 werd onderzocht of het vooraf koppelen van HSA aan ICG 
noodzakelijk is of dat injectie van alleen ICG een even goed resultaat levert. In dit 
geblindeerd, gerandomiseerd onderzoek werd geen verschil gevonden in fluorescent 
contrast of het aantal gevonden schildwachtklieren tussen de ICG:HSA groep en 
de ICG alleen groep. Vooraf koppelen van ICG aan HSA is dus overbodig. Dit kan 
verklaart worden doordat ICG zich snel bindt aan de in de lymfe aanwezige eiwitten. 
Deze resultaten zullen de introductie in de kliniek aanzienlijk vergemakkelijken. Of 
NIR fluorescente beeldvorming de radioactieve tracer en de blauwe kleurstof kan 
vervangen wordt momenteel door onze groep onderzocht (NTR2674). 
ConClusIes
Neoadjuvante therapie moet als een geaccepteerde behandelingsmodaliteit van 
borstkanker beschouwd worden. Deze therapievorm maakt meer borstsparende 
operaties mogelijk en geeft gelijke overlevingscijfers en lokale controle ten opzichte 
van adjuvante therapie. Daarnaast biedt neoadjuvante therapie de mogelijkheid om bij 
tumorresistentie van therapie te veranderen en faciliteert het translationeel onderzoek 
waardoor een belangrijke bijdrage geleverd wordt aan de verdere ontwikkeling van 
geïndividualiseerde behandelplannen voor borstkankerpatiënten. 
NIR fluorescente beeldvorming is een sensitieve techniek om tijdens de operatie 
specifiek tumor- en normaalweefsel te visualiseren om de optimale tumorvrije marges 
te bepalen en de schildwachtklierprocedure te verbeteren. In de komende jaren moet 
blijken of deze vorm van “image-guided surgery” daadwerkelijk de chirurgische 
behandeling van kankerpatiënten kan optimaliseren om daarmee een verbetering van 
de overleving en kwaliteit van leven te bereiken. 
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